AMINOGLYCOSIDES [AMI] (KANAMYCIN/CAPREOMYCIN/AMIKACIN/VIOMYCIN)																																																																																																																																																																																																		
																																																																																																																																																																																																		
	rrs																																																																																																																																																																																																	
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations																																																																																																																																																																																	
AMI	rrs	Maus CE AAC 2005 Aug	1401	A/G		rRNA gene	Published 2005	"M.tb laboratory strains used for in-vitro selection of mutants; clinical isolates obtained from CDC. N=16"	USA	Sequencing	Whole gene	KAmiCap	K >80ug/ml, Ami >64ug/ml, CAP 20-80ug/ml	N.S.	16/16	11/0	"9 isolates had no additional mutaitons; one had a mutation at rrs A514C; and one had a mutation at rrs A514C and T1239C."																																																																																																																																																																																	
AMI	rrs	Sander P MolMicro 1996	1401	A/G		rRNA gene	Published 1996	8 Kanamycin and amikacin resistant Mtb isolates	N.S.	Sequencing	N.S	Kami	N.S.	N.S.	08-aug	8/0	none																																																																																																																																																																																	
AMI	rrs	Suzuki Y JCM 1998	1402 (1401 in ref)	C/T		rRNA gene	Published 1998	K-S (n=71) isolates, K-R (n=43) isolates, and 4 laboratory strains of M.Tb. Total N=118	Japan	Sequencing	300 bp containing the 3' one-fifth of the rrs gene	K	K >100ug/ml	Proportion method	43/118	1/0	None found in gene analyzed.																																																																																																																																																																																	
AMI	rrs	Suzuki Y JCM 1998	1402 (1401 in ref)	C/A		rRNA gene	Published 1998	K-S (n=71) isolates, K-R (n=43) isolates, and 4 laboratory strains of M.Tb. Total N=118	Japan	Sequencing	300 bp containing the 3' one-fifth of the rrs gene	K	K >100ug/ml	Proportion method	43/118	2/0	Both isolates also mutated at rrs G1484T.																																																																																																																																																																																	
AMI	rrs	Taniguchi H JB 1997	1408 (1400 in ref)	A/G		rRNA gene	Published 1997	"Kamycin- and viomycin-resistant M.smegmatis isolated from standard strains in the laboratory (n=15); MDR-M.tb clinical isolates (N=10), out of which 4 were K-R."	Japan	Sequencing	nt 431 to the 3' end	RSEKVio	K >200ug/ml	N.S.	39913	3/0	"Lys43Arg mutation in S12 protein in one isolate; Lys88Gln mutation in S12 protein in second isolate."																																																																																																																																																																																	
AMI	rrs	Suzuki Y JCM 1998	1484 (1483 in ref)	G/T		rRNA gene	Published 1998	K-S (n=71) isolates, K-R (n=43) isolates, and 4 laboratory strains of M.Tb. Total N=118	Japan	Sequencing	300 bp containing the 3' one-fifth of the rrs gene	K	K >100ug/ml	Proportion method	43/118	2/0	Both isolates also mutated at rrs C1402A.																																																																																																																																																																																	
																																																																																																																																																																																																		
																																																																																																																																																																																																		
	tlyA (Rv1694)																																																																																																																																																																																																	
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	7	CGA/TGA	3	Arg/STOP	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap Vio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	26	del C		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005 Feb	40	CGG/TGG	14	Arg/Trp	Published 2005	"Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18"	USA	Sequencing	Whole gene	HRESEthKCapVioAmi	K >80ug/ml	Proportion method	16/18	1/0	Also mutated at rrs A1401G.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	52	CGA/TGA	18	Arg/STOP	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	64	CAG/TAG	22	Gln/STOP	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	Cap 40ug/ml, Vio <10ug/ml	Proportion method	30/30	3/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	23	del A		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	RESKCapVio Ami	Cap 80ug/ml	Proportion method	18/18	1/0	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005 Feb	67-69	del GCC	23	del A	Published 2005	"Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18"	USA	Sequencing	Whole gene	HRESKCapVioAmi	K 20ug/ml	Proportion method	16/18	1/0	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	200	GCG/GAG	67	Ala/Glu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	205	AAA/GAA	69	Lys/Glu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	218	ins C		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	HRESKCapVioAmi	Cap 80ug/ml	Proportion method	18/18	1/0	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	272	GCA/GAA	91	Ala/Glu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	Cap 40ug.ml, Vio <10ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	310	del G		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	353	CTG/CCG	118	Leu/Pro	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 40ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	383	GTG/GAG	128	Val/Glu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	397	ins C		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	400	del A		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005 Feb	449	CTG/CCG	150	Leu/Pro	Published 2005	"Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18"	USA	Sequencing	Whole gene	HRSCap	K <5ug/ml Cap 40ug/ml	Proportion method	16/18	0/1	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	477	del G		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	Cap 40ug/ml, Vio <10ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	548	C/T	183	Pro/Leu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	550	C/T	184	Gln/STOP	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	Cap 40ug/ml, Vio <10ug/ml	Proportion method	30/30	5/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	555	T/G	185	Phe/Leu	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	586	del G		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	653	del T		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005 Feb		ins C	218	Frameshift	Published 2005	"Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18"	USA	Sequencing	Whole gene	HRESKCapVioAmI	K 20ug/ml	Proportion method	16/18	1/0	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	673-674	del GT		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005 Feb	708	AAT/AAG	236	Asn/Lys	Published 2005	"Mutagenized M.smeg; also M.tb strains H37Rv, CDC1551, Beijing F2, and 18 clinical isolates obtained from CDC. N=18"	USA	Sequencing	Whole gene	HSCapVio	K <5ug/ml Cap 80ug/ml	Proportion method	16/18	0/1	None found in region analyzed.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	712	G/A	238	Glu/Lys	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	Cap	N.S.	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	
AG	tlyA	Maus CE AAC 2005	758	del C		Frameshift	Published 2005	"Resistance-selected M.tb strains H37Rv (n=11), CDC1551 (n=11), and Beijing F2 (n=8); also 18 clinical strains from CDC. Total N=48"	USA	Sequencing	Whole gene	CapVio	Cap 40ug/ml, Vio 20ug/ml	Proportion method	30/30	1/0	None identified specifically.																																																																																																																																																																																	

ETHAMBUTOL [EMB]																																																																																																																																																																																																		
																																																																																																																																																																																																		
																																																																																																																																																																																																		
	embC: arabinosyltransferase gene																																																																																																																																																																																																	
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations																																																																																																																																																																																	
EMB	embC	Sreevatsan S AAC 1997	13	GGT/AGT	5	Gly/Ser	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	N.S.	BACTEC 460	16/19	1/0	
EMB	embC	Srivastava S JMM 2009	730-732	GCG/ACC	244	Ala/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368A, S380R, P397Q, R460C; embC G288W, V303G; embR L172R"
EMB	embC	Srivastava S JMM 2009	739-741	GCC/CCG	247	Ala/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, A357V, L359I, E378A, A379D, Y384N, A388G, N399D; embC T270I, I297T"
EMB	embC	Srivastava S CurrMicro 2006	752	CTG/CGT	251	Leu/Arg	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	12ug/ml	Proportion method, E-Test	23/23	1/0	Ala254Gly and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.
EMB	embC	Srivastava S CurrMicro 2006	761	GCC/GGC	254	Ala/Gly	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	12ug/ml	Proportion method, E-Test	23/23	1/0	Leu251Arg and Thr270Ile in embC. R/Tot and R/S calculated from Table 1.
EMB	embC	Sreevatsan S AAC 1997	809	ACC/ATC	270	Thr/Ile	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	16/19	1/0	Met306Val in embB.
EMB	embC	Srivastava S JMM 2009	809-810	ACC/ATT	270	Thr/Ile	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	embB G406A
EMB	embC	Srivastava S JMM 2009	814-815	GGC/GAC	272	Gly/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, A431T; embC H285Y, M300R, A307T; embR A176V, I369T"
EMB	embC	Srivastava S JMM 2009	853	CAT/TAT	285	His/Tyr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, A431T; embC G272S, M300R, A307T; embR A176V, I369T"
EMB	embC	Srivastava S JMM 2009	859-861	GTG/TTT	287	Val/Phe	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC Y309N; embR L320V, S326N, V350G, H351Q, R356G, I369T"
EMB	embC	Srivastava S JMM 2009	862-864	GGC/TGG	288	Gly/Trp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368A, S380R, P397Q, R460C; embC A244T, V303G; embR L172R"
EMB	embC	Srivastava S JMM 2009	863-864	GGC/GTG	288	Gly/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, A356F, L359I, R367P; embC M310K, Y327N"
EMB	embC	Srivastava S JMM 2009	886-888	TAT/CAT	296	Tyr/His	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306I; embC T270I, G308D, G325S"
EMB	embC	Srivastava S JMM 2009	886-888	TAT/AGC	296	Tyr/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embC R302G
EMB	embC	Srivastava S JMM 2009	889-891	ATT/TTG	297	Ile/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	E	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, S380D, P397T, G406D, G448V; embC W326R"
EMB	embC	Srivastava S JMM 2009	889-891	ATT/CTG	297	Ile/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	48ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M; embC A247P, W326R; embR V7G"
EMB	embC	Srivastava S JMM 2009	890-891	ATT/ACC	297	Ile/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB S347I, E368D, R460L; embR R230W, I396T"
EMB	embC	Srivastava S JMM 2009	898-900	ATG/CGT	300	Met/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, A431T; embC G272S, H285Y, A307T; embR A176V, I369T"
EMB	embC	Srivastava S JMM 2009	904-906	CGT/GGC	302	Arg/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embC Y296S
EMB	embC	Srivastava S JMM 2009	908-909	GTG/GGC	303	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	E	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368A, S380R, P397Q, R460C; embC A244T, G288W; embR L172R"
EMB	embC	Srivastava S JMM 2009	919-921	GCG/ACC	307	Ala/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, A431T; embC G272S, H285Y, M300R; embR A176V, I369T"
EMB	embC	Srivastava S JMM 2009	923-924	GGC/GAT	308	Gly/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306I; embC T270I, Y296H', G325S"
EMB	embC	Srivastava S JMM 2009	925-927	TAT/AAC	309	Tyr/Asn	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F; embR L320V, S326N, V350G, H351Q, R356G, I369T"
EMB	embC	Srivastava S JMM 2009	929-930	ATG/AAA	310	Met/Lys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, A356F, L359I, R367P; embC G288V, Y327N"
EMB	embC	Srivastava S JMM 2009	973	GGC/AGC	325	Gly/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306I; embC T270I, Y296H, G308D"
EMB	embC	Srivastava S JMM 2009	976-978	TGG/CGT	326	Trp/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	E	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, S380D, P397T, G406D, G448V; embC I297L"
EMB	embC	Srivastava S JMM 2009	979-981	TAT/AAC	327	Tyr/Asn	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, A356F, L359I, R367P; embC G288V, M310K"
EMB	embC	Ramaswamy SV AAC 2000	1180	AAC/GAC	394	Asn/Asp	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	"Gly350Asp and Pro913Ser in embA; Leu276Arg in Rv3124; -12 G deletion in Rv0340."
EMB	embC	Ramaswamy SV AAC 2000	2213	CGG/CAG	738	Arg/Gln	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	75/108	1/0	"-16 C/T in embA;  Met306Ile in embB, Pro54Ser in RV3124."
EMB	embC	Sreevatsan S AAC 1997	2941	GTG/CTG or GTG/TTG	981	Val/Leu	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	15ug/ml	BACTEC 460, agar diffusion method	16/19		All three isolates also had a synonymous G/A substitution at nt 2898 of embA.
																	
	embA: arabinosyltransferase gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	embA	Ramaswamy SV AAC 2000	-43	del CG		Frameshift	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	20-30ug/ml	BACTEC 460	75/108	2/0	"Met306Ile in embB at MIC=20ug/ml; Gly406Ser in embB at MIC=30ug/ml."
EMB	embA	Ramaswamy SV AAC 2000	-16	C/T			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-40ug/ml	BACTEC 460	75/108	2/0	"Arg738Gln in embC, Met306Ile in embB, and Pro54Ser in Rv3124 at MIC=40ug/ml; Ser501Trp at MIC>10ug/mL."
EMB	embA	Ramaswamy SV AAC 2000	-12	C/T			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460	75/108	2/0	"Gln497Lys in embB in one isolate; Gln497Lys in embB and Ser501Trp in iniA in another isolate."
EMB	embA	Ramaswamy SV AAC 2000	-11	C/A			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	20ug/ml	BACTEC 460	75/108	1/0	Met306Ile in embB.
EMB	embA	Ramaswamy SV AAC 2000	10	GAC/AAC	4	Asp/Asn	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460	75/108	1/0	Gly406Asp in embB
EMB	embA	Ramaswamy SV AAC 2000	601	GCG/ACG	201	Ala/Thr	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460	75/108	1/0	Asp328Tyr and Tyr334His in embB.
EMB	embA	Ramaswamy SV AAC 2000	961	GGC/AGC	321	Gly/Ser	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	1/0	
EMB	embA	Ramaswamy SV AAC 2000	1049	GGC/GAC	350	Gly/Asp	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	2/0	
EMB	embA	Ramaswamy SV AAC 2000	1385	GCG/GTG	462	Ala/Val	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	1/0	
EMB	embA	Ramaswamy SV AAC 2000	2498	GAC/GGC	833	Asp/Ala	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-30ug/ml	BACTEC 460	75/108	1/0	
EMB	embA	Ramaswamy SV AAC 2000	2737	CCG/TCG	913	Pro/Ser	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40-50ug/ml	BACTEC 460	75/108	2/0	"Gln351STOP in iniC at MIC=40ug/ml; Asn394Asp in embC, Gly350Asp in embA, Leu276Arg in Rv3124, and -24 G deletion in Rv0340, at MIC=50ug/ml."
																	
	embB: arabinosyltransferase gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	embB	Srivastava S CurrMicro 2006	383	GTC/GGG	128	Val/Gly	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	5ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	662-663	GCG/GGC	221	Ala/Gly	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	673-674	GCG/AGC	225	Ala/Ser	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	680-681	GTG/GGC	227	Val/Gly	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S CurrMicro 2006	716	CTC/CCC	239	Leu/Pro	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	256ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S CurrMicro 2006	718	GAC/CAC	240	Asp/His	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	4ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	769-771	CGT/TGG	257	Arg/Trp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embC V287F, Y309N; embR A176V, R230W, I369T"
EMB	embB	Jain A IndJMedRes 2008	812	GCG/GTG	271	Ala/Val	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	814	AGC/TGC	272	Ser/Cys	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	815-816	AGC/ATT	272	Ser/Ile	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Wu  X  Chinese J of Antibiotics 2002	821	CGC/CCC	274	Arg/Pro											
EMB	embB	Jain A IndJMedRes 2008	841	GCG/CCG	281	Ala/Pro	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	841-843	TTT/CTG	281	Phe/Leu	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	845	GTG/GGG	282	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	12ug/ml	Proportion method, E-Test	44/44	1/0	None in region embB, embC or embR'
EMB	embB	Jain A IndJMedRes 2008	844	GTG/CTG	282	Val/Leu	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Sreevatsan S AAC 1997	855	TTC/TTA	285	Phe/Leu	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	69/99	1/0	
EMB	embB	Jain A IndJMedRes 2008	860-861	TTT/TGC	287	Phe/Cys	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	859-861	TTT/GTG	287	Phe/Val	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	878-879	ATT/AAC	293	Ile/Asn	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Jain A IndJMedRes 2008	880	GGC/AGC	294	Gly/Ser	2002-2004		India	Sequencing	ERDR	EHRS	>20ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	888	AAT/AAA	296	Asn/Lys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368D, G406S; embC I297T"
EMB	embB	Ramaswamy SV AAC 2000	889	TCG/GCG	297	Ser/Ala	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embB	Plinke C AAC 2006	890	TCG/TTG	297	Ser/Leu	2001	"EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159."	Germany	Sequencing	ERDR	E + INH + RIF  	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S CurrMicro 2006	897	GAC/GAA	299	Asp/Glu	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2-6ug/ml	Proportion method, E-Test	23/23	4/0	"Out of 4 isolates, 2 were WT in all other loci analyzed except for a synonymous mutation (GCA/GCC) at embB259. These isolates had MIC=4-6ug/ml. Both other isolates contained the embB mutation Glu378Ala (GAA/GCG); one of them was also mutated at embB Pro44"
EMB	embB	Sreevatsan S AAC 1997	916	ATG/CTG	306	Met/Leu	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=76"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	69/99	1/0	
EMB	embB	Lee HY YonseiMedJ 2002	916	ATG/TTG	306	Met/Leu	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	Whole gene	E, 	2ug/ml	Proportion method	21/26	1/0	None in region amplified (see Gene coverage). 
EMB	embB	Sreevatsan S AAC 1997	916	ATG/GTG	306	Met/Val	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	69/99	12/0	
EMB	embB	Sreevatsan S AAC 1997	918	ATG/ATA	306	Met/Ile	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	11/0	
EMB	embB	Sreevatsan S AAC 1997	918	ATG/ATT	306	Met/Ile	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	2/0	
EMB	embB	Sreevatsan S AAC 1997	918	ATG/ATC	306	Met/Ile	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	69/99	3/0	
EMB	embB	Lee HY YonseiMedJ 2002	917-918	ATG/ACG	306	Met/Thr	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	2ug/ml	Proportion method	21/26	1/0	None in region amplified (see Gene coverage). 
EMB	embB	Srivastava S JMM 2009	926-927	GTG/GGC	309	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, A310R, D311R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S JMM 2009	928-930	GCG/CGT	310	Ala/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, D311R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S JMM 2009	931-932	GAC/CGT	311	Asp/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A310R, V369A, P375A, F398Y, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S CurrMicro 2006	931	GAC/CAC	311	Asp/His	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	12ug/ml	Proportion method, E-Test	23/23	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	935	CAT/CGT	312	His/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB S317T, A356F, L359I, R367P; embC G288V, M310K, Y327N"
EMB	embB	Lee HY YonseiMedJ 2002	941	GGC/GCG	314	Gly/Ala	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	4ug/ml	Proportion method	21/26	1/0	Tyr322Cys on embB.
EMB	embB	Tracevska T ResMicro 2004	941-942	GGC/GAG	314	Gly/Glu	"Published 2004; isolates collected in 2001-2002"	Patients with primary and relapsed pulmonary MDR-TB: 33 EMB-R and 33 EMB-S (N=66).	Latvia	Sequencing	ERDR	EHRS	N.S.	BACTEC radiorespiratory method (7.5ug/ml EMB), and absolute concentration method on L-J medium (cutoff 2.0ug/ml EMB)	33/66	1/0	None in region amplified (see Gene coverage). 
EMB	embB	Srivastava S JMM 2009	943-945	TAT/CTG	315	Tyr/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, N318S, V377G, E378A, Y384N, N400K, V452L
EMB	embB	Srivastava S JMM 2009	950	AGC/ACC	317	Ser/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, A356F, L359I, R367P; embC G288V, M310K, Y327N"
EMB	embB	Srivastava S JMM 2009	352	AAC/CAT	318	Asn/His	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	embC T270I
EMB	embB	Srivastava S JMM 2009	953	AAC/AGC	318	Asn/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, V377G, E378A, Y384N, N400K, V452L
EMB	embB	Srivastava S JMM 2009	954	AAC/AAA	318	Asn/Lys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, N368A, S380R, P397Q, G459A, R460C; embR T32P, D53H"
EMB	embB	Sugawara I Jpn J Infect Dis 2005	955	TAT/GAT	319	Tyr/Cys											
EMB	embB	Chan RCY JAC 2007	955	TAT/AAT	319	Tyr/Asn											
EMB	embB	Sugawara I Jpn J Infect Dis 2005	956	TAT/TGT	319	Tyr/Cys											
EMB	embB	Plinke C AAC 2006	956	TAT/TCT	319	Tyr/Ser	2001	"EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159."	Germany	Sequencing	ERDR	EHR	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Lee HY YonseiMedJ 2002	965	TAT/TGT	322	Tyr/Cys	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	South Korea	Sequencing	ERDR	E	4ug/ml	Proportion method	21/26	1/0	Ala314Gly on embB.
EMB	embB	Ramaswamy SV AAC 2000	982	GAT/TAT	328	Asp/Tyr	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Ala201Thr in embA, Tyr334His in embB.
EMB	embB	Ramaswamy SV AAC 2000	983	GAT/GGT	328	Asp/Gly	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embB	Plinke C AAC 2006	983-984	GAT/GTG	328	Asp/Val	2001	"EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159."	Germany	Sequencing	ERDR	EHR	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Escalante P TuberLung Dis 1998	983	del A	328	Frameshift	"Published 1998; isolates collected 1995-1996"	Isolates from patients with pulmonary, suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29	Peru	Sequencing	ERDR	E	N.S.	Proportion method	40146	1/0	None in region amplified (see Gene coverage).
EMB	embB	Sreevatsan S AAC 1997	988	TTC/GTC	330	Phe/Val	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	69/99	1/0	
EMB	embB	Srivastava S JMM 2009	991-993	GGC/CGT	331	Gly/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	ER	16ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, G374V, G401S; embC I297T; embR D223E"
EMB	embB	Lee HY YonseiMedJ 2002	991	GAT/TAT	331	Asp/Tyr	Published 2002	Clinical isolates obtained from the Korean Institute of TB, Seoul. N=26.	Korea	Sequencing	ERDR	E	4ug/ml	Proportion method	21/26	1/0	None in region amplified (see Gene coverage). 
EMB	embB	Plinke C AAC 2006	994-995	TGG/CTG	332	Trp/Leu	2001	"EMB-R isolates (n=101; 72 of them also R to RIF); MDR but not EMB-R isolates (n=33); and fully susceptible isolates (n=25). Total N=159."	Germany	Sequencing	ERDR	EHR	N.S.	Proportion method, BACTEC 460	101/159	1/0	None in region amplified (see Gene coverage). R/Tot and R/S calculated from Table 1.
EMB	embB	Sugawara I Jpn J Infect Dis 2005	997	TAT/CAT	333	Tyr/His											
EMB	embB	Ramaswamy SV AAC 2000	1000	TAC/CAC	334	Tyr/His	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Ala201Thr in embA, Asp328Tyr in embB.
EMB	embB	Escalante P TuberLung Dis 1998	1040	AGT/ACT	347	Ser/Thr	"Published 1998; isolates collected 1995-1996"	Isolates from patients with pulmonary, suspected drug-resistant TB on the basis of failure of treatment with first-line drugs. N=29	Peru	Sequencing	ERDR	E	N.S.	Proportion method	40146	1/0	None in region amplified (see Gene coverage).
EMB	embB	Srivastava S JMM 2009	1040	AGT/ATT	347	Ser/Ile	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368D, R460L; embC I297T; embR R230W, I396T"
EMB	embB	Srivastava S JMM 2009	1066-1068	GCG/TTT	356	Ala/Phe	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, L359I, R367P; embC G288V, M310K, Y327N"
EMB	embB	Srivastava S JMM 2009	1066-1068	GCG/AGC	356	Ala/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, P371R, E378K; embR R230W, L292M, L303E"
EMB	embB	Srivastava S JMM 2009	1067	GCG/GTG	356	Ala/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, S366P, W395R, A434G, V435G, V436G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1069-1071	GCG/AGC	357	Ala/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A379T; embC V287F, Y309N; embR L320V S326N, V350G, H351Q, R356G, I369T"
EMB	embB	Srivastava S JMM 2009	1070	GCG/GTG	357	Ala/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, L359I, E378A, A379D, Y384N, A388G, N399D, G406P; embC A247P, T270I, I297T"
EMB	embB	Srivastava S JMM 2009	1073-1074	GGC/GTG	358	Gly/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368Q, S380D, P397T, G406D, G448V; embC I287L, W326R"
EMB	embB	Srivastava S JMM 2009	1075-1077	CTG/ATT	359	Leu/Ile	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, A356F, R367P; embC G288V, M310K, Y327N"
EMB	embB	Srivastava S JMM 2009	1078	GTG/ATG	360	Val/Met	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	ER	16ug/ml	Proportion method, E-Test	44/44	1/0	"embB G331R, G374V, G401S; embC I297T; embR D223E"
EMB	embB	Srivastava S JMM 2009	1096	AGC/CCG	366	Ser/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, W395R, A434G, V435G, V436G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1100-1101	CGT/CCG	367	Arg/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	96ug/ml	Proportion method, E-Test	44/44	1/0	"embB H312R, S317T, A356F, L359I; embC G288V, M310K, Y327N"
EMB	embB	Srivastava S JMM 2009	1102-1104	GAA/CAG	368	Glu/Gln	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, S380D, P397T, G406D, G448V; embC I287L, W326R"
EMB	embB	Srivastava S JMM 2009	1104	GAA/GAT	368	Glu/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB S347I, R460L; embC I297T; embR R230W, I396T"
EMB	embB	Srivastava S CurrMicro 2006	1103-1104	GAA/GCG	368	Glu/Ala	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	32ug/ml	Proportion method	23/23	1/0	Met306Val, Ser380Arg, and Pro397Gln on embB. 
EMB	embB	Srivastava S JMM 2009	1105	GTG/CTG	369	Val/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	12ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306I; embC L251R, A354G, T270I"
EMB	embB	Srivastava S JMM 2009	1106	GTG/GCG	369	Val/Ala	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A310R, D311R, P375A, F398Y, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S JMM 2009	1109-1110	CTG/CGT	370	Leu/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB V377M, E378A, F398H, N399H, E405P, G406A
EMB	embB	Srivastava S JMM 2009	1112-1113	CCG/CGT	371	Pro/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, A356S, E378K; embR R230W, L292M, L303E"
EMB	embB	Srivastava S JMM 2009	1121-1122	GGC/GTG	374	Gly/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	"embC W395C, N400P; embC G288W, V303G; embR A187V, R230W, I369T"
EMB	embB	Srivastava S JMM 2009	1123-1124	CCG/GCG	375	Pro/Ala	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A310R, D311R, V369A, F398Y, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S JMM 2009	1129	GTG/ATG	377	Val/Met	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB L370R, E378A, F398H, N399H, E405P, G406A
EMB	embB	Srivastava S JMM 2009	1130-1131	GTG/GGC	377	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, E378A, Y384N, N400K, V452L
EMB	embB	Srivastava S JMM 2009	1132	GAA/AAA	378	Glu/Lys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, A356S, P371R; embR R230W, L292M, L303E"
EMB	embB	Srivastava S CurrMicro 2006	1103-1104	GAA/GCG	378	Glu/Ala	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method	23/23	2/0	Both of these isolates were mutated at embB Asp299Glu. One was also mutated at embB Pro446His and Ile465Asp, as well as embC Thr270Ile and 254 Synonymous (GCC/GCG). The other isolate was mutated at embBArg469Pro and Arg 471Pro. R/Tot and R/S calculated fr
EMB	embB	Srivastava S JMM 2009	1135-1137	GCG/ACC	379	Ala/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S; embC V287F, Y309N; embR L320V S326N, V350G, H351Q, R356G, I369T"
EMB	embB	Srivastava S JMM 2009	1136-1137	GCG/GAT	379	Ala/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, A357V, L359I, E378A, Y384N, A388G, N399D, G406P; embC A247P, T270I, I297T"
EMB	embB	Srivastava S CurrMicro 2006	1138-1140	AGC/CGT	380	Ser/Arg	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	 32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Pro397Gln on embB. R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	1139	AGC/AAC	380	Ser/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, P397T, G406D, G448V; embC I287L, W326R"
EMB	embB	Srivastava S JMM 2009	1150-1152	TAT/AAC	384	Tyr/Asn	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, V377G, E378A,  N400K, V452L
EMB	embB	Srivastava S JMM 2009	1163-1164	GCG/GGC	388	Ala/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, A357V, L359I, E378A, A379D, Y384N, N399D, G406P; embC A247P, T270I, I297T"
EMB	embB	Srivastava S JMM 2009	1183-1185	TGG/CGT	395	Trp/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, S366P, A434G, V435G, V436G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1185	TGG/TGC	395	Trp/Cys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	"embC G374V, N400P; embC G288W, V303G; embR A187V, R230W, I369T"
EMB	embB	Srivastava S JMM 2009	1189-1190	CCG/ACC	397	Pro/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, S380D, G406D, G448V; embC I287L, W326R"
EMB	embB	Srivastava S CurrMicro 2006	1190	CCG/CAG	397	Pro/Gln	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	 32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.
EMB	embB	Srivastava S JMM 2009	1192-1193	TTT/CAT	398	Phe/His	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB L370R, V377M, E378A, N399H, E405P, G406A
EMB	embB	Srivastava S JMM 2009	1193	TTT/TAT	398	Phe/Tyr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A310R, D311R, V369A, P375A, P461S; embC T270I; embR G240R"
EMB	embB	Srivastava S JMM 2009	1195-1196	TTT/GAT	399	Asn/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, A357V, L359I, E378A, A379D, Y384N, A388G, G406P; embC A247P, T270I, I297T"
EMB	embB	Srivastava S JMM 2009	1195-1196	TTT/CAT	399	Asn/His	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB L370R, V377M, E378A, F398H, E405P, G406A
EMB	embB	Srivastava S JMM 2009	1198-1200	AAC/CCG	400	Asn/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EH	4ug/ml	Proportion method, E-Test	44/44	1/0	"embC G374V, W395C; embC G288W, V303G; embR A187V, R230W, I369T"
EMB	embB	Srivastava S JMM 2009	1200	AAC/AAA	400	Asn/Lys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, E378A, Y384N, V452L
EMB	embB	Srivastava S JMM 2009	1203	ACG/ACA	401	Gly/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	ER	16ug/ml	Proportion method, E-Test	44/44	1/0	"embB G331R, G374V, G374V; embC I297T; embR D223E"
EMB	embB	Srivastava S JMM 2009	1213-1214	GAA/CCG	405	Glu/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	embB L370R, V377M, E378A, F398H, N399H, G406A
EMB	embB	Srivastava S JMM 2009	1216	GGC/CCG	406	Gly/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	"embB A356F, A357V, L359I, E378A, A379D, Y384N, A388G, N399D; embC A247P, T270I, I297T"
EMB	embB	Ramaswamy SV AAC 2000	1216	GGC/AGC	406	Gly/Ser	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	-43 CG deletion in embA.
EMB	embB	Ramaswamy SV AAC 2000	1216	GGC/TGC	406	Gly/Cys	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30-50ug/ml	BACTEC 460, agar diffusion method	75/108	2/0	
EMB	embB	Srivastava S JMM 2009	1217	GGC/GAT	406	Gly/Asp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, S380D, P397T, G448V; embC I287L, W326R"
EMB	embB	Ramaswamy SV AAC 2000	1217	GGC/GAC	406	Gly/Asp	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Asp4Asn in embA
EMB	embB	Ramaswamy SV AAC 2000	1217	GGC/GCC	406	Gly/Ala	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	20ug/ml	BACTEC 460, agar diffusion method	75/108	2/0	In one of the isolates, -11 C/A in embA and Met306Ile in embB.
EMB	embB	Srivastava S CurrMicro 2006	1190	GGC/GCG	406	Gly/Ala	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	 32ug/ml	Proportion method	23/23	1/0	Met306Val, Glu368Ala, and Ser380Arg on embB. R/Tot and R/S calculated from Table 1.
EMB	embB	Lee AS AAC 2004	1269	ATG/ATA	423	Met/Ile	Published 2004	EMB-R (n=25) and EMB-S (n=20) isolates. Total N=45.	Singapore	Sequencing	Whole gene	EI	N.S.	BACTEC 460	25/45	1/0	None in region amplified (see Gene coverage). 
EMB	embB	Srivastava S JMM 2009	1289	CCG/CTG	430	Pro/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB G406D, A431T; embC I297T"
EMB	embB	Srivastava S JMM 2009	1291-1293	GCG/ACC	431	Ala/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB G406D,P430L; embC I297T"
EMB	embB	Srivastava S JMM 2009	1301-1302	GCG/GGC	434	Arg/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, S366P, W395R, V435G, V436G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1304-1305	GTG/GGC	435	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, S366P, W395R, A434G, V436G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1307-1308	GTG/GGC	436	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, S366P, W395R, A434G, V435G, T437A; embC T270I"
EMB	embB	Srivastava S JMM 2009	1309-1311	ACC/GCG	437	Thr/Ala	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, A356V, S366P, W395R, A434G, V435G, V436G; embC T270I"
EMB	embB	Srivastava S CurrMicro 2006	1337-1338	CCG/CAT	446	Pro/His	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	"Asp299Glu, Glu378Ala, and Ile465Asp in embB; Thr270Ile and 254 Synonymous (GCC/GCG) in embC. R/T and R/S calculated from Table 1."
EMB	embB	Srivastava S JMM 2009	1343-1344	GGC/GTG	448	Gly/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	3ug/ml	Proportion method, E-Test	44/44	1/0	"embB G358V, E368Q, S380D, P397T, G406D; embC I287L, W326R"
EMB	embB	Srivastava S JMM 2009	1354	GTG/CTG	452	Val/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	256ug/ml	Proportion method, E-Test	44/44	1/0	embB L239P, Y315L, N318S, E378A, Y384N, N400K
EMB	embB	Srivastava S JMM 2009	1376-1377	GGC/GCG	459	Gly/Ala	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, N318K, N368A, S380R, P397Q,  R460C; embR T32P, D53H"
EMB	embB	Srivastava S JMM 2009	1378-1380	CGT/TGC	460	Arg/Cys	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368A, S380R, P397Q; embC A244T, G288W, V303G embR L172R"
EMB	embB	Srivastava S JMM 2009	1379-1380	CGT/CTG	460	Arg/Leu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB S347I, E368D; embC I297T; embR R230W, I396T"
EMB	embB	Srivastava S JMM 2009	1381-1383	CCG/AGC	461	Pro/Ser	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A310R, D311R, V369A, P375A, F398Y; embC T270I; embR G240R"
EMB	embB	Srivastava S CurrMicro 2006	1393-1394	ATT/GAT	465	Ile/Asp	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	"Asp299Glu, Glu378Ala, and Pro446His in embB; Thr270Ile and 254 Synonymous (GCC/GCG) in embC. R/T and R/S calculated from Table 1."
EMB	embB	Srivastava S CurrMicro 2006	1406-1407	CGT/CCG	469	Arg/Pro	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	Asp299Glu, Glu378Ala, and Arg471Pro in embB. R/T and R/S calculated from Table 1.
EMB	embB	Srivastava S CurrMicro 2006	1412-1413	CGT/CCG	471	Arg/Pro	Published 2006	"Isolates from patients with pulmonary tuberculosis; all samples EMB-R. N=23"	India	Sequencing	ERDR	E, EHR, HR, EH	2ug/ml	Proportion method, E-Test	23/23	1/0	Asp299Glu, Glu378Ala, and Arg469Pro in embB. R/T and R/S calculated from Table 1.
EMB	embB	Ramaswamy SV AAC 2000	1490	CAG/CGG	497	Gln/Arg	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30-50ug/ml	BACTEC 460, agar diffusion method	75/108	3/0	In one of the isolates: -12 C/T in embA, Ser501Trp in iniA.
EMB	embB	Ramaswamy SV AAC 2000	1490	CAG/AAG	497	Gln/Lys	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30-50ug/ml	BACTEC 460, agar diffusion method	75/108	2/0	"-12 C/T in embA at MIC=30ug/ml; -89 C/T in iniB at MIC>50ug/ml."
EMB	embB	Sreevatsan S AAC 1997	1889	ACC/ATC	630	Thr/Ile	Published 1997	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=118"	USA, Mexico, Europe, Yemen, the Philippines, Japan, India	PCR-SSCP, Sequencing	Whole gene	E	>40ug/ml	BACTEC 460, agar diffusion method	69/99	2/0	
EMB	embB	Lee AS AAC 2004	1975	GCG/ACG	659	Ala/Thr	Published 2004	EMB-R (n=25) and EMB-S (n=20) isolates. Total N=45.	Singapore	Sequencing	Whole gene	ES	N.S.	BACTEC 460	25/45	0/1	None in region amplified (see Gene coverage). 
EMB	embB	Ramaswamy SV AAC 2000	2234	GGC/GAC	745	Gly/Asp	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Gly308Arg in iniA
EMB	embB	Ramaswamy SV AAC 2000	2876	GAC/GCC	959	Asp/Ala	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embB	Ramaswamy SV AAC 2000	2999	ATG/AGG	1000	Met/Arg	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embB	Ramaswamy SV AAC 2000	3070	GAC/AAC	1024	Asp/Asn	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10-50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
																	
	embR (Rv1267c): putative regulator																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	embR	Ramaswamy SV AAC 2000	-273	ins A	-273	intergenic	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	20-40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embR	Srivastava S JMM 2009	20-21	GTG/GGC	7	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	48ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M; embC A247P, I297L, W326R"
EMB	embR	Srivastava S JMM 2009	94-96	ACC/CCG	32	Thr/Pro	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, N318K, E368A, S380R, P397Q, G459A, R460C; embR D53H"
EMB	embR	Srivastava S JMM 2009	157	GAT/CAT	53	Asp/His	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	32ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, N318K, E368A, S380R, P397Q, G459A, R460C; embR T32P"
EMB	embR	Srivastava S JMM 2009	329-330	TGC/TAT	110	Cys/Tyr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	8ug/ml	Proportion method, E-Test	44/44	1/0	embC G288W, V303G
EMB	embR	Srivastava S JMM 2009	515-516	CTG/CGT	172	Leu/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB E368A, S380R, P397Q, R460C; embC A244T, G288W, V303G"
EMB	embR	Srivastava S JMM 2009	527	GCG/GTG	176	Ala/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB V360M, A431T; embC G272S, H285Y, M300R, A307T; embR I369T"
EMB	embR	Srivastava S JMM 2009	556-558	CGT/GGC	186	Arg/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	24ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, E368A, S380R, P397Q, R460C; embC I297T; embR S188R, E200A, L211M"
EMB	embR	Srivastava S JMM 2009	559-560	GCG/GTG	187	Ala/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB G374V, W395C, N400P; embC G288W, V303G; embR R230W, I369T"
EMB	embR	Srivastava S JMM 2009	541-543	AGC/CGT	188	Ser/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, E378A, R469P, R471P; embR L211M, L320V"
EMB	embR	Srivastava S JMM 2009	599-600	GAA/GCG	200	Glu/Ala	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	24ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306L, E368A, S380R, P397Q, R460C; embC I297T; embR S186G, S188R, L211M"
EMB	embR	Srivastava S JMM 2009	631	CTG/ATG	211	Leu/Met	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, E378A, R469P, R471P; embR S188R, L320V"
EMB	embR	Srivastava S JMM 2009	669	GAT/GAA	223	Asp/Glu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	16ug/ml	Proportion method, E-Test	44/44	1/0	"embB G331R, V360M, G374V, G401S; embC I297T"
EMB	embR	Srivastava S JMM 2009	688-690	CGT/TGG	230	Arg/Trp	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB S347I, E368D, R460L; embC I297T; embR I396T"
EMB	embR	Srivastava S JMM 2009	718-720	GGC/CGT	240	Gly/Arg	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	128ug/ml	Proportion method, E-Test	44/44	1/0	"embB M306V, V309G, A319R, D311R, V369A, P375A, F398Y, P461S;  embC T270I"
EMB	embR	Srivastava S JMM 2009	874	CTG/ATG	292	Leu/Met	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, A356S, P371R, E378K;  embR R230W, L303E"
EMB	embR	Srivastava S JMM 2009	907-909	CTG/GAA	303	Leu/Glu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	6ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, A356S, P371R, E378K;  embR R230W, L292M"
EMB	embR	Srivastava S JMM 2009	958	CTG/GTG	320	Leu/Val	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB D299E, E378A, R469P, R471P; embR S188R, L211M"
EMB	embR	Srivastava S JMM 2009	977	AGC/AAC	326	Ser/Asn	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F, Y309N; embR L320V, V350G, H351Q, R356G, I369T"
EMB	embR	Srivastava S JMM 2009	1049-1050	GTG/GGC	350	Val/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, H351Q, R356G, I369T"
EMB	embR	Srivastava S JMM 2009	1053	CAT/CAG	351	His/Glu	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, R356G, I369T"
EMB	embR	Srivastava S JMM 2009	1066-1068	CGT/GGC	356	Arg/Gly	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, H351Q, I369T"
EMB	embR	Srivastava S JMM 2009	1106-1107	ATT/ACC	369	Ile/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	2ug/ml	Proportion method, E-Test	44/44	1/0	"embB A357S, A379T; embC V287F, Y309N; embR L320V, S326N, V350G, H351Q, R356G"
EMB	embR	Ramaswamy SV AAC 2000	1136	CAG/CGG	379	Gln/Arg	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	20-40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
EMB	embR	Srivastava S JMM 2009	1187-1188	ATT/ACC	396	Ile/Thr	Published 2009	44 isolates from unrelated adult patients with pulmonary TB. 	India	Sequencing	Whole gene	EHR	4ug/ml	Proportion method, E-Test	44/44	1/0	"embB S347I, E368D, R460L; embC I297T; embR R230W"
																	
																	
	Rv3124: putative regulator																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	Rv3124	Ramaswamy SV AAC 2000	-16	A/G		intergenic	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	10ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Met306Ile in embB.
EMB	Rv3125	Ramaswamy SV AAC 2000			54	Pro/Ser	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Arg728Gln in embC, -16 C/T in embA, and  Met306Ile in embB.
EMB	Rv3126	Ramaswamy SV AAC 2000			276	Leu/Arg	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Asn396Asp in embC, Gly350Asp and Pro913Ser in embA and -12 G deletion in Rv0340.
																	
	Rv0340: EMB-induced gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	Rv0340	Ramaswamy SV AAC 2000	-24	del G			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	75/108	1/0	Asn396Asp in embC, Gly350Asp and Pro913Ser in embA, and Leu276Arg in Rv3124.
EMB	Rv0340	Ramaswamy SV AAC 2000			173	Thr/Met	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	N.S.	BACTEC 460, agar diffusion method	75/108	3/2	"All three resistant isolates also had resistance-associated mutations in embC (n=1) or embB (n=3); see Note."
																	
	iniB: INH- and EMB-induced gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	iniB	Ramaswamy SV AAC 2000	-89	C/T			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Gln497Lys in embB.
EMB	iniB	Ramaswamy SV AAC 2000			47	Ala/Thr	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	30ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	
																	
	iniA: INH- and EMB-induced gene														75/108	7/0	
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	iniA	Ramaswamy SV AAC 2000			308	Gly/Arg	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Gly745Asp in embB
EMB	iniA	Ramaswamy SV AAC 2000			501	Ser/Trp	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	"Two of the seven isolates had the single mutation only, with MICs>50ug/ml; the other five strains each had one or more of the following mutations, with MICs of 5-30ug/ml: one with -12 C/T in embA and Gln497Arg in embB; one with -16 C/G in embA; one with M"
																	
	iniC: INH- and EMB-induced gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	iniC	Ramaswamy SV AAC 2000			248	Pro/Ala	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	5ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Ser501Trp in iniA.
EMB	iniC	Ramaswamy SV AAC 2000			351	Gln/STOP	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	40ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Pro913Ser in embA.
																	
	rmlA2: EMB-induced gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	rmlA2	Ramaswamy SV AAC 2000			152	Asp/Asn	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	Met305Ile in embB.
																	
	rmlD: EMB-induced gene																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
EMB	rmlD	Ramaswamy SV AAC 2000	-71	G/T			Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	2/0	
EMB	rmlD	Ramaswamy SV AAC 2000			257	Ser/Pro	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	No other resistance-associated mutations in the other 11 genes sequenced in the paper.
EMB	rmlD	Ramaswamy SV AAC 2000			284	Thr/Lys	Published 2000	"Isolates from patients with pulmonary and extrapulmonary TB; resistant and susceptible isolates obtained from same areas. N=108"	USA, Russia	Sequencing	Whole gene	E	>50ug/ml	BACTEC 460, agar diffusion method	75/108	1/0	

ETHIONAMIDE [ETH]																	
																	
	inhA																
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations
ETH	inhA	Lee H IntJTuberLungDis 2000	280	TCG/GCG	94	Ser/Ala	Published 2000	"Clinical M.tb isolates; 12 INH-R only and 12 INH-R + ETH-R; none were involved in a single major outbreak of the disease (and so less likely to be related). N=24"	Korea	Sequencing	nt 174-384	HEth, HREth	N.S.	Proportion method.	12/24	0/0	Mutations in the regulatory region (mabA) were found.
ETH	inhA	Ristow M Lancet 1995	304-305	AT/CC	95	Ile/Pro	Published 1995	Clinical M.tb isolates, including pan-susceptible (n=5), INH-R only (n=10), ETH-R only (n=4), INH-R and ETH-R (n=6), and resistant to INH and two or more other drugs (n=22). Total N=47	Germany, Nepal	Sequencing	region around inhA 94	MDR	N.S.	Proportion method.	32/47	7/0	None found in the fragment analyzed.
																	
	ethA/etaA (Rv3854c)																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
ETH	ethA/etaA	DeBarber AE PNAS 2000	65	del 1nt		frameshift	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	110	del A		frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	DeBarber AE PNAS 2000	127	GGC/TGC	43	Gly/Cys	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa.	Sequencing	Whole gene	HEth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	127	GGC/AGC	43	Gly/Ser	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	DeBarber AE PNAS 2000	152	CCC/CTC	51	Pro/Leu	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	EthL	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	167	GAC/GCC	55	Asp/Ala 	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Gly279Asp, mabA -15 C/T
ETH	ethA/etaA	DeBarber AE PNAS 2000	173	GAC/GCC	58	Asp/Ala	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	DeBarber AE PNAS 2000	250	TAC/GAC	84	Tyr/Asp	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	338	ins A		frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	100ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	DeBarber AE PNAS 2000	557	ACG/AAG	186	Thr/Lys	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	Eth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	667	GAG/AAG	223	Glu/Lys	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	mabA -15 C/T
ETH	ethA/etaA	Morlock GP AAC 2003	703	del T		frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	Morlock GP AAC 2003	736	CAG/TAG	246	Gln/STOP	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	mabA -15 C/T
ETH	ethA/etaA	Morlock GP AAC 2003	768	del G		frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	DeBarber AE PNAS 2000	811	ins 1 bp		frameshift	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	HEth	N.S.	Proportion method.	11/15	1/0	None found in region analyzed.
ETH	ethA/etaA	DeBarber AE PNAS 2000	1025	ACG/AAG	342	Thr/Lys	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	HEth	N.S.	Proportion method.	11/15	3/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	1013	ATC/AGC	338	Ile/Ser	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr, mabA -15 C/T
ETH	ethA/etaA	DeBarber AE PNAS 2000	1141	GCC/CCC	381	Ala/Pro	Published 2000	"Clinical isolates of MDR-M.tb (n=14); one ETA-monoresistant strain generated in vitro. N=15."	South Africa	Sequencing	Whole gene	HEth	N.S.	Proportion method.	11/15	2/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	1154	GGC/GAC	385	Gly/Asp	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr, mabA -15 C/T
ETH	ethA/etaA	Morlock GP AAC 2003	1174	ACG/GCG	392	Thr/Ala	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	Morlock GP AAC 2003	1238	GGT/GAT	413	Gly/Asp	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	1290	del C		Frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	katG Ser315Thr
ETH	ethA/etaA	Morlock GP AAC 2003	1322-1323	del GC		Frameshift	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	>200ug/ml	Microplate almar blue assay	41/41	1/0	None found in region analyzed.
ETH	ethA/etaA	Morlock GP AAC 2003	1387	CGT/AGT	463	Arg/Ser	Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole gene	HEth	50ug/ml	Microplate almar blue assay	41/41	1/0	katG Trp341Ser, mabA -15 C/T
																	
																	
	mabA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
ETH	mabA	Lee H IntJTuberLungDis 2000	-15	C/T 			Published 2000	"Clinical M.tb isolates; 12 INH-R only and 12 INH-R + ETH-R; none were involved in a single major outbreak of the disease (and so less likely to be related). N=24"	South Korea	Sequencing	Whole	HEth, HREth	40-80ug/ml	Proportion method.	12/24	12/2	No mutation in inhA94 found.
ETH	mabA	Morlock P AAC 2003	-17	G/T			Published 2003	ETH-R clinical isolates. N=41	USA, Russia, Brazil	Sequencing	Whole	EthH	100ug/ml	Microplate almar blue assay	41/41	1/0	inhA Ile21Thr

FLUOROQUINOLONES [FLQ]																	
																	
	gyrA																
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC (ug/ml)	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations	
FLQ	gyrA	Shi R JCM 2006	220	GCC/TCC	74	Ala/Ser	2002-2003		China	Sequencing 	227bp QRDR gyrA	OFX	OFL 2-32	Absolute concentration method 	87/109	10/0	gyrA: Asp94Gly
FLQ	gyrA	Aubry A AAC 2006	238	ACC/GCC	80	Thr/Ala	Published 2006		France	Sequencing	QRDRs on gyrA and gyrB	The Thr80Ala mutants are resistant to all 5 drugs. The Thr80Ala + Ala90Gly double mutants are hypersusceptible to all 5 drugs, with MICs significantly lowered compared to H37Rv.		Proportion method 	14/15	Single mutants: 2/0. Double mutants: 0/4.	gyrA: Ala90Val
FLQ	gyrA	Matrat S AAC 2006 Dec	263	GGC/GCC	88	Gly/Ala	Published 2006 		N.S.	Sequencing	nt 247-282 of gyrA 	"Resistant to: sparfloxacin, gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ofloxacin, enoxacin, temafloxacin, flumequine, oxolinic acid, nalidixic acid, pipemidic acid; and to coumarin. "	2x to 16x higher than WT (H37Rv) MICs for the same drugs.	Proportion method 	39938	5/0	N.S.
FLQ	gyrA	Von Groll A AAC 2009	265	GAC/AAC	89	Asp/Asn	Published 2006 		N.S.	Sequencing	nt 247-282 of gyrA 	"Resistant to: sparfloxacin, gemifloxacin, gatifloxacin, moxifloxacin, levofloxacin, ofloxacin, enoxacin, temafloxacin, flumequine, oxolinic acid, nalidixic acid, pipemidic acid; and to coumarin. "	2x to 16x higher than WT (H37Rv) MICs for the same drugs.	Proportion method 	39938	5/0	N.S.
FLQ	gyrA	Takiff HE AAC 1994	269	GCG/GTG	90	Ala/Val	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4-8	BACTEC 460	3/54	3/0	gyrA: Ser95Thr
FLQ	gyrA	Aubry A AAC 2006	269	GCG/GGG	90	Ala/Gly	Published 2006		France	Sequencing	QRDRs on gyrA and gyrB	Hypersusceptible to all 5 drugs, with MICs significantly lowered compared to H37Rv.	GAT 0.12-0.5, MOX 0.12-0.25, LVX 0.25-1, OFX 0.25-1, and ENX 2-8 ug/ml.	Proportion method	14/15	0/4	gyrA: Thr80Ala
FLQ	gyrA	Takiff HE AAC 1994	271	TCG/CCG	91	Ser/Pro	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4	BACTEC 460	1/54	1/0	gyrA: Ser95Thr
FLQ	gyrA	Takiff HE AAC 1994	280	GAC/AAC	94	Asp/Asn	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 8	BACTEC 460	1/54	1/0	gyrA: Ser95Thr
FLQ	gyrA	Takiff HE AAC 1994	280	GAC/CAC	94	Asp/His	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4	BACTEC 460	1/54	1/0	gyrA: Ser95Thr
FLQ	gyrA	Bravao LTC JCM 2009	280-281	GAC/GTC	94	Asp/Phe	Published 2009		Phillipines	Sequencing	225-bp gyrA QRDR	HROfx	N.S.	Proportion method	9/102	1/0	gyrA: Ser95Thr
FLQ	gyrA	Takiff HE AAC 1994	280	GAC/TAC	94	Asp/Tyr	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 8	BACTEC 460	2/54	2/0	gyrA: Ser95Thr
FLQ	gyrA	Takiff HE AAC 1994	281	GAC/GGC	94	Asp/Gly	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 8	BACTEC 460	5/54	5/0	gyrA: Ser95Thr
FLQ	gyrA	Takiff HE AAC 1994	281	GAC/GCC	94	Asp/Ala	Published 1994		N.S.	PCR-SSCP, Sequencing	320-bp QRDR of gyrA	CIP	CIP: 4	BACTEC 460	1/54	1/0	gyrA: Ser95Thr
FLQ	gyrA	Sulochana S J Chemother 2007	281	GAC/GTC	94	Asp/Val	Published 2007		India	Sequencing	320-bp gyrA QRDR, 360-bp gyrB QRDR	Moderately resistant to OFX.	OFX: 16-64	Absolute concentration method 	71/118	7/0	gyrA: Ser95Thr
FLQ	gyrA	Kapur V Arch PathLabMEd 1995	284	AGC/ACC	95	Ser/Thr											
FLQ	gyrA	Kam KM Microb Drug Res 2006	305	CCC/CAC	102	Pro/His											
FLQ	gyrA	Sulochana S J Chemother 2007	325	CTG/GTG	109	Leu/Val	Published 2007		India	Sequencing	320-bp gyrA QRDR, 360-bp gyrB QRDR	Moderately susceptible to OFX.	OFX: 2	Absolute concentration method 	71/118	0/1	
																	
																	
	gyrB																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations	
FLQ	gyrB	Feuerriegel S AAC 2009	1369	CGT/TGT	457	Arg/Cys	2003-2006	Isolates from a program for the treatment of MDR in Karakalpakstan	Uzbekistan	Sequencing	QRDRs on gyrA and gyrB	OFX	N.S.	BACTEC 460 and MGIT 960	26/49	1/0	
FLQ	gyrB	Duong DA AAC 2009	1373	TCC/TTC	458	Ser/Phe	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB
FLQ	gyrB	Duong DA AAC 2009	1414	GAC/CAC	472	Asp/His	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB
FLQ	gyrB	Aubry A AAC 2006	1414	GAC/CAC	472	Asp/His	Published 2006		France	Sequencing	QRDRs on gyrA and gyrB	Strongly resistant to OFX	OFX: 60ug/ml	N.S.	14/15	1/0	"Ala90Val in gyrA; no other mutations in QRDR of gyrB."
FLQ	gyrB	Pitaksajjakul P Southeast Asian J Trop Med Public Health 2005	1414	GAC/AAC	472	Asp/Asn	Published 2005		Thailand	PCR-SSCP, Sequencing	"320-bp QRDR of gyrA; 429-bp QRDR of gyrB."	INH+RIF+STR+EMB+OFX 	N.S.	Absolute concentration method	35/35	1/0	No further mutations in gyrA or gyrB QRDRs found.
FLQ	gyrB	Duong DA AAC 2009	1414	GAC/AAC	472	Asp/Asn	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA D94A
FLQ	gyrB	Duong DA AAC 2009	1415	GAC/GCC	472	Asp/Ala	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA A90V
FLQ	gyrB	Duong DA AAC 2009	1442	GGT/GCT	481	Gly/Ala	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB
FLQ	gyrB	Lee AS Int J Infect Dis 2002	1514	GAC/GCC	505	Asp/Ala											
FLQ	gyrB	Aubry A AAC 2006	1528	AAC/GAC	510	Asn/Asp	Published 2006		France	Sequencing	QRDRs on gyrA and gyrB	"GAT, MOX, LVX, and OFX; strongly resistant to ENX."	GAT: >1, MOX and LVX: 2, OFX: 4, and ENX: 64	Proportion method	14/15	1/0	No other mutations in QRDR of gyrA or gyrB.	
FLQ	gyrB	Duong DA AAC 2009	1529	AAC/ACC	510	Asn/Thr	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA A90V	
FLQ	gyrB	Mokrousov I AAC 2008	1530	AAC/AAA	510	Gln/Lys	2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	
FLQ	gyrB	Duong DA AAC 2009	1531	ACC/CCC	511	Thr/Pro	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	gyrA A90V	
FLQ	gyrB	Duong DA AAC 2009	1535	GAA/GTA	512	Glu/Val	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB	
FLQ	gyrB	Duong DA AAC 2009	1536	GAA/	512	Glu/Asp	2005-2007		Vietnam	Sequencing	QRDRs on gyrA and gyrB			Proportion method	109/218	1/0	No other mutation in gyrA or gyrB	
FLQ	gyrB	Mokrousov I AAC 2008	1543	GCG/ACG	515	Ala/Thr	2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	
FLQ	gyrB	Mokrousov I AAC 2008	1544	GCG/GTG	515	Ala/Val	2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	
FLQ	gyrB	Mokrousov I AAC 2008	1647	CAA/CAT	549	Gln/His	2004 - 2005		Taiwan	Sequencing	QRDRs on gyrA and gyrB	OFX, CIP, LVX, and MOX. Out of the 14 FQ-R isolates, 6 (42.9%) were resistant to at least one 1st-line drug, while 4 (28.6%) were multidrug-resistant.	OFX: 8, CIP: 5, LVX: 1, and MOX: 1	Modified proportion method	14/420	1/0	No further mutations in gyrA or gyrB QRDRs found.	

ISONIAZID [INH]													Whole gene screened	Resistanttotwodrugs				
													Large proportion of gene screened	Monoresistant				
													Small proportion of gene screened					
		Cloned and sequenced by: Zhang Y Nature 1992 and Zhang Y JB 1993																
	katG	Transformed and restored INH sensitivity by: Zhang Y Mol Micro 1993																
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations	
INH	katG	Baker LV AAC 2005	-1	ins C		Frameshift	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	CCC-CCG substitution at nt 723, Pro-Pro
INH	katG	Gagneux S PLOS Path 2006	1	GTG/TTG or GTG/CTG	1	Val/Leu											
INH	katG	Heym B MolMicro 1995	2	GTG/GCG	1	Val/Ala	1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	Russia	PCR-SSCP, Sequencing	Whole gene	MDR	1	Proportion method	34/37	1/0	
INH	katG	Cockerill FR JID 1995	4	CCC/TCC	2	Pro/Ser	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		0.12	Proportion method		1/0	Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Asn258Ser, Ala264Thr, Tyr337Phe
INH	katG	Siddiqi N AAC 2002	30	del C	10	TRUNC 26aa	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	H,HRO,HR,HROS	10ug/ml R, 1ug/ml I, 2ug/ml O 2ug/ml S	Proportion method	74/126	6/0	R463L KatG, S95T gyrA, H526R rpo, H526Y rpo, D516V rpo, S531L rpo, D94A gyrA, K121K rpsL
INH	katG	Cockerill FR JID 1995		del 8bp	10	Frameshift	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	>32ug/ml	Proportion method		1/0	Ala424Val and Ala550Asp in katG.
INH	katG	Siddiqi N AAC 2002	31	ACC/GCC	11	Thr/Ala	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	3-239,1187-1600	H,R	10ug/ml R, 1ug/ml I	Proportion method	74/126	1/0	R463L KatG, D516G rpo
INH	katG	Siddiqi N AAC 2002	34	ACC/CCC	12	Thr/Pro	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 1187-1600	H	1ug/ml I	Proportion method	74/126	1/0	R463L KatG
INH	katG	Cockerill FR JID 1995	50	AGC/AAC	17	Ser/Asn	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	0.12-1ug/ml	Proportion method			Gly19Asp, Gln224Glu, Ala243Ser, Ala550Asp
INH	katG	Cockerill FR JID 1995	56	GGC/GAC	19	Gly/Asp	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	0.12ug/ml	Proportion method		0/1	Pro2Ser, Ser17Asn, Gln224Glu, Ala243Ser, Ala550Asp
INH	katG	Ramaswamy SV J Med Micro 2004	85-1059	del	29-353	Truncation	1996-1998	Jose Gonzalez hospital Mexico	Mexico	Directed Oligonucleotide array, Sequencing	codon 228-357	H,R,E	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	"nt 1238; T-C rrs "
INH	katG	Siddiqi N AAC 2002	98	ins A	33	Truncation	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HR,HRS	10ug/ml R, 1ug/ml I	Proportion method	74/126	4/0	S531W rpo, H526L rpo, R463L KatG, D516G rpo, H526R rpo
INH	katG	Siddiqi N AAC 2002	103	AAC/GAC	35	Asn/Asp	2002	Clinical isolates from patients referred to hospital.	India	Sequencing.	237bp + 414bp fragments	I,IRSO	>1ug/ml	Proportion method	74/126	2/0	"One mutant at katG Arg463Leu; both mutant at rpoB Asp516Val."
INH	katG	Siddiqi N AAC 2002	109	del G	37	TRUNC 45aa	1995	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HRO,HR	10ug/ml R, 1ug/ml I 2ug/ml O	Proportion method	74/126	2/0	S531W rpo, S95T gyrA, L511L H526R rpo
INH	katG	Secondary Publication: Hazbon MH AAC 2006	114	TGG/TGA	38	Trp/STOP											
INH	katG	Sekigushi J JCM 2007	143	CTG/CAG	48	Leu/Gln	2007	Japan & Poland	Japan	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0	 -15C/T upstream of mabA
INH	katG	Baker LV AAC 2005	149	del A	50	Frameshift	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	ahpC-34A
INH	katG	Pretorius GS AAC 1995	157-168	del CCGTCGCTGACC	52-57	del Ala Val Ala Asp Pro	1995	South Africa Switzerland, USA	USA	PCR-SSCP, Sequencing	1-221, 202-338, 319-558, 541-741, 722-942, 923-1140, 1120-1342, 1323-1526, 1507-1718, 1699-1915, 1896-2115, 2096-2310	HR	1.0 ug/ml	Proportion method	39/69	1/0	
INH	katG	Siddiqi N AAC 2002	181	GCG/ACG	61	Ala/Thr	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HRO	10ug/ml R, 1ug/ml I, 2ug/ml O 	Proportion method	74/126	1/0	R463L KatG, S95T gyrA, S531L rpo
INH	katG	Siddiqi N AAC 2002	185	ins C	62	Truncation	1995-1998	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	HRS,HO,HR	10ug/ml R, 1ug/ml I 2ug/ml O	Proportion method	74/126	3/0	S531W rpo, K121K rpsL, S95T gyrA,H526R rpo
INH	katG	Rouse DA AAC 1995	189	GAC/GAA	63	Asp/Glu	1995	Clinical isolates.	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	50ug/ml	Absolute concentration method.	26/26	1/0	
INH	katG	Marttila HJ AAC 1996	195	ins CCCC	65	Frameshift	1989-1995	Finland	Finland	Sequencing	Whole gene	H	1ug/ml	Disk elution method	54/56	1/0	
INH	katG	Cockerill FR JID 1995	193	GCC/ACC	65	Ala/Thr	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	0.25ug/ml	Proportion method		0/1	Ala66Pro and others in katG.
INH	katG	Cockerill FR JID 1995	196	GCG/CCG	66	Ala/Pro	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	0.25ug/ml	Proportion method		0/1	Ala65Thr, Met126Ile, Ala243Ser, Asn258Ser, Ala264Thr, Tyr337Phe
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	212	ATC/AAC	71	Ile/Asn											
INH	katG	Chan RCY JAC 2007		GAC/GGC	72	Asp/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Secondary Publication: Hazbon MH AAC 2006	214	GAC/AAC	72	Asp/Lys											
INH	katG	Siddiqi N AAC 2002	?	GAC/AAC	73	Asp/Asn	1995	North India hospitals National Mycobacterium Repository	India	Sequencing	nt 3-239 & 1187-1600	H	1ug/ml I	Proportion method	74/126	1/0	R463L KatG
INH	katG	Chan RCY JAC 2007	220	GAC/TAC	74	Asp/Tyr	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Chan RCY JAC 2007	221	GAC/GGC	74	Asp/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Chan RCY JAC 2007	252	ATG/ATA	84	Met/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Gagneux S PLOS Path 2006	253	ACC/CCC	85	Thr/Pro											
INH	katG	Marttila HJ AAC 1998	263	CAG/CGG	88	Gln/Arg											
INH	katG	Cockerill FR JID 1995	270	TGG/TGA	90	Trp/STOP	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		">32; catalase 5 mm"	Proportion method		1/0	none
INH	katG	Ramaswamy SV AAC 2003	271	TGG/CGG	91	Trp/Arg		38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates	USA, Mexico	Sequencing			2	"BACTEC radiometric method; E-test"	38/121	1/0	D3G (srmR homolog)
INH	katG	Gagneux S PLOS Path 2006	281	GAC/GGC	94	Asp/Gly											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	281	GAC/GCC	94	Asp/Ala											
INH	katG	Chan RCY JAC 2007	?	GGC/TGC	96	Gly/Cys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	296	GGG/GAG	99	Gly/Glu											
INH	katG	Rouse et al MM 1996	311	CGG/CTG	104	Arg/Leu	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb					>500	N.S.	n/a	100 fold reduction in peroxidase activity	
INH	katG	Gagneux S PLOS Path 2006	311	CGG/CAG	104	Arg/Gln											
INH	katG	Gagneux S PLOS Path 2006	317	GCG/GTG	106	Ala/Val											
INH	katG	Gagneux S PLOS Path 2006	319	TGG/CGG or TGG/AGG	107	Trp/Arg											
INH	katG	Baker LV AAC 2005	321	TGG/TGA	107	Trp/STOP	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	ahpC-30T
INH	katG	Rouse et al MM 1996	322	CAC/GAC	108	His/Asp	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S	n/a		
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	322,324	CAC/GAA or CAC/GAG	108	His/Glu											
INH	katG	Rouse DA AAC 1995	324	CAC/CAG	108	His/Gln	1995	Washington D.C, Bethesda, South Korea	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	50	Absolute concentration method	26/26	1/0	
INH	katG	Gagneux S PLOS Path 2006	326	GCT/GTT	109	Ala/Val											
INH	katG	Wei CJ AAC 2003	329	GCC/GTC	110	Ala/Val	2003					H					
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	del	113	Frameshift?											
INH	katG	Lavender C AAC 2005	350	GAC/GCC	117	Asp/Ala	2001-2003	Victorian Infectious Diseases Reference Laboratory	Australia	Sequencing	Whole gene	HR	0.4 ug/ml I	BACTEC 	52/104	1/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	del	120	Frameshift?											
INH	katG	Heym B MolMicro 1995	358-369	del	120-123	del	1995	Isolates from Pitries hospital in France 1991-92	Yugoslavia	PCR-SSCP, Sequencing	Whole gene	H		Proportion method	34/37	2/0	
INH	katG	Gagneux S PLOS Path 2006	361	GGC/TGC	121	Gly/Cys											
INH	katG	Marttila HJ AAC 1998	362	GGC/GTC	121	Gly/Val	1993-1995	Clinical isolates	Russia	Sequencing.	Whole gene	HR	N/A	Proportion method	24/27	1/0	Asp516Val in rpoB
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	del	122	Frameshift?											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	del	123	Frameshift?											
INH	katG	Ramaswamy SV AAC 2003	372	ins G	124	Frameshift		38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates	USA, Mexico	Sequencing			>256	BACTEC 460, E-test	38/121	1/0	G-9A (oxyR-ahpC)
INH	katG	Chan RCY JAC 2007	373	GGC/TGC	125	Gly/Cys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Heym B MolMicro 1995	373-375	ins CAT	125	ins His	1995	Isolates from Pitries hospital in France 1991-92	Yugoslavia	PCR-SSCP, Sequencing	Whole gene	H		Proportion method	34/37	1/0	
INH	katG	Cockerill FR JID 1995	378	ATG/ATT, ATG/ATC or ATG/ATA	126	Met/Ile	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		".025; catalase 14 mm"	Proportion method		1/0	"A65T; A66P; A243S; N258S; A264T; Y337F"
INH	katG	Chan RCY JAC 2007	380	CAG/CCG	127	Gln/Pro	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Fang Z JCM 1999	384	CGG/CCG	128	Arg/Pro	1990-1997	Scottish Mycobacterial refererence lab	United Kingdom	PCR-SSCP, Sequencing	2268-2288&2595-2615,  2781-2801&3115-3135, 3366-3386& 3633-3653, 3661-3681& 3973-3993	H,E,R,P,Rifa,Cip,Ami,S,Proth		BACTEC 460	10/715	1/0	Leu511Pro rpoB
INH	katG	Hazbon MH AAC 2006	412	AAC/CAC	138	Asn/His	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing		H	0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	1/0	
INH	katG	Hazbon MH AAC 2006	412	AAC/GAC	138	Asn/Asp	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing		H	0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	2/0	
INH	katG	Hazbon MH AAC 2006	413	AAC/AGC	138	Asn/Ser	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing		H	0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	1/0	
INH	katG	Morlock GP AAC 2003	413	AAC/ACC	138	Asn/Thr	2003	USA,Russia, Brazil	USA, Russia, Brazil	Sequencing	Whole gene	H	>32ug/ml	Microplate alamar blue assay method	17/41	1/0	
INH	katG	Wei CJ AAC 2003	415	GCC/CCC	139	Ala/Pro	2003										
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	418-419?	AGC/GCC?	140	Ser/Ala											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	419	AGC/AAC	140	Ser/Asn	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing			0.2ug/ml proportion method, 0.1 for BACTEC methods	Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	9/0	
INH	katG	Secondary Publication: Hazbon MH AAC 2006	418	AGC/GGC	140	Ser/Gly											
INH	katG	Hai Hua Lin TubercRespirDis 2007	420	AGC/AGA	140	Ser/Arg	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	katG N238K
INH	katG	Sekigushi J JCM 2007	423	TTG/TTC	141	Leu/Phe	2007	Japan & Poland	Japan, Poland	Sequencing	Whole gene			Proportionmethod, BACTEC MGIT 960	38/138	2/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	425	GAC/GCC	142	Asp/Ala											
INH	katG	Gagneux S PLOS Path 2006	428	AAG/ACG	143	Lys/Thr											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	443	CTG/GCG	148	Leu/Ala											
INH	katG	Rouse et al MM 1996	443	CTG/CGG	148	Leu/Arg	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S.	n/a		
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	See Note	CCG/GCG?? See Note	150	Leu/Ala Error? See Note											
INH	katG	Marttila HJ AAC 1998	464	TAC/TCC	155	Tyr/Ser	1993-1995	Russia	Russia	Sequencing.	Whole gene	HRSK	1 ug/ml I, 5 ug/ml R 	Proportionmethod	24/27	1/0	Arg463Leu katG,     Ser 531Leu rpoB
INH	katG	Gagneux S PLOS Path 2006	464	TAC/TGC	155	Tyr/Cys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	3
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	479	TCA/TTA	160	Ser/Leu											
INH	katG	Gagneux S PLOS Path 2006	484	GCG/ACG	162	Ala/Thr											
INH	katG	Cockerill FR JID 1995	506	GGC/GCC	169	Gly/Ala	1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	1ug/ml	Proportion method		1/0	Pro2Ser, Ser17Asn, Met126Ile,  Gln224Glu, Ala264Val, Ala281Val, Try337Cys, Arg463Leu
INH	katG	Secondary Publication: Hazbon MH AAC 2006	514	GCG/ACG	172	Ala/Thr	2006	Australia, Colombia India, Mexica, New York city, Spain & Texas	USA, Spain	HP asay, molecular beacon assay,  Sequencing		H	0.2ug/ml proportion method, 0.1 for BACTEC methods	Agar Proportion method, BACTEC MGIT 960, BACTEC 460	403/1111	2/0	
INH	katG	Chan RCY JAC 2007	515	GCG/GTG	172	Ala/Val	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Chan RCY JAC 2007	528	ATG/ATA	176	Met/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	3
INH	katG	Secondary Publication: Hazbon MH AAC 2006	539	ACG/AAG	180	Thr/Lys											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	See Note	ACG/???	180	Thr/Cys											
INH	katG	Chan RCY JAC 2007	557	GGC/GTC	186	Gly/Val	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Chan RCY JAC 2007	556-557	GGC/CAC	186	Gly/His	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Baker LV AAC 2005	571	TGG/CGG	191	Trp/Arg	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	
INH	katG	Chan RCY JAC 2007	572	del G	191	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Morlock GP AAC 2003	583	G/A	195	Glu/Lys	2003	USA,Russia, Brazil	USA	Sequencing	Whole gene	Eth	1	Microplate alamar blue assay	17/41	0/1	nt 280 T/G inh ORF
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	594	TGG/TGA	198	Trp/STOP											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	598	AAG/TAG	200	Lys/STOP											
INH	katG	Abe C JCM 2008			204	Trp/Arg	Published in 2008		Japan	Sequencing	Whole gene	H		MGIT 960	96/96	1/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	ins	217	Frameshift?											
INH	katG	Chan RCY JAC 2007	654	AAC/AAA	218	Asn/Lys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Cockerill FR JID 1995	670	CAG/GAG	224	Gln/Glu	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		"1; catalase 8 mm"	Proportionmethod		1/0	Pro2Ser, Ser17Asn, Met126Ile, Gly169Ala, Ala264Val, Ala281Val, Try337Cys, Arg463Leu
INH	katG	Cockerill FR JID 1995	670	CAG/GAG	224	Gln/Glu	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	<0.12-1ug/ml	Proportion method		39815	Ala424Glu, Pro429Ser
INH	katG	Ghiladi RA J Am Chem Soc 2005 	686	TAC/TTC	229	Tyr/Phe											
INH	katG	Chan RCY JAC 2007	689	GTG/GCG	230	Val/Ala	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Baker LV AAC 2005	701	GGG/GAG	234	Gly/Glu	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	
INH	katG	Chan RCY JAC 2007	700	GGG/AGG	234	Gly/Arg	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Chan RCY JAC 2007	707	AAC/ACC	236	Asn/Thr	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Hai Hua Lin TubercRespirDis 2007	714	AAC/AAG	238	Asn/Lys	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	katG S140R
INH	katG	Baker LV AAC 2005	723	CCC/CCG	241	Pro/Pro	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	2/0	
INH	katG	Cockerill FR JID 1995	727	GCC/TCC	243	Ala/Ser	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		"0.12; catalase 28mm"	"Middlebrook 7H11 agar; 1% Proportion method"		1/0	Pro2Ser, Ser17Asn, Gly19Asp, Gln224Glu, Ala550Asp
INH	katG	Ramaswamy SV J Med Micro 2004	745	CGC/TGC	249	Arg/Cys	1996-1998	Jose Gonzalez hospital Mexico	Mexico	Directed Oligonucleotide array,  Sequencing	codon 228-357	HRSE	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	2/0	His445Tyr rpoB, Lys43Arg rpsL, Met306Ile embB 
INH	katG	Gagneux S PLOS Path 2006	752	ACG/ATG	251	Thr/Met											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	754	TTT/CTT	252	Phe/Leu											
INH	katG	Sekigushi J JCM 2007	770	ATG/ACG	257	Met/Thr	2007	Japan & Polan	Japan, Poland	Multiplex  Sequencing	Whole gene			Middlebrook 7H10 agar medium method Ogawa egg based medium method, Rapid broth method(BACTEC)	38/138	1/0	R463L V780P katG, -15C/T upstream of mabA
INH	katG	Lavender C AAC 2005	771	ATG/ATT	257	Met/Ile	2001-2003	Victorian Inf DiseaseReference Lab	Australia	Multiplex allele specific PCR Assay	Whole gene	HR	0.1ug/ml I, 1ug/ml R	BACTEC MGIT960	52/104	1/0	
INH	katG	Cockerill FR JID 1995	773	AAC/AGC	258	Asn/Ser	1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	0.25ug/ml	Proportion method		0/1	Pro2Ser, Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Ala264Thr, Tyr337Phe
INH	katG	Rouse DA AAC 1995	785	ACA/AGA	262	Thr/Arg	1995	washington DC, Bethesda, South Korea, 	USA, South Korea	PCR-SSCP, Sequencing	Whole gene	H	1 ug/ml	Absolute concentration method	26/26	1/0	
INH	katG	Cockerill FR JID 1995	790	GCG/ACG	264	Ala/Thr	1995	clinical strains of mtb	USA, Japan	Sequencing	Whole gene		"0.25; catalase 14mm"	"Middlebrook 7H11 agar; 1% Proportion method"		1/0	Pro2Ser, Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Asn258Ser, Tyr337Phe
INH	katG	Chan RCY JAC 2007		del G	268	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Pretorius GS AAC 1995	820	ACC/GCC	275	Thr/Ala	1995	South Africa Switzerland, USA	South Africa, Switzerland	PCR-SSCP, Sequencing	Whole gene?	HR,HRSEEryB	10 & >2.5 ug/ml	Agar dilution method	39/69	2/0	
INH	katG	Heym B MolMicro 1995	823	ACC/CCC	275	Thr/Pro	1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	France	PCR-SSCP, Sequencing	Whole gene	HMDR	> 10 ug/ml	Proportion method	34/37	1/0	
INH	katG	Ramaswamy SV J Med Micro 2004	823	ACC/TCC	275	Thr/Ser	1996-1998	Jose Gonzalez hospital Mexico	Mexico	Directed Oligonucleotide array, Sequencing	codon 228-357	HR	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	His445Asp rpoB, 
INH	katG	Morlock GP AAC 2003	836	GGC/GAC	279	Gly/Asp	2003	United States, Russia, Brazil	Brazil	Sequencing	fragment encompassing codons 249 to 342	HEth	>32 I, >200 Eth	Microplate alamar blue assay	17/41	1/0	D55/A ethA,L44L inhA ORF, C(-15)T inhA regulator
INH	katG	Gagneux S PLOS Path 2006	839-840	CCG/CAT or CCG/CAC	280	Pro/His											
INH	katG	Cockerill FR JID 1995	842	GCC/GTC	281	Ala/Val	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	1ug/ml	Proportion method		1/0	Pro2Ser, Ser17Asn, Met126Ile, Gly169Ala, Gln224Glu, Ala264Val, Try337Cys, Arg463Leu
INH	katG	Abe C JCM 2008	854	GGC/GAC	285	Gly/Asp	Published in 2008		Japan	Sequencing	Whole gene	H		MGIT 960	96/96	1/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	ins	289	Frameshift?											
INH	katG	Chan RCY JAC 2007	867	GAG/GAC	289	Glu/Asp	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Fang Z JCM 1999	871	GCT/CCT	291	Ala/Pro	1990-1997	Scottish Mycobacterial refererence lab	United Kingdom	PCR-SSCP, Sequencing		HR		BACTEC 	10/715	1/0	His 526Tyr rpoB
INH	katG	Sekigushi J JCM 2007	884	CAG/CCG	295	Gln/Pro	2007	Japan & Poland	Poland	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0	
INH	katG	Sekigushi J JCM 2007	890	GGC/GTC	297	Gly/Val	2007	Japan & Poland	Poland	Sequencing	Whole gene			Proportion method, BACTEC	38/138	1/0	
INH	katG	Chan RCY JAC 2007	895	GGC/TGC	299	Gly/Cys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	1
INH	katG	Huang WL JCM 2009	896	GGC/GCC	299	Gly/Ala	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Lee ASG AAC 1999		TGG/TAA or TGG/TAG or TGG/TGA	300	Trp/STOP	1994-1996	Central Tuberculosis Lab, Singapore	Singapore	Sequencing	Whole gene	H	0.1 ug/ml	BACTEC 460	160/192		
INH	katG	Marttila HJ AAC 1996	898	TGG/GGG	300	Trp/Gly	1989-1995	Finland	Finland	Sequencing	Whole gene	H	1 ug/ml	Disk elution method	54/56	1/0	
INH	katG	Gagneux S PLOS Path 2006	901-902	ins T	301	Frameshift											
INH	katG	Cockerill FR JID 1995	906	AGC/AGG	302	Ser/Arg	1995	Isolates from the Mayo Clinic	USA	Sequencing	Whole gene	H	8ug/ml	Proportion method		1/0	Ser315Thr and Arg463Leu in katG.
INH	katG	Bolotin S JAC 2009	911	TAT/TCT	304	Tyr/Ser	1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0	
INH	katG	Bostanabad SZ Tuberk Torak 2007	913	GGC/GCC	305	Gly/Ala	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	3/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	919	GGA/CGA	307	Gly/Arg	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	920	GGA/GCA	307	Gly/Ala	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Ramaswamy SV J Med Micro 2004	920	GGA/GAA	307	Gly/Glu	1996-1998	Jose Gonzalez hospital Mexico	Mexico	Directed Oligonucleotide array, Sequencing	codon 228-357	HRSE	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	Ser450Leu rpoB, 
INH	katG	Khadka DK Southest Asian J Trop Med Public Health 2007	922	ACC/CCC	308	Thr/Pro	2007	Sirirraj hospital Bangkok, Chest Disease Institute, Nonthaburi	Bangkok	PCR-SSCP, Sequencing	894 bp fragment encompassing codons 254 to 549	HRSEO			29/30	1/0	Arg463Leu katG, C(-15)T inhA
INH	katG	Bostanabad SZ Tuberk Torak 2007	926	GGT/GTT	309	Gly/Cys	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	926	GGT/GCT	309	Gly/Ser	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Kim SY Diagn Micro Inf Dis 2003	926	GGT/GAT	309	Gly/Asp	200-2002	Korean Institute of TB, Neodin Medical instittue, Kangman st Mary hosptial in South Korea	South Korea	PCR-SSCP, Sequencing	210 bp fragment spanning codon 315	HR	0.2 ug/ml I 40 ug/ml R	Proportion method	71/97	2/0	inhA Ribosomal binding site C/T
INH	katG	Bostanabad SZ Tuberk Torak 2007	926-927	GGT/GTC	309	Gly/Phe	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Huang WL JCM 2009	928-929	del A	310	Frameshift	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Bostanabad SZ Tuberk Torak 2007	931	GAC/TAC	311	Asp/Tyr	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	931-932	GAC/TTC	311	Asp/Phe	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Chan RCY JAC 2007	932	GAC/GGC	311	Asp/Gly	2007	Grantham Hosptial and Public Health Lab, Hongkong	Hong Kong	PCR-SSCP, Sequencing	703 bp fragment	HEP	1ug/ml I, 4ug/ml E, 100ug/ml P	Absolute concentration method, BACTEC MGIT 960	241/302	1/0	574Ser/Leu rpoB
INH	katG	Zenteno-Cuevas R MemInstOswaldCruz 2009	933	GAC/GAG	311	Asp/Glu	2007		Mexico	Sequencing	codon 240-390 of katG	HREZ	N.S.	BACTEC 460	17/25	1/0	katG S315T
INH	katG	Bostanabad SZ Tuberk Torak 2007	941	ACC/AAC	314	Ser/Asn	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	941-942	ACC/ACG	314	Ser/Thr	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Haas WA AAC 1997	943	AGC/CGC	315	Ser/Arg	1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	South Africa	PCR-RFLP	894 bp central fragment of katG?	H			124/212	1/0	
INH	katG	Marttila HJ AAC 1996	943	AGC/CTA	315	Ser/Leu	1989-1995	Clinical isolates.	Finland	Sequencing	Whole gene	HS	>1ug/ml	Disk elution method.	17/19	1/0	katG Pro501Ala.
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	943	AGC/GGC	315	Ser/Gly											
INH	katG	Musser JM JID 1996	944	AGC/ACC	315	Ser/Thr											
INH	katG	Haas WA AAC 1997	944	AGC/ATC	315	Ser/Ile	1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Sierra Leone, Lesotho	PCR-RFLP	892 bp central fragment	HRSEth,H			124/212	4/0	
INH	katG	Haas WA AAC 1997	944	AGC/AAC	315	Ser/Asn	1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Gauteng, Sierra leone	PCR-RFLP	890 bp fragment	H,HRE,HR			124/212	9/0	
INH	katG	Heym B MolMicro 1995	944	AGC/ACC	315	Ser/Thr	1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	Mali Ivory coast, France	PCR-SSCP, Sequencing	Whole gene	H	1 in 4 and >5 in 1	Proportional method	34/37	5/0	
INH	katG	Marttila HJ AAC 1996	944-945	AGC/ACA	315	Ser/Thr	1989-1995	Finland	Finland	Sequencing	Whole gene	HS,HRS	1 ug/ml for I 	Disk elution method.	54/56	2/0	 nt1501G/C katG in one
INH	katG	Gagneux S PLOS Path 2006	944-945	AGC/ACG	315	Ser/Thr											
INH	katG	Lipin MY CMI 2007	945	AGC/AGA	315	Ser/Arg	1998-2001	Tula & Serpokov district, Moscow	Russia	Sequencing	nt 872-1568	HRS	1 ug/ml I, 5 ug/ml S, 20ug/ml R	Absolute concentration method	217/217	2/0	335 /GTC katG in one
INH	katG	Secondary Publication: Hazbon MH AAC 2006	945	AGC/AGG	315	Ser/Arg											
INH	katG	Bostanabad SZ Tuberk Torak 2007	946	GGC/AGC	316	Gly/Ser	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	18/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Secondary Publication: Hazbon MH AAC 2006	947	GGC/GAC	316	Gly/Asp											
INH	katG	Chan RCY JAC 2007	949	ATC/CTC	317	Ile/Leu	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	katG	Zenteno-Cuevas R MemInstOswaldCruz 2009	953-954	GAG/GTA	318	Gly/Val	2007		Mexico	Sequencing	codon 240-390 of katG	HRSEZ	N.S.	BACTEC 460	17/25	1/0	katG S315T
INH	katG	Chan RCY JAC 2007	961	TGG/CGG	321	Trp/Arg	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	3
INH	katG	Bostanabad SZ Tuberk Torak 2007	961	TGG/TAG	321	Trp/STOP	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	962	TGG/TTG	321	Trp/Leu	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	962-963	TGG/TCC	321	Trp/Ser	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	963	TGG/TGT	321	Trp/Cys	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	No publication listed	970	ACC/CCC	324	Thr/Pro											
INH	katG	Musser JM JID 1996	982	TGG/GGG	328	Trp/Gly	1996	USA,Brazil, Rwanda, Belgium, Yemen, Japan, Philippines, Netherlands, Hongkong, Mexico		Sequencing	Whole gene	HR	>=1ug/ml for I	Proportion method 	34/46	1/0	
INH	katG	Haas WA AAC 1997	983	TGG/TTG	328	Trp/Leu	1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Lesotho, Eastern Cape, Natal, Swaziland, Gauteng	PCR-RFLP	894 bp central fragment of katG	H			124/212	1/0	
INH	katG	Boonaiam S CMI 2009	984	TGG/TCG	328	Trp/Ser	2005-2006	Molecular Mycology and Mycobacteriology Laboratory	Thailand	Sequencing	Whole gene	MDR	>=1ug/ml for I	Disk elution method	160/170	1/0	
INH	katG	Haas WA AAC 1997	984	TGG/TGC	328	Trp/Cys	1997	NationalTuberculosis Research program South Africa, Sierra Leone, Uganda	Free state, Lesotho, Eastern Cape, Natal, Swaziland, Gauteng	PCR-RFLP	894 bp central fragment of katG	H			124/212	1/0	
INH	katG	Bostanabad SZ Tuberk Torak 2007	984	TGG/TGT	328	Trp/Cys	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	4/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Zenteno-Cuevas R MemInstOswaldCruz 2009	991	AGT/TGT	331	Ser/Cys	2007		Mexico	Sequencing	codon 240-390 of katG	HRS	N.S.	BACTEC 460	17/25	1/0	katG S315T
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	See Note		334	Ile/Thr Error											
INH	katG	Rouse DA AAC 1995	1004	ATC/ACC	335	Ile/Thr											
INH	katG	Lipin MY CMI 2007	1003	ATC/GTC	335	Ile/Val	1998-2001	Tula & Serpokov district, Moscow	Russia	Sequencing	nt 872-1568	HRS	1 ug/ml I, 5 ug/ml S, 20ug/ml R	Absolute concentration method	217/217	1/0	315 AGC/AGA katG
INH	katG	Lee ASG AAC 1999	1007	CTG/CGG	336	Leu/Arg											
INH	katG	Cockerill FR JID 1995	1010	TAC/TTC	337	Tyr/Phe	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	0.25ug/ml	Proportion method			Pro2Ser, Ala65Thr, Ala66Pro, Met126Ile, Ala243Ser, Asn258Ser, Ala264Thr
INH	katG	Cockerill FR JID 1995	1010	TAC/TGC	337	Tyr/Cys	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	1ug/ml	Proportion method		1/0	Arg429Leu, Trp505Arg, Met609Ile
INH	katG	Morlock GP AAC 2003	1022	TGG/TCG	341	Trp/Ser	2003	USA, Brazil, Russia	Brazil	Sequencing	fragment encompassing codons 249 to 342	HEth	5o Eth, >32 I	Microplate alamar blue assay	17/41	1/0	4463S ethA, C(-15)T inhA regulator
INH	katG	Gagneux S PLOS Path 2006	1034	AAG/ACG	345	Lys/Thr											
INH	katG	Chan RCY JAC 2007		del G	346	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	katG	Rouse et al MM 1996	1048	GCT/ACT	350	Ala/Thr	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S.	n/a		
INH	katG	Rouse DA AAC 1995	1048	GCT/TCT	350	Ala/Ser	1995	Washington D.C Bethesda South Korea		PCR SSCP  	Whole gene	H	1 ug/ml	Absolute concentration method	26/26	1/0	
INH	katG	Boonaiam S CMI 2009	1054	CAA/TAA	352	Gln/STOP	2005-2006	Molecular Mycology and Mycobacteriology Laboratory	Thailand	Sequencing	Whole gene	MDR	>=1ug/ml for I	Disk elution method	160/170	1/0	
INH	katG	Bostanabad SZ Tuberk Torak 2007	1069	GAC/CAC	357	Asp/His	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bostanabad SZ Tuberk Torak 2007	1069	GAC/AAC	357	Asp/Asn	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	1/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Huang WL JCM 2009	1082	GCC/GAC	361	Ala/Asp	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Huang WL JCM 2009	1091	del T	364	Frameshift	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Huang WL JCM 2009	1133	CTG/CCG	378	Leu/Pro	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Huang WL JCM 2009	1136	GCC/GTC	379	Ala/Val	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Chan RCY JAC 2007	1139	ACT/ATT	380	Thr/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	katG	Rouse et al MM 1996	1142	GAC/GGC	381	Asp/Gly	1996	INH-resistant clinical isolates and in vitro mutants of katG in mtb						N.S.	n/a		
INH	katG	Gagneux S PLOS Path 2006	1151	CTG/CGG	384	Leu/Arg											
INH	katG	Chan RCY JAC 2007	1169	ACT/ATT	390	Thr/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	katG	Sekigushi J JCM 2007	1170	ins CTA	390	ins Leu	2007	Japam & Poland	Japan	Sequencing	Whole gene			Proportion method, BACTEC	38/138	2/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1178	ATC/AAC	393	Ile/Asn											
INH	katG	Gagneux S PLOS Path 2006	1180	ACG/GCG	394	Thr/Ala											
INH	katG	Secondary Publication: Hazbon MH AAC 2006	1191	TGG/TAG	397	Trp/STOP											
INH	katG	Huang WL JCM 2009		del C	401	Frameshift	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Pretorius GS AAC 1995	1225-1226	GCC/CGC	409	Ala/Arg	1995	USA, Switzerland, South Africa	South Africa	PCR-SSCP, Sequencing		HRSEryB	2.5 ug/ml	Agar dilution method	39/69	1/0	
INH	katG	Chan RCY JAC 2007	1226	GCC/GAC	409	Ala/Asp	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	katG	Huang WL JCM 2009	1237	TAC/CAC	413	Tyr/His	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Bolotin S JAC 2009	1242	AAG/AAC	414	Lys/Asn	1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0	
INH	katG	Ghiladi RA J Am Chem Soc 2005 	1253	CGA/CTA	418	Arg/Leu											
INH	katG	Mo L Microb Drug Res 2004 	1253	CGA/CAA	418	Arg/Gln											
INH	katG	Huang WL JCM 2009	1255	GAC/CAC	419	Asp/His	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	katG	Cockerill FR JID 1995	1271	GCG/GAG	424	Ala/Glu	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	<0.12ug/ml	Proportion method		0/1	Gln224Glu and Pro429Ser in katG.
INH	katG	Cockerill FR JID 1995	1271	GCG/GTG	424	Ala/Val	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	>32ug/ml	Proportion method		1/0	8-bp deletion in codon 10 + Ala550Asp in katG.
INH	katG	Cockerill FR JID 1995	1285	CCG/TCG	429	Pro/Ser	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	<0.12ug/ml	Proportion method		0/1	Gln224Glu and Ala 424Glu in katG.
INH	katG	Ramaswamy SV AAC 2003	1300	CAG/TAG	434	Gln/STOP		38 epidemiologically unrelated INH-monoresistant and 86 INH-susceptible isolates	USA, Mexico	Sequencing			>256	"BACTEC radiometric method (0.1ug/ml); E-test"	38/121	1/0	V163I (Rv0340)
INH	katG	Zhang M J Clin Microb 2005	1329	ins A	438	Frameshift	2005	Clinical isolates	China	"IS6110-based RFLP; Sequencing."	Whole gene	H		BACTEC MGIT 960	1/87	1/0	"Arg463Leu in katG; also 1 mutation in oxy-ahpC, and 1 in efpA."
INH	katG	Hai Hua Lin TubercRespirDis 2007	1330	GCG/ACG	444	Ala/Thr	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	None
INH	katG	Doustdar F MDR 2008	1345	CTC/TTC	449	Leu/Phe	2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	None
INH	katG	Bostanabad SZ Tuberk Torak 2007	1360	GAG/CGA	454	Glu/Arg	2004-2005	Clinical INH-R MTB isolates.	Belarus	PCR, Sequencing.	209-bp segment.	H	>1ug/ml	Proportion method, BACTEC	42/42	2/0	Most had 1-4 other katG mutations (most often in codon 315).
INH	katG	Bolotin S JAC 2009	1370	AGC/ATC	457	Ser/Ile	1999-2001	Ontario Agency for Health Protection and Promotion	Canada	Sequencing	codon 250-500	H, HR		MGIT 960	154/504	1/0	
INH	katG	Hai Hua Lin TubercRespirDis 2007	1385	ATC/ACC	462	Ile/Thr	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)
INH	katG	Heym B MolMicro 1995	1389	CGG/CTG	463	Arg/Leu											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1431	TGG/TGA	477	Trp/STOP											
INH	katG	Baker LV AAC 2005	1450	CGT/AGT	484	Arg/Ser	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1454	GGT/GTT	485	Gly/Val											
INH	katG	Marttila HJ AAC 1996	1464	G/C	488	Lys/Asn	1989-1995	Clinical isolates.	Finland	PCR, Sequencing.	Whole gene	H	>1ug/ml	Disk elution method.	17/19	1/0	katG Gln295STOP
INH	katG	Baker LV AAC 2005	1469	CGC/TGC	490	Arg/Cys	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	
INH	katG	Lavender C AAC 2005	1471	GGC/TGC	491	Gly/Cys	2001-2003	Victorian Inf DiseaseReference Lab	Australia	Multiplex allele specific PCR assay	Whole gene	H	0.4 ug/ml	BACTEC MGIT960 method	52/104	1/0	
INH	katG	Hai Hua Lin TubercRespirDis 2007	1506	CAA/CAT	502	Gln/His	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)
INH	katG	Abe C JCM 2008	1513	TGG/TCG	505	Trp/Ser	Published in 2008		Japan	Sequencing	Whole gene	H		MGIT 960	96/96	1/0	
INH	katG	Cockerill FR JID 1995	1513	TGG/CGG	505	Trp/Arg	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	>32ug/ml	Proportion method		1/0	Tyr337Phe, Arg429Leu, Met609Ile
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	ins ?	511	Frameshift											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	ins ?	513	Frameshift											
INH	katG	Zhang M J Clin Microb 2005	1543	CGC/TGC	515	Arg/Cys	2005	Clinical isolates	China	Sequencing.	Whole gene	H	8ug/ml	BACTEC MGIT 960	87/137	1/0	Arg463Leu in katG.
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	?	ins ?	521	Frameshift											
INH	katG	Zhang M J Clin Microb 2005	1559	ins 64bp	521	Frameshift	2005	Clinical isolates	China	Sequencing.	Whole gene	H	>256ug/ml	BACTEC MGIT 960	87/137	1/0	"Arg463Leu in katG; also 1 mutation in oxy-ahpC, and 1 in efpA."
INH	katG	Marttila HJ AAC 1996	1574	CAG/CCG	525	Gln/Pro	1989-1995	Finland	Finland	Sequencing	Whole gene	H	0.4 ug/ml for I	disk elution method	54/56	1/0	
INH	katG	Ramaswamy SV AAC 2003	1585	AAC/GAC	529	Asn/Asp	2003	Clinical isolates.	USA, Mexico, Central America, Southeast Asia, and Africa.	Sequencing	Whole gene	H	N/A	E-Test	38/124	1/0	katG Trp397Tyr, no other mutations in the 19 genes sequenced.
INH	katG	Cockerill FR JID 1995	1649	GCC/GAC	550	Ala/Asp	1995	Isolates from the Mayo Clinic	USA	Sequencing.	Whole gene	H	0.12->32ug/ml	Proportion method			"R strain also Ala424Val; S strain also Gln224Glu,  Ala243Ser."
INH	katG	Hai Hua Lin TubercRespirDis 2007	1652	GCC/GGC	551	Ala/Gly	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	None
INH	katG	Secondary Publication: Hazbon MH AAC 2006	1667	del C	556	Frameshift											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1700	TTC/TCC	567	Phe/Ser											
INH	katG	Gagneux S PLOS Path 2006	1717	GAT/AAT	573	Asp/Asn											
INH	katG	Secondary Publication: Hazbon MH AAC 2006	1721	GCG/GAG	574	Ala/Glu											
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1721	GCG/GTG	574	Ala/Val											
INH	katG	Secondary Publication: Hazbon MH AAC 2006	1759	CTG/ATG	587	Leu/Ile											
INH	katG	Heym B MolMicro 1995	1759	CTG/ATG	587	Leu/Met	1995	Isolates from patients of Pitie Salpietre hospital in France during 1991-92	N.S.	PCR-SSCP, Sequencing	Whole gene	H	>5 ug/ml	Proportion method	39/39	1/0	
INH	katG	Marttila HJ AAC 1996	1760	CTG/CCG	587	Leu/Pro	1989-1995	Finland	Finland	Sequencing	Whole gene	H	0.4ug/ml	disk elution method	54/56	1/0	
INH	katG	Cockerill FR JID 1995	1765	CCC/ACC	589	Pro/Thr	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	32ug/ml	Proportion method		1/0	Arg429Leu, Ala264Thr in katG.
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	1778	GGC/GAC	593	Gly/Asp											
INH	katG	Gagneux S PLOS Path 2006	1819	GAG/AAG	607	Glu/Lys											
INH	katG	Cockerill FR JID 1995	1827	ATG/ATT, ATG/ATC or ATG/ATA	609	Met/Ile	1995	Isolates from the Mayo Clinic	USA	PCR, RFLP,  Sequencing.	Whole gene	H	<0.12-32ug/ml	Proportion method			"The 2 R isolates also had Arg463Leu + one other mutation each; the S isolate had no other mutations."
INH	katG	Marttila HJ AAC 1996	1849	ins AC	617	Frameshift	1989-1995	Finland	Finland	Sequencing	Whole gene	H	1 ug/ml	disk elution method	54/56	1/0	
INH	katG	Wei CJ AAC 2003	1856	CTC/CCC	619	Leu/Pro	2003										
INH	katG	Rouse DA AAC 1995	1888	GGC/AGC	629	Gly/Ser	1995	WashingtonD.C, Bethesda, South Korea		PCR SSCP analysis	Whole gene	H	1ug/ml	Absolute concentration method	26/26	1/0	
INH	katG	Wei CJ AAC 2003	1900	CTC/TTC	634	Leu/Phe	2003										
INH	katG	Gagneux S PLOS Path 2006	1907	GCA/GAA	636	Ala/Glu											
INH	katG	Gagneux S PLOS Path 2006	1958	CTG/CCG	653	Leu/Pro											
INH	katG	Zhang M J Clin Microb 2005	2053	GGC/CGC	685	Gly/Arg	2005	Clinical isolates	China	Sequencing.	Whole gene	H	2ug/ml	BACTEC MGIT 960	1/87	1/0	Ser315Thr in katG.
INH	katG	Pretorius GS AAC 1995	2084	GAC/GCC	695	Asp/Ala	1995	USA,South Africa, Switzerland	South Africa	PCR-SSCP, Sequencing		HRS	40	Agar dilution method	39/69	1/0	
INH	katG	Baker LV AAC 2005	2096	GGG/GAG	699	Gly/Gln	1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Whole gene	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	
INH	katG	Marttila HJ AAC 1996	2098	TCC/CCC	700	Ser/Pro	1989-1995	Finland	Finland	Sequencing	Whole gene	H	1 ug/ml	disk elution method	54/56	1/0	
INH	katG	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	2129	GTC/GCC	710	Val/Ala											
INH	katG	Secondary Publication: Hazbon MH AAC 2006	2137	GCC/CCC	713	Ala/Pro											
INH	katG	Secondary Publication: Hazbon MH AAC 2006	2150	CAG/CCG	717	Gln/Pro											
INH	katG	Rouse DA AAC 1995	2146	GCG/CCG	716	Ala/Pro	1995	WashingtonD.C, Bethesda, South Korea	USA, South Korea	PCR-SSCP	Whole gene	HRP	50ug/ml	Absolute concentration method	26/26	1/0	
INH	katG	Ramaswamy SV J Med Micro 2004	2180	GCC/GAC	727	Ala/Asp	1996-1998	Jose Gonzalez Hospital Mexica	Mexico	Directed Oligonucleotide array,  Sequencing	codon 228-357	HRS	>=1% growth 0.2ug/ml I, 40ug/ml R, 4ug/ml S, 2ug/ml E	Proportion method	37/50	1/0	Ser450Leu rpoB, nt491C/T rrs, Met306Ile embB
INH	katG	Gagneux S PLOS Path 2006	2184	TGG/TGT or TGG/TGC	728	Trp/Cys											
INH	katG	Gagneux S PLOS Path 2006	2203-2205	del GAC	735	del Asp											
INH	katG	Gagneux S PLOS Path 2006	2203	GAC/AAC	735	Asp/Asn											
INH	katG	Wei CJ AAC 2003	2204	GAC/GCC	735	Asp/Ala	2003										
																	
																	
	kasA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	kasA	Mdluli K Science 1998	196	GAT/AAT	66	Asp/Asn	1998			Sequencing	Whole gene	H			28/71	1/0	not mentioned
INH	kasA	Ramaswamy SV AAC 2003 	231	ATG/ATA	77	Met/Ile	2004	Jose Gonzalez tuberculosis clinic in Mexico	Mexico								
INH	kasA	Lee ASG AAC 1999	362	AGG/AAG	121	Arg/Lys	1994-1996	Central Tuberculosis Lab, Singapore	Singapore	Sequencing	Whole gene	H	0.1ug/ml	BACTEC 460	160/192	1/0	present but not mentioned
INH	kasA	Mdluli K Science 1998	805	GGT/AGT	269	Gly/Ser	1998			Sequencing	Whole gene	H			28/71	1/0	not mentioned
INH	kasA	Mdluli K Science 1998	934	GGC/AGC	312	Gly/Ser				Sequencing	Whole gene	H			28/71	1/0	not mentioned
INH	kasA	Lee ASG AAC 1999	1160	GGC/GAC	387	Gly/Asp	1994-1996	Central Tuberculosis Lab, Singapore	Singapore	Sequencing	Whole gene	H	0.1ug/ml	BACTEC 460	160/192	1/0	present but not mentioned
INH	kasA	Mdluli K Science 1998	1239	TTC/TTA	413	Phe/Leu	1998			Sequencing	Whole gene	H	0.1ug/ml		28/71	1/0	not mentioned
																	
																	
	ndh Rv1584c																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	ndh	Cardoso RF Mem Inst Oswaldo Cruz 2007	37	CGT/TGT	13	Arg/Cys	2006	Institute Adofe Lutz of Ribeirao Preto, Sorocaba, Institute Clemente Ferreira, Sao Paulo and Clinical Bacteriology Lab Parana	Brazil	Sequencing	Whole gene	H	>32ug/ml	Microplate alamar blue assay	24/36	1/0	S315T katG
INH	ndh	Cardoso RF Mem Inst Oswaldo Cruz 2007	53	GTG/GCG	18	Val/Ala	2006	Institute Adofe Lutz of Ribeirao Preto, Sorocaba, Institute Clemente Ferreira, Sao Paulo and Clinical Bacteriology Lab Parana	Brazil	Sequencing	Whole gene	H	32ug/ml	Microplate alamar blue assay	24/36	1/0	insA at nt17 katG
INH	ndh	Lee ASG AAC 2001	328	ACC/GCC	110	Thr/Ala	1994-1996	Central Tuberculosis Laboratory, Singapore General Hospital	Singapore	Sequencing	Whole gene	H		BACTEC 460 	84/106	1/0	none
INH	ndh	?	716	CTG/CCG	239	Leu/Pro											
INH	ndh	Lee ASG AAC 2001	804	CGC/CAC	268	Arg/His	1994-1996	Central Tuberculosis Laboratory, Singapore General Hospital	Singapore	Sequencing	Whole gene	H		BACTEC 460 	84/106	7/0	
																	
	oxyR-ahpC																
																	
	oxyR																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	OxyR	Sreevatsan S AAC 1997  (*)	331	A/C			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA  	Sequencing	Whole gene	H		Proportion method, BACTEC 460	70/181	only in susceptible	not mentioned
INH	OxyR	Sreevatsan S AAC 1997  (*)	325	G/T			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene	H		Proportion method, BACTEC 460	70/181	1/0	not mentioned
INH	OxyR	Sreevatsan S Escalante P JCM 1996  (*)	285	G/A			1996		Brazil, Chile, Ecuador, India, Trinidad-Tobago, Mongolia, Romania, Yugoslavia, Spain, Israel, Turkey, Guinea, Algeria, Kenya, Zaire, Somalia,  Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	410 bp of oxyR						
INH	OxyR	Sreevatsan S AAC 1997  (*)	67	ins GGCG			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene			Proportion method, BACTEC 460	70/181	not mentioned	not mentioned
INH	OxyR	Sreevatsan S AAC 1997  (*)	37	C/T			1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	Whole gene			Proportion method, BACTEC 460	70/181	found in both susceptible and resistant	not mentioned
INH	OxyR	Lee ASG AAC 1999	28	C/A			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	mostly S315T katG or inhA promoter mutation
INH	OxyR	Lee ASG AAC 1999	27	G/T			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	mostly S315T katG or inhA promoter mutation
INH	OxyR	Lee ASG AAC 1999	18	G/A			1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/1	mostly S315T katG or inhA promoter mutation
																	
	OxyR-ahpC intergenic																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	OxyR-ahpC intergenic	Rindi L Int J Tuberc Lung Dis 2005	-74	G/A	-74		1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 583-819	36H,9MDR	0.1ug/ml	BACTEC 460	45/45	1/0	not mentiond
INH	OxyR-ahpC intergenic	Huang WL JCM 2009	-66	G/A	-66		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	2/0	not mentiond
INH	OxyR-ahpC intergenic	Rindi L Int J Tuberc Lung Dis 2005	-54	C/T	-54		1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 583-819	36H,9MDR	0.1ug/ml	BACTEC 460	45/45	1/0	not mentiond
INH	OxyR-ahpC intergenic	Gagneux S PLOS Path 2006	-54	ins ATGT	-54												
INH	OxyR-ahpC intergenic	No Publication Listed	-52	C/T	-52												
INH	OxyR-ahpC intergenic	Doustdar F MDR 2008	-49	T/G	-49		2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	None
INH	OxyR-ahpC intergenic	Ramaswamy SV AAC 2003	-48	G/A	-48												
INH	OxyR-ahpC intergenic	Lee ASG AAC 1999	-46	G/A	-46		1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	oxyRahpC intergenic region 	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA  mutation
INH	OxyR-ahpC intergenic	Secondary Publication: Hazbon MH AAC 2006	-46	del G	-46												
INH	OxyR-ahpC intergenic	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	-45	C/T	-45												
INH	OxyR-ahpC intergenic	Sreevatsan S AAC 1997  (*)	-44	T/A	-44		1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	oxyRahpC intergenic region 			Proportion method, BACTEC 460	70/169	1/0	katG deletion
INH	OxyR-ahpC intergenic	Silva MS JCM 2003	-40	T/C	-40		1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	oxyRahpC intergenic region 	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportion method	69/69	1/0	S315T kat G
INH	OxyR-ahpC intergenic	Silva MS JCM 2003	-39	C/T	-39		1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	oxyRahpC intergenic region 	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportion method	69/69	2/0	none
INH	OxyR-ahpC intergenic	Baker LV AAC 2005	-34	T/A	-34		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	oxyRahpC intergenic region 	H,HS,HE,HSE,MDR	ratio>=1	Resistance ratio method	202/378	1/0	Arg463Leu katG
INH	OxyR-ahpC intergenic	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	-34	T/C	-34												
INH	OxyR-ahpC intergenic	Baker LV AAC 2005	-34	del T	-34		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array, Sequencing	oxyR'-ahpC intergenic region 	H,HS,HE,HSE,MDR	ratio>=1	Resistance ratio method	202/378	1/0	S315T, Arg463Leu katG
INH	OxyR-ahpC intergenic	Sreevatsan S AAC 1997  (*)	-32	G/A	-32		1997		Brazil, Chile, Mexico, Venezuela, Kenya, Yemen, Philippines, Japan, Netherlands, Romania, USA	Sequencing	oxyRahpC intergenic region 	H		BACTEC 460 radiometric method or Proportion method for MTB and Mafricanum isolates only	70/169	1/0	none
INH	OxyR-ahpC intergenic	Huang WL JCM 2009	-32	C/T	-32		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	OxyR-ahpC intergenic	Lee ASG AAC 1999	-30	C/T	-30		1994-1996	Singapore Gnereal Hospital Pathology Lab	Singapore	Sequencing	oxyRahpC intergenic region 	H	0.1ug/ml	BACTEC 460	160/192	2/0	katG del/mut or inhA mut
INH	OxyR-ahpC intergenic	Baker LV AAC 2005	-20	C/T	-20		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	oxyRahpC intergenic region 	H,HS,HE,HSE,MDR	ratio>=1	resistance ratio method	202/378	1/0	none
INH	OxyR-ahpC intergenic	Gagneux S PLOS Path 2006	-15	C/T	-15												
INH	OxyR-ahpC intergenic	Lee ASG AAC 1999	-12	C/T	-12		1994-1996	Singapore Gnereal Hospital Pathology Lab									
INH	OxyR-ahpC intergenic	Gagneux S PLOS Path 2006	-10	C/A	-10												
INH	OxyR-ahpC intergenic	Gagneux S PLOS Path 2006	-10	C/T	-10												
INH	OxyR-ahpC intergenic	Secondary Publication: Hazbon MH AAC 2006	-10	C/G	-10												
INH	OxyR-ahpC intergenic	Silva MS JCM 2003	-9	G/A	-9		1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	Promoter region of ahpC	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportionmethod on Ogawa medium	69/69	1/0	none
INH	OxyR-ahpC intergenic	Lee ASG AAC 1999	-6	G/A	-6		1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA mut
INH	OxyR-ahpC intergenic	Huang WL JCM 2009	-5	G/A	-5		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	OxyR-ahpC intergenic	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	-4	A/G	-4												
INH	OxyR-ahpC intergenic	Huang WL JCM 2009	-4	ins A	-4		2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	OxyR-ahpC intergenic	Secondary Publication: Hazbon MH AAC 2006	-4	ins T	-4												
INH	OxyR-ahpC intergenic	Gagneux S PLOS Path 2006	0	T/C	0												
																	
	ahpC																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	ahpC	Lee ASG AAC 1999	4	CCA/TCA	2	Pro/Ser	1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA mut
INH	ahpC	Kiepiela P Tuber Lung Dis 2000	7	CTG/AAG	3	Leu/Lys	1995	King George V Hospital Mycobacterial Lab,Durban	South Africa	PCR-SSCP, Sequencing	N.S	H	>8ug/ml	BACTEC 460	79/96	1/0	Pro2Pro ahpC, katG mut present but not specified
INH	ahpC	Lee ASG AAC 1999	14	ACC/ATC	5	Thr/Ile	1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of ahpC	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG del/mut or inhA mut
INH	ahpC	Silva MS JCM 2003	28	TTC/ATC	10	Phe/Ile	1996-1999	Lab Central Rio Grande  De Sul, Rio de Janeiro, Instituto Adolfo Lutz, Sao Paulo	Brazil	PCR-SSCP, Sequencing	Promoter region of ahpC	H,HR,HRS,HRP,HS,HRE,HRES,HRESP		Proportionmethod on Ogawa medium	69/69	1/0	S315T katG
INH	ahpC	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	97	GAC/AAC	33	Asp/Asn											
INH	ahpC	Secondary Publication: Hazbon MH AAC 2006	217	GAC/CAC	73	Asp/His											
INH	ahpC	Chan RCY JAC 2007	226	GAG/AAG	76	Glu/Lys	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	N.S.		Absolute concentration method	250	241	2
INH	ahpC	Secondary Publication: Hazbon MH AAC 2006	572	CTC/CGC	191	Leu/Arg											
																	
																	
	mabA-inhA intergenic																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	mabA, fabG1	Ramaswamy SV AAC 2003	-147	G/T	-147												
INH	mabA, fabG1	Lee ASG AAC 1999	-92	A/T	-92		1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1ug/ml	BACTEC 460	160/192	1/0	katG or ahpC-oxyR mut
INH	mabA, fabG1	Doustdar F MDR 2008	-67	G/C	-67		2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	inhA 40 G/C and ahpC -6 G/A
INH	mabA, fabG1	Rindi L Int J Tuberc Lung Dis 2005	-24	G/T	-24		1994-2002	Clinical Mycobacterial Lab, Pisa and Regional reference centre ,Careggi Hospital	Italy	Sequencing	nt 56-303				45/45	1/0	not mentioned
INH	mabA, fabG1	Rouse DA AAC 1995	-24	G/T	-24		1995	WashingtonD.C, Bethesda, South Korea		PCR SSCP analysis,	N.S.	HS	0.2ug/ml I, 4ug/mlS	Absolute concentration method	26/26	1/0	R463l katG
INH	mabA, fabG1	Baker LV AAC 2005	-24	G/T	-24		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	inhA promoter region	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	S315T Arg463Leu in katG, -46G/A in oxyRahpc intergenic region
INH	mabA, fabG1	Morlock GP AAC 2003	-17	G/T	-17		2003	USA CDC, Brazil, Russia	USA	Sequencing	284 bp of inhA promoter and nt 13-379 of inhA	HEth	100ug/ml E, 8 ug/ml I	Proportion method	41/42	1/0	I21T inhA ORF
INH	mabA, fabG1	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	-16	A/G	-16												
INH	mabA, fabG1	Lee ASG AAC 1999	-15	C/T	-15		1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1UG/ML	BACTEC 460 radimetric method	160/192	43/0	katG or ahpC-oxyR mut
INH	mabA, fabG1	Secondary Publication: Hazbon MH AAC 2006	-11	A/T	-11												
INH	mabA, fabG1	Lee ASG AAC 1999	-8	T/A	-8		1994-1996	Singapore general hospital Pathology Lab	Singapore	Sequencing	Promoter region of inhA	H	0.1UG/ML	BACTEC 460 radimetric method	160/192	1/0	katG or ahpC-oxyR mut
INH	mabA, fabG1	Baker LV AAC 2005	-8	T/C	-8		1998	records from National  laboratory Myco resistance network database	United Kingdom	Directed Oligonucleotide array,  Sequencing	Promoter region of inhA	H,HS,HE,HSE,MDR	ratio>=4	Resistance ratio method	202/378	1/0	none
INH	mabA, fabG1	Rouse DA AAC 1995	-8	T/G	-8		1995	WashingtonD.C, Bethesda, South Korea		PCR SSCP analysis	not specified	H	0.2ug/ml	Absolute concentration method	39990	1/0	none
INH	mabA, fabG1	Sekigushi J JCM 2007	-5	T/A	-5		2007	Japan & Poland		Sequencing	nt-217 to -198, 1145-1126			Proportion method, BACTEC	38/138	1/0	M257T R463L katG
																	
	mabA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	mabA, fabG1	Doustdar F MDR 2008	13	GCC/CCC	5	Ala/Pro	2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	mabA -15 C/T and ahpC -6 G/A
INH	mabA, fabG1	Doustdar F MDR 2008	40	GTA/CTA	14	Val/Leu	2005-2006		Iran	Sequencing	250bp around 315 and 212 bp around 463, 238bp of inhA and 293bp of ahpC	H	N.S.	Proportion method	48/93	1/0	mabA -67 G/C and ahpC -6 G/A
INH	mabA, fabG1	Secondary Publication: Hazbon MH AAC 2006	61	ACC/GCC	21	Thr/Ala											
																	
	inhA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	inhA	Hai Hua Lin TubercRespirDis 2007	24	AAA/AAC	8	Lys/Asn	2004		South Korea	Sequencing	Whole gene	MDR	N.S.	N.S	29/29	1/0	inhA -15 (C/T)
INH	inhA	Basso L JID 1998 	47	ATC/ACC	16	Ile/Thr	1998		USA	Sequencing	Whole gene	H	1.0ug/ml	BACTEC	N.S.	1/0	none
INH	inhA	Morlock GP AAC 2003	61	ATC/GTC	21	Ile/Val	2003	USA CDC, Brazil, Russia	USA	Sequencing	284 bp inhA promoter and nt 13-379 of inhA	HEth	8ug/mlI, >200ug/ml Eth	Proportion metho	41/42	2/0	C(-15)T inhA regulator
INH	inhA	Morlock GP AAC 2003	62	ATC/ACC	21	Ile/Thr	2003	USA CDC, Brazil, Russia	USA	Sequencing	284 bp inhA promoter and nt 13-379 of inhA	HEth	>32ug/ml, 8ug/ml I, >200 ug/ml or 100ug/ml Eth	Proportion method	41/42	3/0	C(-15)T, G(-17)T inhA regulator,
INH	inhA	Basso L JID 1998 	140	ATT/ACT	47	Ile/Thr	1998		USA	Sequencing	Whole gene	H	1.0 ug/ml	BACTEC	N.S.	1/0	none
INH	inhA	Basso L JID 1998 	233	GTG/GCG	78	Val/Ala	1998		USA	Sequencing	Whole gene	H	1.0 ug/ml	BACTEC	N.S.	1/0	none
INH	inhA	Lee H Int J Tuberc Lung Dis 2000	280	TCG/GCG	94	Ser/Ala	2000	Korean Institute of TB Seoul	South Korea	Sequencing	nt174-382	HR	0.2ug/ml I, 20ug/ml R		24/24	1/0	
INH	inhA	Vilcheze C Nat Med 2006 	281	TCG/TTG	94	Ser/Leu											
INH	inhA	Ristow M Lancet 1995	283-284	ATT/CCT	95	Ile/Pro	1995		Germany, Nepal	Sequencing	inhA codon 94	HEth	All 7 were resistant to I or Eth or both.	Proportion method	38/47	 7/0 	not mentioned
INH	inhA	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	284	ATT/ACT	95	Ile/Thr											
INH	inhA	Leung ET AAC 2006	581	ATC/ACC	194	Ile/Thr	1999-2002	HongKong, South China	Hong Kong, China	Sequencing	  -38 to-13, 250-268,381-399,510-492,860-840,	H	>1ug/ml	Proportion method	102/375	1/0	not mentioned
INH	inhA	Huang WL JCM 2009			202	Arg/Gly	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
INH	inhA	Huang WL JCM 2009			217	Glu/Asp	2007-2008		Taiwan	Sequencing	N.S.	242MDR	N.S.	MGIT 960	242/272	1/0	not mentiond
																	
	embB																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	embB	Shi R AAC 2007 	997	TAT/CAT	333	Tyr/His	2000		China	Sequencing	Whole gene	HRS			141/181	1/0	not mentioned
																	
	furA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	furA	Ramaswamy S AAC 2003	13	TCC/CCC	5	Ser/Pro	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	Rv0340																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	Rv0340	Ramaswamy S AAC 2003	487	GTT/ATT	163	Val/Ile	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	iniB																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	iniB	Ramaswamy S AAC 2003	665	del 12 bp	222		2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	iniA																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	iniA	Ramaswamy S AAC 2003	7	CCC/GCC	3	Pro/Ala	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	iniA	Ramaswamy S AAC 2003	282	del 5 bp	94	Frameshift	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	iniA	Ramaswamy S AAC 2003	1610	CGC/CAC	537	Arg/His	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	iniC																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	iniC	Ramaswamy S AAC 2003	247	TGG/GGG	83	Trp/Gly	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	Rv1592c																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	Rv1592c	Ramaswamy S AAC 2003	-29	G/A			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	Rv1592c	Ramaswamy S AAC 2003	125	CCT/CTT	42	Pro/Leu	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	Rv1592c	Ramaswamy S AAC 2003	1289	GTG/GCG	430	Val/Ala				Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	Rv1772																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	Rv1772	Ramaswamy S AAC 2003	10	ACA/GCA	4	Thr/Ala	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	srm R homolog																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	srm R homolog	Ramaswamy S AAC 2003	8	GAC/GGC	3	Asp/Gly	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	srm R homolog	Ramaswamy S AAC 2003	968	ATG/ACG	323	Met/Thr	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	fabD																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	fabD	Ramaswamy S AAC 2003	824	AGC/AAC	275	Ser/Asn	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	accD6																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	accD6	Ramaswamy S AAC 2003	686	GAC/GGC	229	Asp/Gly	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	fbpC																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations
INH	fbpC	Ramaswamy S AAC 2003	-63	C/T			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
INH	fbpC	Ramaswamy S AAC 2003	472	GGC/AGC	158	Gly/Ser	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test			
																	
	fadE24																
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations	
INH	fadE24	Ramaswamy S AAC 2003	-64	ins 2 bp			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				
INH	fbpC	Ramaswamy S AAC 2003	-23	A/C			2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				
																		
	efpA																	
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations	
INH	efpA	Ramaswamy S AAC 2003	218	ATC/ACC	73	Ile/Thr	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				
																		
	nhoA																	
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations	
INH	nhoA	Ramaswamy S AAC 2003	201	GGC/GGT	67	Gly/Arg	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				
INH	nhoA	Ramaswamy S AAC 2003	620	GGG/GAG	207	Gly/Glu	2003		USA, Mexico	Sequencing	Whole gene	H		Resistance ratio method, E-test				

PARA-AMINOSALISYLIC ACID [PAS]																		
																		
	thyA																	
Drug	Gene	Primary reference	nt	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations		
PAS	thyA	Rengarajan J MolMicro 2004	604	ACC/GCC	202	Thr/Ala	Published 2004	PAS-resistant (n=8) and PAS-sensitive (n=10) clinical M.tb isolates. Total N=18	Russia	Sequencing	Whole gene	PAS	N.S.	N.S.	8/18	2/0	None in region analyzed.		
PAS	thyA	Rengarajan J MolMicro 2004	664	CGC/GGC	222	Arg/Gly	Published 2004	PAS-resistant (n=8) and PAS-sensitive (n=10) clinical M.tb isolates. Total N=18	Russia	Sequencing	Whole gene	PAS	N.S.	N.S.	8/18	1/0	None in region analyzed.		

PYRAZINAMIDE [PZA]																			
																			
	pncA																		
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistancepattern	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations		
PZA	pncA	Morlock GP AAC 2000	-16/-11	AACGTA/GGCAGTT			1999			Sequencing	Whole gene	Z	400	Proportion method	37/60	1/0			
PZA	pncA	Marttila HJ AAC 1999	-12	T/G			1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested		
PZA	pncA	Scorpio A AAC 1997	-11	A/C			1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0			
PZA	pncA	Sreevatsan S AAC 1997	-11	A/G			1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460 	67/118	2/0			
PZA	pncA	Morlock GP AAC 2000	-7	T/C			1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0			
PZA	pncA	Hou L Epi Infect 2000	1	del 8bp	1	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	>2000	Proportion method, BACTEC 460	35/65	1/0			
PZA	pncA	Scorpio A AAC 1997	1	del 11bp	1	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	2/0			
PZA	pncA	Portugal I AAC 2004	2	ATG/ACG	1	Met/Thr	2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55			
PZA	pncA	Lee KW J Korean Med Sci 2001	3	ATG/ATT	1	Met/Ile	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	7	GCG/CCG	3	Ala/Pro	1986		France	Sequencing	Whole gene	ZHR	1000			1/0	
PZA	pncA	Sekiguchi JI JCM 2007	8	GCG/GAG	3	Ala/Glu	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	11	TTG/TGG	4	Leu/Trp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	11	TTG/TCG	4	Leu/Ser	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	14	ATC/AGC	5	Ile/Ser	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	19	GTC/ATC	7	Val/Ile	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRPES		Proportion method	11/29	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Escalante P TuberLung Dis 1998	19	GTC/TTC	7	Val/Phe	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRPS		Proportion method	11/29	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; embB, 328, GAT:A del"
PZA	pncA	Hirano  TLD 1997	20	GTC/GGC	7	Val/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	20	GTC/GAC	7	Val/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	22	GAC/TAC	8	Asp/Tyr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	23	GAC/GGC	8	Asp/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	24	GAC/GAG	8	Asp/Glu	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	26	GTG/GCG	9	Val/Ala	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	26	GTG/GGG	9	Val/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	26	GTG/TTG	9	Val/Leu	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Chan RCY JAC 2007	27	GTG/TCG	9	Val/Ser	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Scorpio A AAC 1997	28	del C	10	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Marttila HJ AAC 1999	28	CAA/AAA	10	Gln/Lys	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	28	CAA/TAA	10	Gln/STOP	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Cheng SJ AAC 2000	29	CAG/CGA	10	Gln/Arg	1990-1992		USA	Sequencing	Whole gene	ZHREO	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hirano  TLD 1998	29	CAG/CCG	10	Gln/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Morlock GP AAC 2000	29	CAG/CCA	10	Gln/Pro	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	34	GAC/AAC	12	Asp/Asn	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	35	GAC/GCC	12	Asp/Ala	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lemaitre N AAC 1999	38	TTC/TCC 	13	Phe/Ser	1987		France	Sequencing	Whole gene	ZHRES	>2000		19/35	1/0	
PZA	pncA	Scorpio A AAC 1997	40	TGC/CGC	14	Cys/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	40	TGC/CGC	14	Cys/His	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	41	TGC/TAC	14	Cys/Tyr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Chan RCY JAC 2007	47	del G	16	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hirano  TLD 1998	50	GGC/GAC	17	Gly/Asp	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	2/0	
PZA	pncA	Chan RCY JAC 2007	50	GGC/GTC	17	Gly/Val	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Cheng SJ AAC 2000	52	ins GG		Frameshift			USA	Sequencing	Whole gene	ZHR	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Chan RCY JAC 2007	56	CTG/CGG	19	Leu/Arg	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Sreevatsan S AAC 1997	56	CTG/CCG	19	Leu/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460 	67/118	1/0	
PZA	pncA	Chan RCY JAC 2007	62	GTA/GGA	21	Val/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Chan RCY JAC 2007	64	del A	22	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hou L Epi Infect 2000	59	del C	20	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRSE	1800	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	68-69	GGT/GTC	23	Gly/Val	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	70	del G	24	Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	7/0	
PZA	pncA	Hou L Epi Infect 2000	71	del G	24	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRH	600	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	74-75	GCC/GAA	25	Ala/Glu	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	77	GCG/GGG	26	Ala/Gly	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Marttila HJ AAC 1999	84	del C	28	Frameshift	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	83	GCC/GAC	28	Ala/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hannan MM JCM 2001	88-112	del 24bp		Frameshift	1996-1999	isolates from 5 counties in California	California	Sequencing	Whole gene	Z		BACTEC radiometric testing	3/11	1/0	
PZA	pncA	Scorpio A AAC 1997	98-216	del 118bp		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	100	ins T	34	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  TLD 1998	101	TAC/TCC	34	Tyr/Ser	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	104	CTG/CGG	35	Leu/Arg	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	109-110	GGA/TAA	37	Glu/STOP	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Morlock GP AAC 2000	106	del 5.3kb		Frame/TRUNC	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Hou L Epi Infect 2000	121	TAC/CAC	41	Tyr/His	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRE	600	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Hirano  TLD 1998	123	TAC/TAA	41	Tyr/STOP	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Sreevatsan S AAC 1997	123	TAC/TAG	41	Tyr/STOP	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Hirano  TLD 1998	128	CAC/CCC	43	His/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	134	GTG/GGG	45	Val/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  TLD 1998	136	G ins	46	Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHE	>800	Proportion method	33/168	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	136	GCA/CCA	46	Ala/Pro	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Cheng SJ AAC 2000	137	GCA/GAA	46	Ala/Glu			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Cheng SJ AAC 2000	137	GCA/GTA	46	Ala/Val			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hou L Epi Infect 2000	139	ACC/CCC	47	Thr/Pro	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRSE	1500	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Marttila HJ AAC 1999	139	ACC/TCC	47	Thr/Ser	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Sreevatsan S AAC 1997	139	ACC/GCC	47	Thr/Ala	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	11/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	145	GAC/CAC	49	Asp/His	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	146	GAC/GCC	49	Asp/Ala	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	146	GAC/GTC	49	Asp/Val	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	146	GAC/GGC	49	Asp/Gly	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Rodrigues V de F AAC 2005	151	CAC/AAC	51	His/Asn	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40	
PZA	pncA	Mestdagh M AAC 1999	151	CAC/TAC	51	His/Tyr	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	151-230	del 80bp		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  TLD 1998	152	CAC/CCC	51	His/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Hirano  TLD 1998	152	CAC/CGC	51	His/Arg	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	153	CAC/CAG	51	His/Gln	2006	TB patients in Japan and Poland	Poland	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	153	CAC/CAA	51	His/Gln	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	2/0	
PZA	pncA	Sekiguchi JI JCM 2007	151	GAC/AAC	53	Asp/Asn	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Cheng SJ AAC 2000	158	GAC/GCC	53	Asp/Ala			South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	158	del A	53	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	160 	CCG/ACG	54	Pro/Thr	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	161	CCG/CTG	54	Pro/Leu	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	161	del C	54	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	162	ins T	54	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A Nature Med 1996	162	del G	54	Frameshift		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	"7H9 liquid medium, pH5.6; PZase activity assayed according to Wayne's method "	4/7	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	169	CAC/TAC	57	His/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sreevatsan S AAC 1997	169	CAC/GAC	57	His/Asp	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	
PZA	pncA	Brown TJ JMedMicro 2000	170	CAC/CCC	57	His/Pro	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		"BACTEC radiometric-based culture method, standard protocol; and PZase activity"	13/18	1/0	A2416T (rpoB)
PZA	pncA	Chan RCY JAC 2007	170	CAC/CTC	57	His/Leu	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	172	del T	58	Frameshift	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Escalante P TuberLung Dis 1998	172	TTC/CTC	58	Phe/Leu	1995-1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHR		Proportion method	11/29	1/0	"katG, 315, AGC/ACC; rpoB, 526 cac/ctc; embB, 306, ATG/ATA "
PZA	pncA	Hirano  TLD 1998	174	TTC/TTG	58	Phe/Leu	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	400	Proportion method	33/168	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	175	TCC/CCC	59	Ser/Pro	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	C2431T (rpoB)
PZA	pncA	Lemaitre N AAC 1999	181	ACA/CCA	61	Thr/Pro	1992		France	Sequencing	Whole gene	ZHRES	500ug/ml		19/35	1/0	
PZA	pncA	Mestdagh M AAC 1999	185	CCG/CAG??	62	Pro/His 	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Morlock GP AAC 2000	185	CCG/CGG	62	Pro/Arg	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Chan RCY JAC 2007	186	CCG/CTG	62	Pro/Leu	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hirano  TLD 1998	188	GAC/GGC	63	Asp/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Scorpio A Nature Med 1996	187	GAC/CAC	63	Asp/His		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	Colorado	Sequencing	Whole gene	MDR	>500ug/ml	PZase test with Wayne's method	4/7	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	190	TAT/GAT	64	Tyr/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	192	ins A	64	Frameshift	1996		France	Sequencing	Whole gene	ZSHE	1000ug/ml			1/0	
PZA	pncA	Mestdagh M AAC 1999	195-263	del 68bp		Frameshift	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Marttila HJ AAC 1999	196	TCG/CCG	66	Ser/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Hirano  TLD 1998	199	TCG/CCG	67	Ser/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	202	TGG/CGG	68	Trp/Arg	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	202	TGG/GGG	68	Trp/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Cheng SJ AAC 2000	203	TGG/TCA	68	Trp/STOP			USA	Sequencing	Whole gene	Z	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	203	TGG/TCG	68	Trp/Ser	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	203	TGG/TTG	68	Trp/Leu	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Scorpio A AAC 1997	206	CCA/CGA	69	Pro/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>300ug/ml	Pzase testing by Wayne's method	46/46	2/0	
PZA	pncA	Hou L Epi Infect 2000	206	CCA/CGA	69	Pro/Arg	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1200	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lemaitre N AAC 1999	206	CCA/CTA 	69	Pro/Leu	1994		France	Sequencing	Whole gene	ZHR	(pH 5.6, 5.8) >2000/>2000		19/35	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	211	CAT/TAT	71	His/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	212	CAT/GAT	71	His/Asp	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Morlock GP AAC 2000 	212	CAT/CGT	71	His/Arg	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Cheng SJ AAC 2000	213	CAT/CAG	71	His/Glu			USA	Sequencing	Whole gene	ZHRS	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Scorpio A AAC 1997	214	TGC/CGC	72	Cys/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	215	TGC/TAC	72	Cys/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sekiguchi JI JCM 2007	216	TGC/TGG	72	Cys/Trp	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Lemaitre N AAC 1999	215	ins 29bp		Frameshift	1986		France	Sequencing	Whole gene	ZHRS	>2000		19/35	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	218	ins CGCATTGCCG		Frameshift	2006	TB patients in Japan and Poland		Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Mestdagh M AAC 1999	221	ins G	74	Frameshift	1999	54 MDR mtb clinical strains	United Kingdom	Sequencing	Whole gene	Z		BACTEC 460 	23/62	2/0	
PZA	pncA	Chan RC JAC 2007	224	ATG/ACG	75	Met/Thr	1994-2004	250 drug-res. Mtb from Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZORH	100ug/ml	BACTEC MGIT 960 	89/250	1/0	"Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB); Ser315Thr(katG)"
PZA	pncA	Sreevatsan S AAC 1997	226	ACT/CCT	76	Thr/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	227	ACT/ATT	76	Thr/Ile	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	United kindom, Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460	13/18	8/0	C2431T (rpoB)
PZA	pncA	Morlock GP AAC 2000	233	GGC/GAC	78	Gly/Asp	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Chan RCY JAC 2007	236	GCG/GGG	79	Ala/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Brown TJ JMedMicro 2000	239	del A		Frameshift	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	Z		BACTEC 460 	13/18	1/0	C2431T (rpoB)
PZA	pncA	Sachais BS MolDiag 1998	241	TTC/GTC	80	Phe/Val	1993-1999	clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA	USA	Sequencing	Whole gene	Z		BACTEC at pH 6.4	2/12	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	244	CAT/TAT	82	His/Tyr	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	A2386T (rpoB)
PZA	pncA	Cheng SJ AAC 2000	245	CAT/CGT	82	His/Arg			USA	Sequencing	Whole gene	ZHRES	300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	246	CAT/CTT	82	His/Leu	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40	
PZA	pncA	Mestdagh M AAC 1999	254	CTG/CGG	85	Leu/Arg	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Scorpio A AAC 1997	254	CTG/CCG	85	Leu/Pro	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	3/0	
PZA	pncA	Lemaitre N AAC 1999	260	ACG/ATG	87	Thr/Met	1987		France	Sequencing	Whole gene	ZHRES	1000-1500		19/35	1/0	
PZA	pncA	Hou L Epi Infect 2000	263	TCG/TAG	88	Ser/STOP	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRES	>2000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Hannan MM JCM 2001	269	ATC/AGC	90	Ile/Ser	1996-1999	isolates from 5 counties in California	USA	Sequencing	Whole gene	Z		BACTEC radiometric testing	3/11	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	269	ATC/AGC	90	Ile/Ser	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sreevatsan S AAC 1997	280	TTC/CCC	94	Phe/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	T281C
PZA	pncA	Lee KW J Korean Med Sci 2001	286	AAG/CAG	96	Lys/Gln	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	286	AAG/GAG	96	Lys/Glu	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Scorpio A AAC 1997	287	AAG/ACG	96	Lys/Thr	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  TLD 1998	287	ins T		Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	287	ins T		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	288	AAG/AAT	96	Lys/Asn	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A Nature Med 1996	288	del G		Frameshift		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	Z	>500ug/ml	PZase test with Wayne's method	4/7	1/0	
PZA	pncA	Cheng SJ AAC 2000	289	GGT/AGT	97	Gly/Ser			USA	Sequencing	Whole gene	ZHRES	>900	Proportion method, BACTEC 460	59/59	2/0	
PZA	pncA	Morlock GP AAC 2000	290	GGT/GAT	97	Gly/Asp	1999			Sequencing	Whole gene	Z	400	Proportion method	37/60	1/0	
PZA	pncA	Hirano  TLD 1998	297	TAC/TAA	99	Tyr/STOP	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Morlock GP AAC 2000	297	TAC/TAG	99	Tyr/STOP	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	2/0	
PZA	pncA	Cheng SJ AAC 2000	301	ins G		Frameshift			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hou L Epi Infect 2000	301	ins A		Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	900	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Marttila HJ AAC 1999	304	GCG/ACG	102	Ala/Thr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	305	GCG/GTG	102	Ala/Val	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Lemaitre N AAC 1999	306	ins C		Frameshift	1989		France	Sequencing	Whole gene	ZHRES	500-1500		19/35	1/0	
PZA	pncA	Mestdagh M AAC 1999	307	TAC/CAC	103	Tyr/His	1999	54 MDR mtb clinical strains	Canada	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	307	del TACAG		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	308	TAC/TCC	103	Tyr/Ser	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Lemaitre N AAC 1999	308	TAC/TGC	103	Tyr/Cys	1994		France	Sequencing	Whole gene	ZHRE	1500			1/0	
PZA	pncA	Marttila HJ AAC 1999	309	TAC/TAG	103	Tyr/STOP	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Morlock GP AAC 2000	309	TAC/TAA	103	Tyr/STOP	1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	312	del C	104	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  TLD 1998	312	AGC/AGG	104	Ser/Arg	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	319	GAA/AAA	107	Gly/Lys	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Hirano  TLD 1998	340	ACG/CCG	114	Thr/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHR	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Cheng SJ AAC 2000	341	del C		Frameshift			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Lemaitre N AAC 1999	341	ins 1355bp			1989		France	Sequencing	Whole gene	ZHRE	1000		19/35	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	346	CTG/GTG	116	Leu/Val	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Marttila HJ AAC 1999	347	CTG/CGG	116	Leu/Arg	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Hou L Epi Infect 2000	353	AAT/ACT	118	Asn/Thr	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Sreevatsan S AAC 1997	353	TGG/CGG	119	Trp/Arg	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	357	TGG/TGA	119	Trp/STOP	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Portugal I AAC 2004	359	CTG/CCG	120	Leu/Pro	2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55	
PZA	pncA	Sreevatsan S AAC 1997	362	CGG/CCG	121	Arg/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Hou L Epi Infect 2000	368	ins AG		Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	368	ins 18bp		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	374	GTC/GAC	125	Val/Asp	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	379-389	del 11bp		Frameshift	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	381	del GG		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	382	ins AG		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	384	GTC/GGC	128	Val/Gly	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method and Pzase test	59	40	
PZA	pncA	Lee KW J Korean Med Sci 2001	386-389	del ATGT		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	388	ins GAGGTCGAT		ins Glu Val Asp	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Sreevatsan S AAC 1997	388	ins AGGTCGATG		Ins Arg Ser Met	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	4/0	
PZA	pncA	Hirano  TLD 1998	389	GTG/GGG	130	Val/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	391	ins GG		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	391	ins GG		Frameshift	1988		France	Sequencing	Whole gene	ZHRES	500-1000		19/35	1/0	
PZA	pncA	Scorpio A AAC 1997	391	del G		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	392	ins G		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  TLD 1998	395	GGT/GAT	132	Gly/Asp	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	Z	>800	Proportion method	33/168	1/0	
PZA	pncA	Scorpio A AAC 1997	394	GGT/AGT	132	Gly/Ser	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	2/0	
PZA	pncA	Hirano  TLD 1998	395-411 del	del 16bp		Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	India	Sequencing	Whole gene	ZR	>800	Proportion method	33/168	1/0	
PZA	pncA	Sreevatsan S AAC 1997	397	ins T		Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Marttila HJ AAC 1999	398	ATT/ACT	133	Ile/Thr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Morlock GP AAC 2000	398	ATT/AAT	133	Ile/Asn	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	401	GCC/GTC	134	Ala/Val	1995-1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRP		Proportion method	11/29	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Morlock GP AAC 2000	403	ACC/CCC	135	Thr/Pro	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Hou L Epi Infect 2000	403	ins CC		Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRE	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Sreevatsan S AAC 1997	403	ins C		Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	GAT/TAT	136	Asp/Tyr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	GAT/AAT	136	Asp/Asn	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Mestdagh M AAC 1999	406	GAT/CAT	136	Asp/His	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	del G		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	407	GAT/GGT	136	Asp/Gly	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Mestdagh M AAC 1999	407-408	ins C		Frameshift	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Scorpio A AAC 1997	410	CAT/CCT	137	His/Pro	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Sreevatsan S AAC 1997	410	CAT/CGT	137	His/Arg	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	
PZA	pncA	Cheng SJ AAC 2000	413	TGT/TCT	138	Cys/Ser			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Scorpio A Nature Med 1996	413	TGT/TAT	138	Cys/Tyr		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	Colorado	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	4/7	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	414	ins G		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Cheng SJ AAC 2000	415	GTG/ATG	139	Val/Met			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Morlock GP AAC 2000	415	GTG/CTG	139	Val/Leu	1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0	
PZA	pncA	Morlock GP AAC 2000	416	GTG/GGG	139	Val/Gly	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Sreevatsan S AAC 1997	416	GTG/GCG	139	Val/Ala	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Scorpio A AAC 1997	416	del TG		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	418	CGC/AGC	140	Arg/Ser				Sequencing	Whole gene	Z		Proportion method, BACTEC 460	59/59	20/0	
PZA	pncA	Lemaitre N AAC 1999	419	del 68bp		Frameshift	1992		France	Sequencing	Whole gene	ZHRE	1000		19/35	1/0	
PZA	pncA	Cheng SJ AAC 2000	420	ins G		Frameshift			USA	Sequencing	Whole gene	ZR	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Cheng SJ AAC 2000	420	ins GG		Frameshift			USA	Sequencing	Whole gene	ZHRSO	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	421	CAG/TAG	141	Gln/STOP	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A Nature Med 1996	422	CAG/CCG	141	Gln/Pro		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	invitro	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	424	ACG/CCG	142	Thr/Pro	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	MDR		Proportion method	11/29	1/0	rpoB, 516, GAC/TAC
PZA	pncA	Hirano  TLD 1998	424	ACG/GCG	142	Thr/Ala	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Scorpio A AAC 1997	425	ACG/AAG	142	Thr/Lys	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	425	ACG/ATG	142	Thr/Met	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	428	ins GG		Frameshift			South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Lee KW J Korean Med Sci 2001	436	GCG/ACG	146	Ala/Thr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	436	del G		Frameshift	1987		France	Sequencing	Whole gene	ZHRE	1000-1500		19/35	1/0	
PZA	pncA	Hirano  TLD 1998	437	GCG/GTG	146	Ala/Val	1997	168 mtb strain isolated in 9 Asian countries and Canada	India	Sequencing	Whole gene	ZRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	442	CGC/AGC	148	Arg/Ser	2006	TB patients in Japan and Poland	Poland	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	442	C/A	148	Arg/Ser	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	C2431G(rpoB)
PZA	pncA	Scorpio A AAC 1997	443	del G		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	446	del 8bp		Frameshift	1990-1992	Canadians	Canada	Sequencing	Whole gene	ZHRE	>300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Scorpio A AAC 1997	446	ins 8bp		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	452	del T		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	458	ACC/AAC	153	Thr/Asn	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Marttila HJ AAC 1999	460	AGG/GGG	154	Arg/Gly	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lemaitre N AAC 1999	464	GTG/GGG	155	Val/Gly	1987		France	Sequencing	Whole gene	ZHRE	1500		19/35	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	464	GTG/GCG	155	Val/Ala	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRES		Proportion method	11/29	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Lee KW J Korean Med Sci 2001	465	ins T		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Scorpio A AAC 1997	475	del C		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	476	CTG/CCG	159	Leu/Pro	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	476	CTG/CGG	159	Leu/Arg	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	478	ACA/CCA	160	Thr/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	480	ins TGAC		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	481	GCG/CCG	161	Ala/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Chan RC JAC 2007	485	GGT/GAT	162	Gly/Asp	1994-2004	250 drug-res. Mtb from Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZOREth	100mg/L	BACTEC MGIT 960	89/250	1/0	"Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB)"
PZA	pncA	Hou L Epi Infect 2000	501	ins CG		Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZSHE	900	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Cheng SJ AAC 2000	503	ACC/AAC	168	Thr/Asn			Canada	Sequencing	Whole gene	ZRO	300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Mestdagh M AAC 1999	511	GCG/ACG	171	Ala/Thr	1999	54 MDR mtb clinical strains	Bangladesh	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Sachais BS MolDiag 1998	511	GCG/CCG	171	Ala/Pro	1993-1999	clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA	USA	Sequencing	Whole gene	Z		BACTEC at pH 6.4	2/12	1/0	
PZA	pncA	Mestdagh M AAC 1999	512	GCG/GTG	171	Ala/Val	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	512	GCG/GAG	171	Ala/Glu	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40	
PZA	pncA	Mestdagh M AAC 1999	512	del C		Frameshift	1999	54 MDR mtb clinical strains	Rwanda	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Hirano  TLD 1998	515	CTG/CCG	172	Leu/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Mestdagh M AAC 1999	514-515	CTG/GCG	172	Leu/Ala	1999	54 MDR mtb clinical strains	Belgium	Sequencing	Whole gene	Z		BACTEC 460 	23/62	2/0	
PZA	pncA	Scorpio A AAC 1997	518	ins 5bp		Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	523	ATG/GTG	175	Met/Val	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	532	ins C		Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	535	AGC/CGC	179	Ser/Arg	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	538	GTC/TTC	180	Val/Phe	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	543	GAG/GAT	181	Glu/Asp	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lemaitre N AAC 1999	545	TTG/TCG	182	Leu/Ser	1997		France	Sequencing	Whole gene	ZHRS	500-2000ug/ml		19/35	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	554	AGC/ACC	185	Ser/Thr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Chan RCY JAC 2007	554	AGC/ATC	185	Ser/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Marttila HJ AAC 1999	-12	T/G	-12		1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Scorpio A AAC 1997	-11	A/C	-11		1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Sreevatsan S AAC 1997	-11	A/G	-11		1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460 	67/118	2/0	
PZA	pncA	Morlock GP AAC 2000	-7	T/C	-7		1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0	
PZA	pncA	Hou L Epi Infect 2000	1	del 8bp	1	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	>2000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Scorpio A AAC 1997	1	del 11bp	1	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	2/0	
PZA	pncA	Portugal I AAC 2004	2	ATG/ACG	1	Met/Thr	2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55	
PZA	pncA	Lee KW J Korean Med Sci 2001	3	ATG/ATT	1	Met/Ile	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	7	GCG/CCG	3	Ala/Pro	1986		France	Sequencing	Whole gene	ZHR	1000			1/0	
PZA	pncA	Sekiguchi JI JCM 2007	8	GCG/GAG	3	Ala/Glu	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	11	TTG/TGG	4	Leu/Trp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	11	TTG/TCG	4	Leu/Ser	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	14	ATC/AGC	5	Ile/Ser	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	19	GTC/ATC	7	Val/Ile	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRPES		Proportion method	40146	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Escalante P TuberLung Dis 1998	19	GTC/TTC	7	Val/Phe	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRPS		Proportion method	40146	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; embB, 328, GAT:A del"
PZA	pncA	Hirano  K TLD 1997	20	GTC/GGC	7	Val/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	20	GTC/GAC	7	Val/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	22	GAC/TAC	8	Asp/Tyr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	23	GAC/GGC	8	Asp/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	24	GAC/GAG	8	Asp/Glu	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	26	GTG/GCG	9	Val/Ala	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	26	GTG/GGG	9	Val/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	26	GTG/TTG	9	Val/Leu	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Chan RCY JAC 2007	27	GTG/TCG	9	Val/Ser	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Scorpio A AAC 1997	28	del C	10	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Marttila HJ AAC 1999	28	CAA/AAA	10	Gln/Lys	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	28	CAA/TAA	10	Gln/STOP	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Cheng SJ AAC 2000	29	CAG/CGA	10	Gln/Arg	1990-1992		USA	Sequencing	Whole gene	ZHREO	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hirano  K TLD 1997	29	CAG/CCG	10	Gln/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Morlock GP AAC 2000	29	CAG/CCA	10	Gln/Pro	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	34	GAC/AAC	12	Asp/Asn	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	35	GAC/GCC	12	Asp/Ala	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lemaitre N AAC 1999	38	TTC/TCC 	13	Phe/Ser	1987		France	Sequencing	Whole gene	ZHRES	>2000		19/35	1/0	
PZA	pncA	Scorpio A AAC 1997	40	TGC/CGC	14	Cys/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	40	TGC/CGC	14	Cys/His	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	41	TGC/TAC	14	Cys/Tyr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Chan RCY JAC 2007	47	del G	16	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hirano  K TLD 1997	50	GGC/GAC	17	Gly/Asp	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	2/0	
PZA	pncA	Chan RCY JAC 2007	50	GGC/GTC	17	Gly/Val	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Cheng SJ AAC 2000	52	ins GG	17	Frameshift			USA	Sequencing	Whole gene	ZHR	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Chan RCY JAC 2007	56	CTG/CGG	19	Leu/Arg	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Sreevatsan S AAC 1997	56	CTG/CCG	19	Leu/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460 	67/118	1/0	
PZA	pncA	Chan RCY JAC 2007	62	GTA/GGA	21	Val/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Chan RCY JAC 2007	64	del A	22	Frameshift	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP, Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hou L Epi Infect 2000	59	del C	20	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRSE	1800	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	68-69	GGT/GTC	23	Gly/Val	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	70	del G	24	Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	7/0	
PZA	pncA	Hou L Epi Infect 2000	71	del G	24	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRH	600	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	74-75	GCC/GAA	25	Ala/Glu	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	77	GCG/GGG	26	Ala/Gly	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Marttila HJ AAC 1999	84	del C	28	Frameshift	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	83	GCC/GAC	28	Ala/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hannan MM JCM 2001	88-112	del 24bp	29	Frameshift	1996-1999	isolates from 5 counties in California	California, USA	Sequencing	Whole gene	Z		BACTEC radiometric testing	39883	1/0	
PZA	pncA	Scorpio A AAC 1997	98-216	del 118bp	33	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	100	ins T	34	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  K TLD 1997	101	TAC/TCC	34	Tyr/Ser	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	2/0	
PZA	pncA	Stavrum R PlosOne 2009	104	CTG/CCG	35	Leu/Pro	Published 2009		India	Sequencing	Whole gene			N.S.		1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	104	CTG/CGG	35	Leu/Arg	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	109-110	GGA/TAA	37	Glu/STOP	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Morlock GP AAC 2000	106	del 5.3kb	35	Frameshift/Truncation	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Hou L Epi Infect 2000	121	TAC/CAC	41	Tyr/His	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRE	600	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Hirano  K TLD 1997	123	TAC/TAA	41	Tyr/STOP	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Sreevatsan S AAC 1997	123	TAC/TAG	41	Tyr/STOP	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Hirano  K TLD 1997	128	CAC/CCC	43	His/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	134	GTG/GGG	45	Val/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  K TLD 1997	136	ins G	46	Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHE	>800	Proportion method	33/168	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	136	GCA/CCA	46	Ala/Pro	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Cheng SJ AAC 2000	137	GCA/GAA	46	Ala/Glu			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Cheng SJ AAC 2000	137	GCA/GTA	46	Ala/Val			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hou L Epi Infect 2000	139	ACC/CCC	47	Thr/Pro	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRSE	1500	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Marttila HJ AAC 1999	139	ACC/TCC	47	Thr/Ser	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Sreevatsan S AAC 1997	139	ACC/GCC	47	Thr/Ala	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	11/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	145	GAC/CAC	49	Asp/His	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	146	GAC/GCC	49	Asp/Ala	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	146	GAC/GTC	49	Asp/Val	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	146	GAC/GGC	49	Asp/Gly	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Rodrigues V de F AAC 2005	151	CAC/AAC	51	His/Asn	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40	
PZA	pncA	Mestdagh M AAC 1999	151	CAC/TAC	51	His/Tyr	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	151-230	del 80bp	50	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  K TLD 1997	152	CAC/CCC	51	His/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Hirano  K TLD 1997	152	CAC/CGC	51	His/Arg	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHR	>800	Proportion method	33/168	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	153	CAC/CAG	51	His/Gln	2006	TB patients in Japan and Poland	Poland	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	153	CAC/CAA	51	His/Gln	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	2/0	
PZA	pncA	Sekiguchi JI JCM 2007	151	GAC/AAC	53	Asp/Asn	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Cheng SJ AAC 2000	158	GAC/GCC	53	Asp/Ala			South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	158	del A	53	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	160	CCG/ACG	54	Pro/Thr	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	161	CCG/CTG	54	Pro/Leu	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	161	del C	54	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	162	ins T	54	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A Nature Med 1996	162	del G	54	Frameshift		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	"7H9 liquid medium, pH5.6; PZase activity assayed according to Wayne's method "	39910	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	169	CAC/TAC	57	His/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sreevatsan S AAC 1997	169	CAC/GAC	57	His/Asp	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	
PZA	pncA	Brown TJ JMedMicro 2000	170	CAC/CCC	57	His/Pro	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		"BACTEC radiometric-based culture method, standard protocol; and PZase activity"	13/18	1/0	A2416T (rpoB)
PZA	pncA	Chan RCY JAC 2007	170	CAC/CTC	57	His/Leu	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	172	del T	58	Frameshift	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Escalante P TuberLung Dis 1998	172	TTC/CTC	58	Phe/Leu	1995-1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHR		Proportion method	40146	1/0	"katG, 315, AGC/ACC; rpoB, 526 cac/ctc; embB, 306, ATG/ATA "
PZA	pncA	Hirano  K TLD 1997	174	TTC/TTG	58	Phe/Leu	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	400	Proportion method	33/168	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	175	TCC/CCC	59	Ser/Pro	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	C2431T (rpoB)
PZA	pncA	Lemaitre N AAC 1999	181	ACA/CCA	61	Thr/Pro	1992		France	Sequencing	Whole gene	ZHRES	500ug/ml		19/35	1/0	
PZA	pncA	Mestdagh M AAC 1999	185	CCG/CAG??	62	Pro/His 	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Morlock GP AAC 2000	185	CCG/CGG	62	Pro/Arg	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Chan RCY JAC 2007	186	CCG/CTG	62	Pro/Leu	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Hirano  K TLD 1997	188	GAC/GGC	63	Asp/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Scorpio A Nature Med 1996	187	GAC/CAC	63	Asp/His		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA (Colorado)	Sequencing	Whole gene	MDR	>500ug/ml	PZase test with Wayne's method	39910	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	190	TAT/GAT	64	Tyr/Asp	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	192	ins A	64	Frameshift	1996		France	Sequencing	Whole gene	ZSHE	1000ug/ml			1/0	
PZA	pncA	Mestdagh M AAC 1999	195-263	del 68bp	65	Frameshift	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Marttila HJ AAC 1999	196	TCG/CCG	66	Ser/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Hirano  K TLD 1997	199	TCG/CCG	67	Ser/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	202	TGG/CGG	68	Trp/Arg	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	202	TGG/GGG	68	Trp/Gly	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Cheng SJ AAC 2000	203	TGG/TCA	68	Trp/STOP			USA	Sequencing	Whole gene	Z	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	203	TGG/TCG	68	Trp/Ser	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Sreevatsan S AAC 1997	203	TGG/TTG	68	Trp/Leu	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Scorpio A AAC 1997	206	CCA/CGA	69	Pro/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>300ug/ml	Pzase testing by Wayne's method	46/46	2/0	
PZA	pncA	Hou L Epi Infect 2000	206	CCA/CGA	69	Pro/Arg	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1200	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lemaitre N AAC 1999	206	CCA/CTA 	69	Pro/Leu	1994		France	Sequencing	Whole gene	ZHR	(pH 5.6, 5.8) >2000/>2000		19/35	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	211	CAT/TAT	71	His/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	212	CAT/GAT	71	His/Asp	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Morlock GP AAC 2000 	212	CAT/CGT	71	His/Arg	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Cheng SJ AAC 2000	213	CAT/CAG	71	His/Glu			USA	Sequencing	Whole gene	ZHRS	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Scorpio A AAC 1997	214	TGC/CGC	72	Cys/Arg	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	215	TGC/TAC	72	Cys/Tyr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sekiguchi JI JCM 2007	216	TGC/TGG	72	Cys/Trp	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Lemaitre N AAC 1999	215	ins 29bp	72	Frameshift	1986		France	Sequencing	Whole gene	ZHRS	>2000		19/35	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	218	ins CGCATTGCCG	73	Frameshift	2006	TB patients in Japan and Poland		Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Mestdagh M AAC 1999	221	ins G	74	Frameshift	1999	54 MDR mtb clinical strains	United Kingdom	Sequencing	Whole gene	Z		BACTEC 460 	23/62	2/0	
PZA	pncA	Chan RCY JAC 2007	224	ATG/ACG	75	Met/Thr	1994-2004	250 drug-res. Mtb from Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZORH	100ug/ml	BACTEC MGIT 960 	89/250	1/0	"Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB); Ser315Thr(katG)"
PZA	pncA	Sreevatsan S AAC 1997	226	ACT/CCT	76	Thr/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	227	ACT/ATT	76	Thr/Ile	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	United Kindom, Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460	13/18	8/0	C2431T (rpoB)
PZA	pncA	Morlock GP AAC 2000	233	GGC/GAC	78	Gly/Asp	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Chan RCY JAC 2007	236	GCG/GGG	79	Ala/Gly	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89	
PZA	pncA	Brown TJ JMedMicro 2000	239	del A	80	Frameshift	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	Z		BACTEC 460 	13/18	1/0	C2431T (rpoB)
PZA	pncA	Sachais BS MolDiag 1998	241	TTC/GTC	80	Phe/Val	1993-1999	clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA	USA	Sequencing	Whole gene	Z		BACTEC at pH 6.4	39856	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	244	CAT/TAT Error? This makes Tyr not Asp.	82	His/Asp	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	A2386T (rpoB)
PZA	pncA	Cheng SJ AAC 2000	245	CAT/CGT	82	His/Arg			USA	Sequencing	Whole gene	ZHRES	300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	246	CAT/CTT	82	His/Leu	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40	
PZA	pncA	Peridgao J MDR 2008	250	ins C		Frameshift	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	3/0	
PZA	pncA	Mestdagh M AAC 1999	254	CTG/CGG	85	Leu/Arg	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Scorpio A AAC 1997	254	CTG/CCG	85	Leu/Pro	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	3/0	
PZA	pncA	Lemaitre N AAC 1999	260	ACG/ATG	87	Thr/Met	1987		France	Sequencing	Whole gene	ZHRES	1000-1500		19/35	1/0	
PZA	pncA	Hou L Epi Infect 2000	263	TCG/TAG	88	Ser/STOP	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRES	>2000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Hannan MM JCM 2001	269	ATC/AGC	90	Ile/Ser	1996-1999	isolates from 5 counties in California	USA	Sequencing	Whole gene	Z		BACTEC radiometric testing	39883	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	269	ATC/AGC	90	Ile/Ser	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Sreevatsan S AAC 1997	280	TTC/CCC	94	Phe/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	T281C
PZA	pncA	Peridgao J MDR 2008	282	ins T		Frameshift	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0	
PZA	pncA	Peridgao J MDR 2008	285	TAC/TAA	95	Tyr/STOP	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	286	AAG/CAG	96	Lys/Gln	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	286	AAG/GAG	96	Lys/Glu	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Scorpio A AAC 1997	287	AAG/ACG	96	Lys/Thr	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  K TLD 1997	287	ins T	96	Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	287	ins T	96	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A AAC 1997	288	AAG/AAT	96	Lys/Asn	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A Nature Med 1996	288	del G	96	Frameshift		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	Z	>500ug/ml	PZase test with Wayne's method	39910	1/0	
PZA	pncA	Cheng SJ AAC 2000	289	GGT/AGT	97	Gly/Ser			USA	Sequencing	Whole gene	ZHRES	>900	Proportion method, BACTEC 460	59/59	2/0	
PZA	pncA	Morlock GP AAC 2000	290	GGT/GAT	97	Gly/Asp	1999			Sequencing	Whole gene	Z	400	Proportion method	37/60	1/0	
PZA	pncA	Hirano  K TLD 1997	297	TAC/TAA	99	Tyr/STOP	1997	168 mtb strain isolated in 9 Asian countries and Canada	Thailand	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0	
PZA	pncA	Morlock GP AAC 2000	297	TAC/TAG	99	Tyr/STOP	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	2/0	
PZA	pncA	Cheng SJ AAC 2000	301	ins G	100	Frameshift			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Hou L Epi Infect 2000	301	ins A	100	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	900	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Marttila HJ AAC 1999	304	GCG/ACG	102	Ala/Thr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Marttila HJ AAC 1999	305	GCG/GTG	102	Ala/Val	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Lemaitre N AAC 1999	306	ins C	102	Frameshift	1989		France	Sequencing	Whole gene	ZHRES	500-1500		19/35	1/0	
PZA	pncA	Mestdagh M AAC 1999	307	TAC/CAC	103	Tyr/His	1999	54 MDR mtb clinical strains	Canada	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	307	del TACAG	102	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	308	TAC/TCC	103	Tyr/Ser	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Lemaitre N AAC 1999	308	TAC/TGC	103	Tyr/Cys	1994		France	Sequencing	Whole gene	ZHRE	1500			1/0	
PZA	pncA	Marttila HJ AAC 1999	309	TAC/TAG	103	Tyr/STOP	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Morlock GP AAC 2000	309	TAC/TAA	103	Tyr/STOP	1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0	
PZA	pncA	Scorpio A AAC 1997	312	del C	104	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Hirano  K TLD 1997	312	AGC/AGG	104	Ser/Arg	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	319	GAA/AAA	107	Gly/Lys	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Hirano  K TLD 1997	340	ACG/CCG	114	Thr/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Yemen	Sequencing	Whole gene	ZHR	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Cheng SJ AAC 2000	341	del C	114	Frameshift			South Korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Lemaitre N AAC 1999	341	ins 1355bp	114	Frameshift	1989		France	Sequencing	Whole gene	ZHRE	1000		19/35	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	346	CTG/GTG	116	Leu/Val	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Marttila HJ AAC 1999	347	CTG/CGG	116	Leu/Arg	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Hou L Epi Infect 2000	353	AAT/ACT	118	Asn/Thr	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZHRS	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Sreevatsan S AAC 1997	355	TGG/CGG	119	Trp/Arg	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Stavrum R PlosOne 2009	357	TGG/TGC	119	Trp/Cys	Published 2009		India	Sequencing	Whole gene	RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	"1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present"
PZA	pncA	Lee KW J Korean Med Sci 2001	357	TGG/TGA	119	Trp/STOP	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Portugal I AAC 2004	359	CTG/CCG	120	Leu/Pro	2000-2001	several hospitals in Lisbon	Portugal	Sequencing	Whole gene	Z		BACTEC MGIT 960	55	55	
PZA	pncA	Sreevatsan S AAC 1997	362	CGG/CCG	121	Arg/Pro	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Hou L Epi Infect 2000	368	ins AG	123	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRHSE	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	368	ins 18bp	123	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	374	GTC/GAC	125	Val/Asp	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Peridgao J MDR 2008	374	GTC/GGC	125	Val/Gly	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	19/0	
PZA	pncA	Marttila HJ AAC 1999	379-389	del 11bp	126	Frameshift	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	381	del GG	127	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Peridgao J MDR 2008	381	del 9bp	127	Frameshift	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	382	ins AG	127	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	384	GTC/GGC	128	Val/Gly	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method and Pzase test	59	40	
PZA	pncA	Lee KW J Korean Med Sci 2001	386-389	del ATGT	129	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	388	ins GAGGTCGAT	129	ins Glu Val Asp	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Sreevatsan S AAC 1997	388	ins AGGTCGATG	129	Ins Arg Ser Met	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	4/0	
PZA	pncA	Hirano  K TLD 1997	389	GTG/GGG	130	Val/Gly	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	391	ins GG	130	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	391	ins GG	130	Frameshift	1988		France	Sequencing	Whole gene	ZHRES	500-1000		19/35	1/0	
PZA	pncA	Scorpio A AAC 1997	391	del G	130	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	392	ins G	131	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Hirano  K TLD 1997	395	GGT/GAT	132	Gly/Asp	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	Z	>800	Proportion method	33/168	1/0	
PZA	pncA	Scorpio A AAC 1997	394	GGT/AGT	132	Gly/Ser	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	2/0	
PZA	pncA	Hirano  K TLD 1997	395-411 del	del 16bp	132	Frameshift	1997	168 mtb strain isolated in 9 Asian countries and Canada	India	Sequencing	Whole gene	ZR	>800	Proportion method	33/168	1/0	
PZA	pncA	Sreevatsan S AAC 1997	397	ins T	132	Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Marttila HJ AAC 1999	398	ATT/ACT	133	Ile/Thr	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Morlock GP AAC 2000	398	ATT/AAT	133	Ile/Asn	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	401	GCC/GTC	134	Ala/Val	1995-1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRP		Proportion method	40146	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Morlock GP AAC 2000	403	ACC/CCC	135	Thr/Pro	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Hou L Epi Infect 2000	403	ins CC	134	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZRE	1000	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Sreevatsan S AAC 1997	403	ins C	134	Frameshift	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	GAT/TAT	136	Asp/Tyr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	GAT/AAT	136	Asp/Asn	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Mestdagh M AAC 1999	406	GAT/CAT	136	Asp/His	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	406	del G	135	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	407	GAT/GGT	136	Asp/Gly	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Mestdagh M AAC 1999	407-408	ins C	136	Frameshift	1999	54 MDR mtb clinical strains	Azerbaijan	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Scorpio A AAC 1997	410	CAT/CCT	137	His/Pro	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Sreevatsan S AAC 1997	410	CAT/CGT	137	His/Arg	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	2/0	
PZA	pncA	Cheng SJ AAC 2000	413	TGT/TCT	138	Cys/Ser			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Scorpio A Nature Med 1996	413	TGT/TAT	138	Cys/Tyr		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA (Colorado)	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	39910	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	414	ins G	138	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Cheng SJ AAC 2000	415	GTG/ATG	139	Val/Met			South korea	Sequencing	Whole gene	Z	>500	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Morlock GP AAC 2000	415	GTG/CTG	139	Val/Leu	1999			Sequencing	Whole gene	Z	100	Proportion method	37/60	1/0	
PZA	pncA	Morlock GP AAC 2000	416	GTG/GGG	139	Val/Gly	1999			Sequencing	Whole gene	Z	>800	Proportion method	37/60	1/0	
PZA	pncA	Sreevatsan S AAC 1997	416	GTG/GCG	139	Val/Ala	1996		Diverse geographical locations	Sequencing	Whole gene	Z		BACTEC 460	67/118	1/0	
PZA	pncA	Scorpio A AAC 1997	416	del TG	139	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	418	CGC/AGC	140	Arg/Ser				Sequencing	Whole gene	Z		Proportion method, BACTEC 460	59/59	20/0	
PZA	pncA	Lemaitre N AAC 1999	419	del 68bp	140	Frameshift	1992		France	Sequencing	Whole gene	ZHRE	1000		19/35	1/0	
PZA	pncA	Cheng SJ AAC 2000	420	ins G	140	Frameshift			USA	Sequencing	Whole gene	ZR	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Cheng SJ AAC 2000	420	ins GG	140	Frameshift			USA	Sequencing	Whole gene	ZHRSO	>900	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	421	CAG/TAG	141	Gln/STOP	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Scorpio A Nature Med 1996	422	CAG/CCG	141	Gln/Pro		clinical isolates from L. Heifets, National Jewish Center for Immunology and Resp. Diseases	USA	Sequencing	Whole gene	MDR	>500ug/ml	Pzase testing by Wayne's method	invitro	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	424	ACG/CCG	142	Thr/Pro	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	MDR		Proportion method	40146	1/0	rpoB, 516, GAC/TAC
PZA	pncA	Hirano  K TLD 1997	424	ACG/GCG	142	Thr/Ala	1997	168 mtb strain isolated in 9 Asian countries and Canada	Myanmar	Sequencing	Whole gene	ZHRSE	>800	Middlebrook 7H11 agar w/ pH of 6.0	33/168	1/0	
PZA	pncA	Scorpio A AAC 1997	425	ACG/AAG	142	Thr/Lys	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Scorpio A AAC 1997	425	ACG/ATG	142	Thr/Met	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	428	ins GG	143	Frameshift			South korea	Sequencing	Whole gene	Z	>100	Proportion method, BACTEC 460	59/59	1/0?	
PZA	pncA	Lee KW J Korean Med Sci 2001	436	GCG/ACG	146	Ala/Thr	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Lemaitre N AAC 1999	436	del G	145	Frameshift	1987		France	Sequencing	Whole gene	ZHRE	1000-1500		19/35	1/0	
PZA	pncA	Hirano  K TLD 1997	437	GCG/GTG	146	Ala/Val	1997	168 mtb strain isolated in 9 Asian countries and Canada	India	Sequencing	Whole gene	ZRS	>800	Proportion method	33/168	1/0	
PZA	pncA	Peridgao J MDR 2008	439	ins CG	147	Frameshift	2003	National Institute of Health, Lisbon	Portugal	Sequencing	Whole gene	ZHRS		MGIT 960	48/58	1/0	
PZA	pncA	Sekiguchi JI JCM 2007	442	CGC/AGC	148	Arg/Ser	2006	TB patients in Japan and Poland	Poland	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0	
PZA	pncA	Brown TJ JMedMicro 2000	442	C/A	148	Arg/Ser	2000	"4 sensitive, 6 MDR from Turkey; 8 isolates from nosocomial MDR TB outbreak in UK "	Turkey	Sequencing	Whole gene	ZHRP		BACTEC 460 	13/18	1/0	C2431G(rpoB)
PZA	pncA	Scorpio A AAC 1997	443	del G	148	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Cheng SJ AAC 2000	446	del 8bp	149	Frameshift	1990-1992	Canadians	Canada	Sequencing	Whole gene	ZHRE	>300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Scorpio A AAC 1997	446	ins 8bp	149	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Lee KW J Korean Med Sci 2001	452	del T	151	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South Korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Morlock GP AAC 2000	458	ACC/AAC	153	Thr/Asn	1999			Sequencing	Whole gene	Z	800	Proportion method	37/60	1/0	
PZA	pncA	Marttila HJ AAC 1999	460	AGG/GGG	154	Arg/Gly	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	1/0	not tested
PZA	pncA	Lemaitre N AAC 1999	464	GTG/GGG	155	Val/Gly	1987		France	Sequencing	Whole gene	ZHRE	1500		19/35	1/0	
PZA	pncA	Escalante P TuberLung Dis 1998	464	GTG/GCG	155	Val/Ala	1995, 1996	patients w/ pulmonary TB	Peru	Sequencing	Whole gene	ZHRES		Proportion method	40146	1/0	"katG, 315, AGC/ACC; rpoB, 531, TCG/TTG; "
PZA	pncA	Lee KW J Korean Med Sci 2001	465	ins T	155	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	2/0	
PZA	pncA	Scorpio A AAC 1997	475	del C	158	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0	
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	476	CTG/CCG	159	Leu/Pro	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68	
PZA	pncA	Lee KW J Korean Med Sci 2001	476	CTG/CGG	159	Leu/Arg	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	478	ACA/CCA	160	Thr/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Lee KW J Korean Med Sci 2001	480	ins TGAC	160	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0	
PZA	pncA	Marttila HJ AAC 1999	481	GCG/CCG	161	Ala/Pro	1994-1997	St. Petersburg Institute of Phthisiopulmonology	Russia	Sequencing	Whole gene	Z		BACTEC 460 	36/44	2/0	not tested
PZA	pncA	Chan RCY JAC 2007	485	GGT/GAT	162	Gly/Asp	1994-2004	250 drug-res. Mtb from Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	ZOREth	100mg/L	BACTEC MGIT 960	89/250	1/0	"Asp94Gly (gyrA); Ser531Leu(rpoB); Met306Val(embB)"
PZA	pncA	Hou L Epi Infect 2000	501	ins CG	167	Frameshift	1996-1998	patients from China	China	PCR-SSCP	Whole gene	ZSHE	900	Proportion method, BACTEC 460	35/65	1/0	
PZA	pncA	Cheng SJ AAC 2000	503	ACC/AAC	168	Thr/Asn			Canada	Sequencing	Whole gene	ZRO	300	Proportion method, BACTEC 460	59/59	1/0	
PZA	pncA	Mestdagh M AAC 1999	511	GCG/ACG	171	Ala/Thr	1999	54 MDR mtb clinical strains	Bangladesh	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Sachais BS MolDiag 1998	511	GCG/CCG	171	Ala/Pro	1993-1999	clinical isolates from Microbio. Lab of Hospital of Univ. of Penn. & Episcopal Hosp. in PA	USA	Sequencing	Whole gene	Z		BACTEC at pH 6.4	39856	1/0	
PZA	pncA	Mestdagh M AAC 1999	512	GCG/GTG	171	Ala/Val	1999	54 MDR mtb clinical strains	Scotland	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0	
PZA	pncA	Rodrigues V de F AAC 2005	512	GCG/GAG	171	Ala/Glu	1998-2003	Selected according to culture availability in health centers in Brazl	Brazil	Sequencing	Whole gene	Z		Proportion method	59	40		
PZA	pncA	Mestdagh M AAC 1999	512	del C	171	Frameshift	1999	54 MDR mtb clinical strains	Rwanda	Sequencing	Whole gene	Z		BACTEC 460 	23/62	1/0		
PZA	pncA	Hirano  K TLD 1997	515	CTG/CCG	172	Leu/Pro	1997	168 mtb strain isolated in 9 Asian countries and Canada	Canada	Sequencing	Whole gene	ZHRSE	>800	Proportion method	33/168	1/0		
PZA	pncA	Mestdagh M AAC 1999	514-515	CTG/GCG	172	Leu/Ala	1999	54 MDR mtb clinical strains	Belgium	Sequencing	Whole gene	Z		BACTEC 460 	23/62	2/0		
PZA	pncA	Scorpio A AAC 1997	518	ins 5bp	173	Frameshift	1992-1995	"38 clinical isolates; 8 mutants made in vivo"		PCR-SSCP	Whole gene	Z	>900ug/ml	Pzase testing by Wayne's method	46/46	1/0		
PZA	pncA	Sekiguchi JI JCM 2007	523	ATG/GTG	175	Met/Val	2006	TB patients in Japan and Poland	Japan	Multi-plex PCR	Whole gene	Z		Proportion method, rapid broth method	17/138	1/0		
PZA	pncA	Lee KW J Korean Med Sci 2001	532	ins C	177	Frameshift	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	535	AGC/CGC	179	Ser/Arg	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		
PZA	pncA	Lee KW J Korean Med Sci 2001	538	GTC/TTC	180	Val/Phe	2001	mtb sputum cultures from Korean Institute of TB	South korea	Sequencing	Whole gene	Z		PZase test with Wayne's method	92/95	1/0		
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	543	GAG/GAT	181	Glu/Asp	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		
PZA	pncA	Lemaitre N AAC 1999	545	TTG/TCG	182	Leu/Ser	1997		France	Sequencing	Whole gene	ZHRS	500-2000ug/ml		19/35	1/0		
PZA	pncA	Louw GE Int J Tuberc Lung Dis 2006	554	AGC/ACC	185	Ser/Thr	2001-2002	Randomized selection from previously treated patients from 72 primary health care clinics in the BOKS region of Wester Cape Province. 	South Africa	Sequencing	Whole gene	ZHRSEthK		BACTEC MGIT 960	115	68		
PZA	pncA	Chan RCY JAC 2007	554	AGC/ATC	185	Ser/Ile	1994-2004	All isolates exhibiting resistance to one or more drugs R,I,E,P,O from Grantham Hospital and Public Health Laboratory of Hong Kong. 	Hong Kong	PCR-SSCP , Sequencing	Whole gene	Z		BACTEC MGIT 960	250	89		

RIFAMPICIN [RIF]																		
																		
	rpoB																	
Drug	Gene	Primary reference	Review reference 1	SNP	Codon position in Ecoli	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations	
RIF	rpoB	Heep M AAC 2000	O'Sullivan DM JAntiChemo 2005	GTC/TTC	146	Val/Phe	Published 2003	6 isolates from Japan for which MICs of rifampin were elevated but with wild-type sequence in the rpoB cluster region. N=6	Japan	Sequencing	Whole gene	R	1-4, 8-32 ug/ml	N.S.	(6/6 || 3 high level of resistance / 6 total)	(3/0)		
RIF	rpoB	Taniguchi H FEMS Micro 1996		GCG/GTG	381	Ala/Val	Published 1997	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	200 ug/ml	Proportion method, absolute concentration method	21/39	(1/0)		
RIF	rpoB	Cavusoglu C JCM 2002	O'Sullivan DM JAntiChemo 2005	CAG/CAT	490	Gln/His	Published 2002	41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41	Turkey	Line probe assay, Sequencing 	RRDR	R, RE, RHE, RH, RHES, RHS	N.S.	Proportion method	41/41	(1/0)		
RIF	rpoB	Schilke K IntJTubLungDis 1999		GAG/GCG	504	Glu/Ala	Published 1999	87 MDR strains from 12 hospitals in Southern African regions + 13 RIF-resistant strains of M. africanum + 3 RIF-resistant strains of M. tuberculosis from Sierra Leone and Uganda + 2 RIF-resistant strains of M. tuberculosis from Namibia. N=105	South Africa	Sequencing	RRDR	MDR	N.S.	Not specified	105/105	(2/0)	Double mutation with 531	
RIF	rpoB	Heym B Lancet 1994		TTC/TTG	505	Phe /Leu	1991-1992	###############################################################################################################################################################################################################################################################	La Reunion	PCR-SSCP		RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	"1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present"	
RIF	rpoB	Stavrum R PlosOne 2009		TTC/TTA	505	Phe /Leu	Published 2009		India	Sequencing	Whole gene	RSHE	> 100 mg/L	Proportion method	13/39	(2/0)	"1) rpoB L511P; S531C; rpsL K42R; katG no mutation; inhA mutation present 2) rpoB L511P; S531C; rpsL K42R; katG mutation present; inhA mutation present"	
RIF	rpoB	Wang Q JProtRes 2007		TTC/TCC	505	Phe/Ser	Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0		
RIF	rpoB	Bahrmand AR JCM 2009		GGC/AGC	507	Gly/Ser	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	<50 ug/ml	Proportion method	41/286	1/0	rpoB T508P	
RIF	rpoB	Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998	GGC/GAC	507	Gly/Asp	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	PCR-SSCP, Sequencing	RRDR	R	N.S.	Absolute concentration method. 	32/58	1/0	Location of double mutants not specified.	
RIF	rpoB	Bahrmand AR JCM 2009		GGC/GAT	507	Gly/Asp	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB Q513STOP, H526Y, S531F	
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	del GGC ACC	507	del Gly Thr												
RIF	rpoB	Bahrmand AR JCM 2009		ACC/CAC	508	Thr/His	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	6/0	rpoB H526Q, S531F	
RIF	rpoB	Bahrmand AR JCM 2009		ACC/CCC	508	Thr/Pro	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	<50 ug/ml	Proportion method	41/286	4/0	rpoB G507S	
RIF	rpoB	Bahrmand AR JCM 2009		ACC/GCC	508	Thr/Ala	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	<75 ug/ml	Proportion method	41/286	2/0	rpoB G523A	
RIF	rpoB	Mani C JCM 2001		ACC/AGC	508	Thr/Ser	Published 2001	RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50	India	Sequencing	RRDR	R	>128ug/ml	Proportion method	44/50	1/0	None described in the region sequenced.
RIF	rpoB	Matsiota-Bernard P JCM 1998		ACC/GCT	508	Thr/Ser	1995-1996	RIF-R clinical isolates. N=17	Greece	Line probe assay, Sequencing	RRDR	RHSEth	N.S.	Proportion method	17/17	1/0	None described in the region sequenced.
RIF	rpoB	Zenteno-Cuevas R MemInstOswaldCruz 2009		AGC/CAG	509	Ser/Gln	2007		Mexico	Sequencing	RRDR	HRSEZ	N.S.	BACTEC 460	15/25	1/0	None
RIF	rpoB	Williams D AAC 1994		AGC/ACC	509	Ser/Thr	Published 1994	110 RIF-resistant and 10 RIF-susceptible strains from different geographic regions across the world. N=120	Canada	Sequencing	RRDR	RHES	N.S.	Proportion method	108/120	(1/0)	Double mutation with 526 (Asp)
RIF	rpoB	Sekiguchi J JCM 2007 Jan		AGC/AGG	509	Ser/Arg	Published 2007	105 and 33 clinical isolates were obtained from patients with pulmonary tuberculosis in Japan and Poland, respectively. N=138	Japan 	Sequencing	RRDR	R, MDR	N.S.	Proportion method, BACTEC	28/138	(0/1)	
RIF	rpoB	Zenteno-Cuevas R MemInstOswaldCruz 2009		CAG/AAG	510	Gln/Lys	2007		Mexico	Sequencing	RRDR	HREZ	N.S.	BACTEC 460	15/25	1/0	None
RIF	rpoB	Sajduda A JCM 2004	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAG/CAC	510	Gln/His	2000	###############################################################################################################################################################################################################################################################	Poland	real-time sequencing FRET 	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(2/0)	rpoB: double mutation with 516 GAC/TAC
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CTG/CCG	511	Leu/Pro	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	4/0	"One of the strains was also Asp441Glu; another was Asp441Tyr; the third was also Ser437Thr."
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CTG/CGG	511	Leu/Arg	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.
RIF	rpoB	Siddiqi N AAC 2002	O'Sullivan DM JAntiChemo 2005	CTG/GTG	511	Leu/Val	1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	R,O	Not listed in Table	Proportion method	94/126	(2/0)	"1) rpoB dual mutation with N518T; gyrA S95T; 2) gyrA S95T"
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	AGC/ACC	512	Ser/Thr	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	Also mutated at Leu436Pro.
RIF	rpoB	Sajduda A JCM 2004		AGC/ATC	512	Ser/Ile	2001	###############################################################################################################################################################################################################################################################	Poland	real-time sequencing FRET 	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	rpoB: double mutation with 516 GAC/GGC
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	AGC/CGC	512	Ser/Arg											
RIF	rpoB	Chan RCY JAC 2007		AGC/GGC	512	Ser/Gly	1994-2004	Consecutive isolates that exhibited resistance to one or more drugs. Grantham Hospital and Public Health Laboratory of Hong Kong	Hong Kong	PCR-SSCP, Sequencing	RRDR			Absolute concentration method	250	221	
RIF	rpoB	Bahrmand AR JCM 2009		CAA/TAA	513	Gln/STOP	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB G507D, H526Y, S531F
RIF	rpoB	Bahrmand AR JCM 2009		CAA/AAT	513	Gly/Asn	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB S512T, H526F, S531L
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAA/CTA	513	Gln/Leu	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAA/AAA	513	Gln/Lys	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.
RIF	rpoB	Prammananan T CMI 2008		CAA/GAA	513	Gln/Glu	2003-2005		Thailand	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	154/113	1/0	None described in the region sequenced.
RIF	rpoB	Kim BJ JCM 1997		CAA/CCA	513	Gln/Pro	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	Sequencing	RRDR	R	N.S.	Absolute concentration method. 	32/58	2/0	Location of double mutants not specified.
RIF	rpoB	Valim A JCM 2000		CAA/CAC	513	Gln/His									82/100	1/0	
RIF	rpoB	Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005	CAA/CGA	513	Gln/Arg											
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	ins TTC	513	ins Phe	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	ins TTC ATG	513	ins Phe Met	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	del CAA TTC	513	del Gln Phe											
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	del AA TTC ATG G	513	Gln/His and del Phe Met											
RIF	rpoB	Valim A JCM 2000		del TTC	514	del Phe	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had deletions: 515 (ATG-Met), 516(GAC-Asp) and change in codon 513 CAA(Gln)/CAC(His)
RIF	rpoB	Taniguchi H FEMS Micro 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998	TTC/TTG	514	Phe/Leu	Published  1996	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	12.5 ug/ml	Proportion method, absolute concentration method	21/39	(1/0)	
RIF	rpoB	Valim A JCM 2000		TTC/GTC	514	Phe/Val	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had change in codon 531 TCG(Ser)/TTG(Leu)
RIF	rpoB	Cavusoglu C JCM 2002		ins CGG	514	ins Arg	Published 2002	41 RIF-resistant isolates from Reion Tuberculosis Laboratory and Ege University Mycobacteriology Laboratory. N=41	Turkey	Line probe assay, Sequencing	RRDR	R, RE,  RHE, RH, RHES, RHS	N.S.	Proportion method	41/41	(1/0)	
RIF	rpoB	Lipin MY CMI 2007		del C AT	514	Phe/Leu and del Met	1998-2001	"MDR-TB isolates from pulmonary TB patients. Most patients were male (92%); mean age 43yrs; none were co-infected with HIV. N=217"	Russia	Sequencing	RRDR	RHS, RHSK, RHSE	N.S.	Absolute concentration method. 	217/217	1/0	None described in the region sequenced.
RIF	rpoB	Valim A JCM 2000		del TTC ATG GAC	514	del Phe Met Asp	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSZEth	N.S.	Proportion method	82/100	(1/0)	Same isolate had change in codon 513 CAA(Gln)/CAC(His)
RIF	rpoB	Hillemann D Int J Tuberc Lung Dis 2005		ins TTC	515	ins Phe	2004	"92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152"	Kazakhstan, Germany	real-time sequencing FRET 	RRDR	MDR	N.S.	N.S.	92/152	(1/0)	
RIF	rpoB	Sajduda A JCM 2004		ATG/ATT	515	Met/Ile	2003	###############################################################################################################################################################################################################################################################	Poland	real-time sequencing FRET 	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(8/0)	rpoB: double mutation with 516 GAC/TAC
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	ATG/ATA	515	Met/Ile											
RIF	rpoB	Valim A JCM 2000		del ATG GAC CAG AAC	515	del Met Asp Gln Asn	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)	
RIF	rpoB	Schilke K IntJTubLungDis 1999		GAC/AAC	516	Asp/Asn	Published  1999	87 MDR strains from 12 hospitals in Southern African regions + 13 RIF-resistant strains of M. africanum + 3 RIF-resistant strains of M. tuberculosis from Sierra Leone and Uganda + 2 RIF-resistant strains of M. tuberculosis from Namibia. N=105	South Africa	Sequencing	RRDR	MDR	N.S.	N.S.	105/105	(1/0)	
RIF	rpoB	Bahrmand AR JCM 2009		GAC/CAC	516	Asp/His	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	50-75 ug/ml	Proportion method	41/286	3/0	rpoB D516H, H526R
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	GAC/GTC	516	Asp/Val	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	GAC/GAG	516	Asp/Glu	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	Also mutated at Leu436Pro.
RIF	rpoB	Hillemann D Int J Tuberc Lung Dis 2005	Ramaswamy S Musser JM Tubercle lung Dis 1998	GAC/GGC	516	Asp/Gly	2004	"92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152"	Kazakhstan, Germany	real-time sequencing FRET 	RRDR	MDR	N.S.	N.S.	92/152	(1/0)	
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	GAC/GCC	516	Asp/Ala											
RIF	rpoB	Sajduda A JCM 2004		GAC/GTG	516	Asp/Val	2004	###############################################################################################################################################################################################################################################################	Poland	real-time sequencing FRET 	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	None
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	GAC/TAC	516	Asp/Tyr	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	Also mutated at Leu436Pro.
RIF	rpoB	Hillemann D Int J Tuberc Lung Dis 2005		GAC/TTC	516	Asp/Phe	2004	"92 MDR (73 also resistant to EMB; 89 to SM; 40 to PZA; 31 to PTH); 50 single INH but RMP-susceptible (16 also resistant to EMB; 44 to SM; 7 to PZA; 12 to PTH); 10 fully susceptible strains that were randomly selected from 42 susceptible strains. N=152"	Kazakhstan, Germany	real-time sequencing FRET 	RRDR	MDR	N.S.	N.S.	92/152	(1/0)	
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	del GAC CAG	516	del Asp Gln	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.
RIF	rpoB	Xueqiong W MolBiotech 2009		GAC/CAC	517	Gln/His	2002-2005		China	Sequencing	RRDR	RSE	N.S.	Absolute concentration method	112/148	1/0	rpoB N518D
RIF	rpoB	Mani C JCM 2001		del GAC	517	del Gln	Published 2001	RIF-R (n=44) and RIF-S (n=6) isolates from 50 patients. Total N=50	India	Sequencing	RRDR	R	>128ug/ml	Proportion method	44/50	1/0	None described in the region sequenced.
RIF	rpoB	Sajduda A JCM 2004		CAA/CTA	517	Gln/Leu	2005	###############################################################################################################################################################################################################################################################	Poland	real-time sequencing FRET	RRDR	R, MDR	N.S.	BACTEC 460	64/113	(1/0)	None
RIF	rpoB	Hillemann D AAC 2005		del CAG AAC	517	del Gln Asn	2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(1/0)	katG 315 AGC-ACC/Ser-Thr 
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	del CAG AAC	517	del Gln Asn	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	None described in the region sequenced.
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	del G AAC AA	517	Gln/His and del Asn Asn											
RIF	rpoB	Wang Q JProtRes 2007		AAC/TAC	518	Asn/Tyr	Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0	
RIF	rpoB	Siddiqi N AAC 2002		AAC/ACC	518	Asn/Thr	1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	RHO, ROS,  RO, RH	N.S.	Proportion method	94/126	(6/0)	"1) rpoB dual mutaton with L511L; katG and inhA NM; gyrA A90A, S95T 3) rpoB dual mutation with R528P; gyrA S95T; rpsL NM; 4) rpoB dual mutaton with L511V; gyrA S95T; 5) gyrA S95T; 6) gyrA NM; 7) rpoB dual mutation with D516V; katG and inhA R463L"
RIF	rpoB	Hillemann D AAC 2005		AAC/ATC	518	Asn/Ile	2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(1/0)	None
RIF	rpoB	Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998	AAC/CAC	518	Asn/His	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	Sequencing and PCR-SSCP	RRDR	R	N.S.	Absolute concentration method. 	32/58	1/0	Location of double mutants not specified.
RIF	rpoB	Chan RCY JAC 2007		AAC/GAC	518	Asn/Asp	1994-2004	Consecutive isolates that exhibited resistance to one or more drugs. Grantham Hospital and Public Health Laboratory of Hong Kong	Hong Kong	PCR-SSCP, Sequencing	RRDR			Absolute concentration method. 	250	221	
RIF	rpoB	Bahrmand AR JCM 2009		AAC/AAG	519	Asn/Lys	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	50 ug/ml	Proportion method	41/286	2/0	rpoB L511V, Q513E, H526R
RIF	rpoB	Heym B Lancet 1994		del AAC	519	del Asn	1991-1992	###############################################################################################################################################################################################################################################################	Russia, Netherlands	PCR-SSCP		MDR	10-100ug/ml	Proportion method	13/39	(2/0)	"1) katG mutation present; inhA no mutation present; 2) katG no mutation present"
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	CTG/ATG	521	Leu/Met											
RIF	rpoB	Taniguchi H FEMS Micro 1996		CTG/CCG	521	Leu/Pro	Published  1998	39 clinical isolates (including MDR-TB strains) from Koga Hospital, Nougata central hospital, and Fukuoka-Higashi hospital. N=39	Japan	Sequencing	Whole gene	R	< 0.39 ug/ml	Proportion method, absolute concentration method	21/39	(0/1)	
RIF	rpoB	Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005	CTG/CTA	521	Leu/Leu											
RIF	rpoB	Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	TCG/TTG	522	Ser/Leu	Published  1998	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(1/0)	
RIF	rpoB	Yuen LK JCM 1999	O'Sullivan DM JAntiChemo 2005	TCG/CAG	522	Ser/Gln	1990-1997	"50 clinical isolates collected from different reference laboratories in Australia: 17 RIF sensistive; 33 RIF resistant. N=50"	Timor	Sequencing	RRDR	RH	32-256 ug/ml	Resistance ratio method, ,BACTEC 460, E-test	33/50	(2/0)	None
RIF	rpoB	Secondary Publication: O'Sullivan DM JAntiChemo 2005	O'Sullivan DM JAntiChemo 2005	TCG/TGG	522	Ser/Trp											
RIF	rpoB	El Baghdadi J IJTLD 2003		CCC/ACC	523	Gly/Trp	1996-2001	"122 isolates from 112 different patients; 42 Mtb isolates analyzed (37 resistant, 5 sensitive). N=122"	Morocco	Sequencing	RRDR	RHS	N.S.	Resistance ratio method	101/122	(1/0)	
RIF	rpoB	Pozzi G JCM 1999		GGG/TGG	523	Gly/Trp	Published April 2000	"MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37"	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ 	8-128ug/ml	Absolute concentration method	37/37	(1/0)	Triple mutation with GAC516TAC and ACC525ATC
RIF	rpoB	Bahrmand AR JCM 2009		GGG/GCG	523	Gly/Ala	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	25/0	rpoB T508A or S531L or L511V, or H526R
RIF	rpoB	Valim A JCM 2000		TTG/TGG	524	Leu/Trp	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	MDR	N.S.	Proportion method	82/100	(1/0)	"Same isolate had changes in codons 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu); 527 del AAG(Lys)"
RIF	rpoB	Zenteno-Cuevas R MemInstOswaldCruz 2009		TTG/TCG	524	Leu/Ser	2007		Mexico	Sequencing	RRDR	HR	N.S.	BACTEC 460	15/25	1/0	rpoB S531L
RIF	rpoB	Valim A JCM 2000		ACC/CCC	525	Thr/Pro	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	MDR	N.S.	Proportion method	82/100	(1/0)	"Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 526 CAC(His)/CTG(Leu); 527 del AAG(Lys)"
RIF	rpoB	Pozzi G JCM 1999		ACC/ATC	525	Thr/Ile	Published April 2001	"MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37"	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ 	8-128ug/ml	Proportion method	37/37	(1/0)	Triple mutation with GAC516TAC and GGG523TGG
RIF	rpoB	Bahrmand AR JCM 2009		CAC/TTC	526	His/Phe	2005-2006	286 isolates from sputa of patients with active pulmonary TB from the southern border of Iran, Zabol province, Afghanistan border.	Iran	Sequencing	411bp fragment of rpoB	41R, 37MDR	>100 ug/ml	Proportion method	41/286	2/0	rpoB S512T, G513N, S531L
RIF	rpoB	Ramaswamy SV J Med Micro 2004	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/AAC	526	His/Asn	1996-2001	Subset of 186 strains initially isolated from patients who attended the Jose E. Gonzalez University Hospital TB clinic. N=37	Mexico	Sequencing		RHSE	N.S.	Proportion method	37/50	(1/0)	"rpoB: Double mutation with 435 GAC/GAG; embB: 306 ATG/ATA1 "
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/GAC	526	His/Asp	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	8/0	None described in the region sequenced.
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/TAC	526	His/Tyr	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	39/0	None described in the region sequenced.
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/ACC	526	His/Thr											
RIF	rpoB	Prammananan T CMI 2008		CAC/AGC	526	His/Ser	2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 515 ATG/CTG
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/GGC	526	His/Gly											
RIF	rpoB	Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/TGC	526	His/Cys	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	PCR-SSCP, Sequencing	RRDR	R	N.S.	Absolute concentration method. 	32/58	2/0	Location of double mutants not specified.
RIF	rpoB	Kim BJ JCM 1997	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/CGC	526	His/Arg	Published 1997	Clinical isolates, both RIF-R (n=32) and RIF-S (n=26) from different patients. Total N=58	South Korea	PCR-SSCP, Sequencing	RRDR	R	N.S.	Absolute concentration method. 	32/58	1/0	Location of double mutants not specified.
RIF	rpoB	Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/CCC	526	His/Pro	Published  2001	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(2/0)	
RIF	rpoB	Valim A JCM 2000		CAC/CTG	526	His/Leu	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)	"Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 527 del AAG(Lys)"
RIF	rpoB	Sheng J JApplMicro 2008		CAC/CTT	526	His/Leu	2002-2003	56 isolates from patients with pulmonary TB in Zhejiang province	China	PCR-SSCP , Sequencing	RRDR	R	N.S.	Agar proportion method 	49/56	1/0	None in rpoB
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/CTC	526	His/Leu	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	2/0	None described in the region sequenced.
RIF	rpoB	Kapur V JCM 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/CAA	526	His/Gln	Published 1994	"Clinical isolates, both RIF-R (n=121) and RIF-S (n=7); some of them had been studied previously. Total N=128"	USA	Sequencing	Whole gene	R	N.S.	Proportion method, BACTEC	121/128	1/0	Also mutated at Ser456Cys.
RIF	rpoB	Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	CAC/CAG	526	His/Gln	Published 2003	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	>8ug/ml	BACTEC 460	26/36	(2/0)	Double mutation with 498 Val/Ala
RIF	rpoB	Siddiqi N AAC 2002	O'Sullivan DM JAntiChemo 2005	AAG/AAT	527	Lys/Asn	1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	HRH	40 ug/ml	Proportion method	94/126	(2/0)	"1) katG or inhA R463L; 2) katG or inhA R463L, rpoB dual mutation with L521L"
RIF	rpoB	Valim A JCM 2000		del AAG	527	del Lys	1996-1998	"100 isolates from different regions of Brazil: 26 samples (25 RIF-resistant; 1 RIF-susceptible) from Rio de Janeiro. N=100"	Brazil	Sequencing	RRDR	RHSEZEth	N.S.	Proportion method	82/100	(1/0)	"Same isolate had changes in codons 524 TTG(Leu)/TGG(Trp); 525 ACC(Thr)/CCC(Pro); 526 CAC(His)/CTG(Leu)"
RIF	rpoB	Williams D AAC 1994		AAG/CAG	527	Lys/Gln	Published 1995	110 RIF-resistant and 10 RIF-susceptible strains from different geographic regions across the world. N=120	USA	PCR-HDF,  Sequencing	RRDR	RHEEt	N.S.	Proportion method	108/120	(1/0)	Double mutation with 526 (His)
RIF	rpoB	Siddiqi N AAC 2002		CGC/CAC	528	Arg/His	1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	HR, ROS	64-128 ug/ml	Proportion method	94/126	(2/0)	"1) rpoB dual mutation with H526Y; gyrA S95T; rpsL NM;  2) rpoB 1 dual mutation with with S531W; katG and inhA R463L, Inh (C/T)"
RIF	rpoB	Siddiqi N AAC 2002	O'Sullivan DM JAntiChemo 2005	CGC/CCC	528	Arg/Pro	1995-1998	126 clinical isolates that were drug resistant. N=126	India	Sequencing	RRDR	ROS, RHO, RHS, RH	40-64 ug/ml*	Proportion method	94/126	(4/0)	"1) rpoB dual mutation with N518T; gyrA S95T; rpsL NM; 2) katG or inhA NA; gyrA S95T; 3) katG or inhA R463L; rpsL K121K;  4) katG or inhA R463L; rpoB dual mutation with H526Y"
RIF	rpoB	Zenteno-Cuevas R MemInstOswaldCruz 2009		CGC/CCT	528	Arg/Pro	2007		Mexico	Sequencing	RRDR	HRSEZ	N.S.	BACTEC 460	15/25	1/0	None
RIF	rpoB	Wang Q JProtRes 2007		TCG/TAG	538	Leu/STOP	Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0	
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	TCG/CAG	531	Ser/Gln											
RIF	rpoB	Donabella V Am J Respir Cell Mol Biol 1994	Ramaswamy S Musser JM Tubercle lung Dis 1998	TCG/TTG	531	Ser/Leu	Published 1994		USA	Sequencing	RRDR	R	N.S.		(1/9)	(1/0)	
RIF	rpoB	Bodmer T JAC 1995		TCG/TGG	531	Ser/Trp	Published 2005	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	8ug/ml	BACTEC 460	26/36	(1/0)	
RIF	rpoB	Bodmer T JAC 1995	Ramaswamy S Musser JM Tubercle lung Dis 1998	TCG/TAT	531	Ser/Tyr	Published 2006	122 clinical isolates from patients from diverse geographical locations (Telenti et al, 1993a). 10 RMP-susceptible and 26 RMP-resistant isolates were examined. N=36	N.S.	PCR-SSCP	RRDR	R	>8ug/ml	BACTEC 460	26/36	(1/0)	
RIF	rpoB	Hillemann D AAC 2005		TCG/TTT	531	Ser/Phe	2001	113 strains (103 MDR and 10 randomly chosen fully susceptible). N=113	Germany	real-time sequencing	RRDR	MDR	N.S.		103/113	(2/0)	katG 315 AGC-ACC/Ser-Thr 
RIF	rpoB	Secondary Publication: Ramaswamy S Musser JM Tubercle lung Dis 1998	Ramaswamy S Musser JM Tubercle lung Dis 1998	TCG/TGT	531	Ser/Cys											
RIF	rpoB	Moghazeh SL AAC 1996	Ramaswamy S Musser JM Tubercle lung Dis 1998	CTG/CCG	533	Leu/Pro	1992-1995	RIF-R clinical isolates from strain database. N=24	USA	Sequencing	N.S	R	>32ug/ml	Proportion method	24/24	1/0	None described in the region sequenced.
RIF	rpoB	Valim A JCM 2000		CTG/CCT	533	Leu/Pro	1996-1998	"100 isolates from different regions of Brazil: 20 samples (19 RIF-resistant; 1 RIF-susceptible) from Sao Paulo. N=100"	Brazil	Sequencing	RRDR	RH, RHS	N.S.	Proportion method	82/100	(2/0)	Same isolate had double mutation: 526 CAC(His)/CTG(Leu)
RIF	rpoB	Tracevska T JCM 2002 		CCC/TCC	535	Pro/Ser	1999-2000	"70 patients admitted to State Centre for Tuberculosis and Lung Diseases with clinical symptoms of lung or renal TB or TB meningitis. 25-60 yrs old; 2/3 male. 19 drug-susceptible; 34 MDR isolates were analyzed by LiPA. N=70"	Latvia	Line probe assay, Sequencing	RRDR	R, RH	N.S.	Absolute concentration method, BACTEC 	51/70	(4/0)	Double mutation with D516Y
RIF	rpoB	Prammananan T CMI 2008		CCC/CAC	535	Pro/His	2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 526 CAC/AGC His/Ser
RIF	rpoB	Wang Q JProtRes 2007		CTG/CCG	538	Leu/Pro	Published 1997		China	Sequencing	Whole gene	R	N.S.	Proportion method, absolute concentration method	112/30	1/0	
RIF	rpoB	Prammananan T CMI 2008		GAG/GGG	541	Glu/Gly	2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 526 CAC/TAC His/Tyr
RIF	rpoB	Pozzi G JCM 1999		GAG/GAT	541	Glu/Gly	Published 2002	"MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37"	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ 	32-128 ug/ml	Proportion method	37/37	(1/0)	Triple mutation with CAC526GAC and TCG553GCG
RIF	rpoB	Aslan G JpnJInfectDis 2008		CTG/ATG	545	Leu/Met	2003-2006	Isolates from patients in Mersin University hospital in southern Turkey	Turkey	Sequencing	RRDR	R or MDR	N.S.	BACTEC 460	19/41	3/0	rpoB S531A, katG S315T
RIF	rpoB	Pozzi G JCM 1999		TCG/GCG	553	Ser/Ala	Published 2003	"MDR isolates from three clinical microbiology laboratories; 37 isolates, proven to be from different patients, analyzed for this study. N=37"	Italy	Sequencing	RRDR	RH, RHS, RHSCip, RHSAmi, RHSZ, RHSZAmi, RHSCZ 	32-128 ug/ml	Proportion method	37/37	(1/0)	Triple mutation with CAC526GAC and GAG541GAT
RIF	rpoB	Ramaswamy SV J Med Micro 2004		ATC/GTC	561	Ile/Val	1996-1998	Subset of 186 strains initially isolated from patients who attended the Jose E. Gonzalez University Hospital TB clinic + 13 pan-susceptible isolates. N=50	Mexico	Sequencing	RRDR	RHSE	N.S.	Proportion method	37/50	(1/0)	"rpoB: Double mutation with 450 TCG/TTG; embB: 306 ATG/ATA"
RIF	rpoB	Heep M JCM 2001		ATC/ACC	561	Ile/Thr	1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	N.S.	N.S.	Proportion method	111/111	(1/0)	Double mutation with S456L
RIF	rpoB	Hauck Y JAC 2009		GAA/GGA	562	Glu/Gly	Published 2009	126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Santˇ des Armˇes in a total of 18 countries. This mutation confer low level RIF resistance	Various	Sequencing	RRDR	R	<1 ug/ml	MGIT 960	122/122	1/0	rpoB P564L
RIF	rpoB	Hauck Y JAC 2009		CCT/CTT	564	Pro/Leu	Published 2009	126 RIF resistant isolates were recovered from 142 patients by the reference centre for mycobacteria of the Service de Santˇ des Armˇes in a total of 18 countries. This mutation confer low level RIF resistance	Various	Sequencing	RRDR	R	<1 ug/ml	MGIT 960	122/122	1/0	rpoB E562G			
RIF	rpoB	Heep M JCM 2001		CTG/GTG	571	Leu/Val	1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	RHEZ	N.S.	Proportion method	111/111	(2/0)	Double mutation with D441Y			
RIF	rpoB	Yuen LK JCM 1999	O'Sullivan DM JAntiChemo 2005	ATC/TTC	572	Ile/Phe	1990-1997	"51 clinical isolates collected from different reference laboratories in Australia: 17 RIF sensistive; 33 RIF resistant. N=50"	Vietnam	Sequencing	RRDR	RHE	> 256 ug/ml	Resistance ratio method, BACTEC 460, E-test	33/50	(1/0)	None			
RIF	rpoB	Chan RCY JAC 2007		TCG/TTG	574	Ser/Leu	1994-2004	250 resistant isolates (resistant to 5 anti-tiuberculosis drugs) - none had apparent clonal features + 50 susceptible controls + 2 reference strains: ATCC 27294 H37Rv and ATCC 25117 H37Rag. N=302 isolates	Hong Kong	PCR-SSCP, Sequencing	RRDR	RHEZ	>64 ug/ml	Absolute concentration method. 	221/250	1	katG 311 Asp/Gly			
RIF	rpoB	Prammananan T CMI 2008		TCG/GCG	622	Ser/Ala	2003-2005		Thailand	Sequencing	Whole gene	MDR	N.S.	Proportion method	154/113	1/0	rpoB 531 TCG/TTG ser/Leu			
RIF	rpoB	Heep M JCM 2001		CGC/TGC	633	Arg/Cys	1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	RH	N.S.	Proportion method, BACTEC 460	111/111	(1/0)	Double mutation with S456L			
RIF	rpoB	Heep M JCM 2001		GAG/GAT	672	Glu/Asp	1997	80 RIF-resistant patients obtained during the year by the German National Reference Center for Mycobacteria + 18 samples (16 DNA samples and 2 culture samples) from previous studies were analyzed. N=98	Germany	Sequencing	RRDR	RH, RHE, RHZ, RHEZ	N.S.	Proportion method, BACTEC 460	111/111	(7/0)	Double mutation with S456W			
																				
																				
																				
	embB																			
	Gene	Primary reference	Review reference 1	SNP		Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations			
RIF	embB	Shi R AAC 2007		TAT/CAT		Tyr/His		74 clinical isolates from Beijing Tuberculosis Resaerch Institute. N=74	China	Sequencing	N.S	RHS	50-250 ug/ml	Proportion method	24/74 but not clear about differences between mutations					
RIF	embB	Shi R AAC 2007 		TAT/GAT		Tyr/Asp		74 clinical isolates from Beijing Tuberculosis Resaerch Institute. N=74	China	Sequencing	N.S	RH	50-250 ug/ml	Proportion method	24/74 but not clear about differences between mutations					
																				
STREPTOMYCIN [SM]																				
																				
	gidB																			
Drug	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	Resistant isolates/Total isolates tested for mutation	Resistant/Sensitive isolates with mutation	Additional mutations			
SM	gidB	Okamoto S MolMicro 2007	47	T/G	16	Leu/Arg	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	HRSE	20 ug/ml	Absolute concentration method	57/132	1/0	G257C(rpsL)			
SM	gidB	Okamoto S MolMicro 2007	102	del G	34	Frameshift	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	"R, H; S; E, K, PAS, "	20 ug/ml	Absolute concentration method	57/132	1/0	"A276C (gidB); A908G (rrs) "			
SM	gidB	Okamoto S MolMicro 2007	115	del C	39	Frameshift	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S	20 ug/ml	Absolute concentration method	57/132	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	118	G/T	40	Glu/STOP	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	H, SM, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A262C(rpsL)			
SM	gidB	Spies FS AAC 2008		TGG/TGC	45	Trp/Cys	Published 2008	Rio Grande do Sul	Brazil	Sequencing	675bp fragment	H,R,S,E	15,6 ug/ml	Resazurin microtiter assay	47/32	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	140	G/A	47	Arg/Gln	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A908G(rrs)			
SM	gidB	Okamoto S MolMicro 2007	164	T/G	55	Ile/Ser	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB), A513C (rrs)			
SM	gidB	Okamoto S MolMicro 2007	199	G/C	67	Asp/His	After 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	S	8 ug/ml	Absolute concentration method	57/132	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	208	A/C	70	Ser/Arg	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	"A276C (gidB); A513C (rrs) "			
SM	gidB	Okamoto S MolMicro 2007	210	C/A	70	Ser/Arg	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	212	G/T	71	Gly/Val	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, 	20 ug/ml	Absolute concentration method	57/132	1/0	A276C (gidB)			
SM	gidB	Okamoto S MolMicro 2007	223	C/G	75	Pro/Ala	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	H, S, E, K	20 ug/ml	Absolute concentration method	57/132	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	276	A/C	92	Glu/Asp	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	A128G(rpsL)			
SM	gidB	Okamoto S MolMicro 2007	307	G/T	103	Glu/STOP		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E	N.S	Absolute concentration method	57/132	1/0	A513C (rrs)			
SM	gidB	Okamoto S MolMicro 2007	351	del G	117	Frameshift	After 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	S	8ug/ml	Absolute concentration method	57/132	2/0				
SM	gidB	Okamoto S MolMicro 2007	373	C/T	125	Gln/STOP		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0				
SM	gidB	Okamoto S MolMicro 2007	380	A/C	127	Gln/Pro		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0				
SM	gidB	Okamoto S MolMicro 2007	401	C/A	134	Ala/Glu		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0				
SM	gidB	Okamoto S MolMicro 2007	413	C/T	138	Ala/Glu		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0				
SM	gidB	Spies FS AAC 2008		TGG/CGG	148	Trp/Arg	Published 2008	Rio Grande do Sul	Brazil	Sequencing	675bp fragment	H,R,S,E	15,6 ug/ml	Resazurin microtiter assay	47/32	1/0	none			
SM	gidB	Okamoto S MolMicro 2007	548	C/A	183	Ala/Glu		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0				
SM	gidB	Okamoto S MolMicro 2007	563	T/G	188	Val/Gly		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0	a276C (gidB), G888A (rrs)			
SM	gidB	Okamoto S MolMicro 2007	599	C/A	200	Ala/Glu		132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing	Whole gene	N.S	N.S	Absolute concentration method	57/132	1/0				
																				
	rpsL																			
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations			
SM	rpsL	Sreevatsan S AAC 1996	23	CGC/CAC	9	Arg/His														
SM	rpsL	Brzostek A IntJ TubLungDis 2004	119	ACC/ATC	40	Thr/Ile	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	4/88	4/0				
SM	rpsL	Brzostek A IntJ TubLungDis 2004	122	ACT/AGT	41	Thr/Ser	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr41Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly84Val, Arg86Trp, Val87Leu			
SM	rpsL	Nair J Mol Micro 1993	128	AAG/AGG	43	Lys/Arg	1950		USA	Sequencing	Whole gene	S, H, E	N.S	N.S	8/8	1/0				
SM	rpsL	Finken M Mol Micro 1993	128	AAG/ACG	43	Lys/Thr	1993	m. luteus, m.tb		Sequencing	Whole gene	MDR	N.S	Proportion method, BACTEC 460	38/73	5/0	not specified			
SM	rpsL	Brzostek A IntJ TubLungDis 2004	153	AAG/AAC	51	Lys/Asn	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr51Ser is one of 18 silent mutations and 6 a.a. sub: Lys41Asn, Val52Gly, Gly84Val, Arg86Trp, Val87Leu			
SM	rpsL	Brzostek A IntJ TubLungDis 2004	155	GTT/GGT	52	Val/Gly	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr52Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val41Gly, Gly84Val, Arg86Trp, Val87Leu			
SM	rpsL	Brzostek A IntJ TubLungDis 2004	251	GGC/GTC	84	Gly/Val	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr84Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly41Val, Arg86Trp, Val87Leu			
SM	rpsL	Brzostek A IntJ TubLungDis 2004	256	CGG/TGG	86	Arg/Trp	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr86Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly84Val, Arg41Trp, Val87Leu			
SM	rpsL	Okamoto S MolMicro 2007	257	CGG/CCG	86	Arg/Pro	Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing		RHSE	20 ug/ml	Absolute concentration method	57/132	1/0	T47G (gidB)			
SM	rpsL	Brzostek A IntJ TubLungDis 2004	259	GTG/TTG	87	Val/Leu	2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	region of rpsL	S	N.S	Proportion method, BACTEC 460	1/88	1/0	Thr87Ser is one of 18 silent mutations and 6 a.a. sub: Lys51Asn, Val52Gly, Gly84Val, Arg86Trp, Val41Leu			
SM	rpsL	Sreevatsan S AAC 1996	262	AAG/CAG	88	Lys/Gln	1995	139 strains of mtb	Vietnam	Sequencing	Whole gene	S	>200ug/ml	Proportion method, BACTEC 460	78/139	1/0	GTG/ATG, Val/Met			
SM	rpsL	Finken M Mol Micro 1993	263	AAG/AGG	88	Lys/Arg 	1993	m. luteus, m.tb		Sequencing	Whole gene	S	N.S	Proportion method	38/73	2/0	n/a			
SM	rpsL	Katsukawa C J Appl Micro 1997	263	AAG/ATG	88	Lys/Met														
SM	rpsL	Katsukawa C J Appl Micro 1998	263	AAG/ACG	88	Lys/Thr														
SM	rpsL	Sreevatsan S AAC 1996	277	GTG/ATG	93	Val/Met														
																				
	rrs																			
	Gene	Primary reference	nt position	SNP	Codon position	Amino acid	Time period	Study population	Origin	Molecular detection method	Gene coverage	Resistance pattern 	MIC 	Susceptibility testing method	R/Total isolates 	R/S isolates with mutation	Additional mutations			
SM	rrs	Ramaswamy SV J Med Micro 2004	189	G/A	189		1996-1998	patients from Jose E. Gonzalez Univ. Hosp	Mexico	Sequencing	Whole rrs	RHS	N.S	Proportion method	39838	1/0	"15 ups; C/T (inhA)"			
SM	rrs	Ramaswamy SV J Med Micro 2004	426	G/T	426		1996-1998	patients from Jose E. Gonzalez Univ. Hosp	Mexico	Sequencing	Whole rrs	RHS	N.S	Proportion method	39838	1/0	"315, AGC/ACC, Ser/Thr (katG); 450, TCG/TTG, Ser/Leu (rpoB)"			
SM	rrs	Spies FS AAC 2008	426	G/C	426		Published 2008	Rio Grande do Sul	Brazil	Sequencing	530 loop, 912 region	RHSE	>31,5ug/ml	Resazurin microtiter assay	47/32	1/0	"gidB: CCT/CGT; L16R"			
SM	rrs	Brzostek A IntJ TubLungDis 2004	461	C/T	461		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	530 loop, 912 region	S	N.S	Proportion method	4/88	4/0	none			
SM	rrs	Meier A AAC 1994	491	C/T	491					Sequencing	Whole rrs	HS	N.S	Proportion method	3/38	1/0				
SM	rrs	Meier A AAC 1994	512	C/T	512					Sequencing	"505 bp gene fragment; complete S12 gene"	RHS	N.S	Proportion method	3/38	1/0				
SM	rrs	Honore N AAC 1995	512	ins C	512							N.S	N.S							
SM	rrs	Dobner P MolCellProbes  1997	513	A/C	513		1996	Germans, Eastern European immigrants in Germany, Sierra Leone	Germany, Sierra Leone	Sequencing	530 loop, 912 region	S	N.S		1/50	1/0	AAG/AGG, 43 Lys/Arg (rpsL)			
SM	rrs	Katsukawa C J Appl Micro 1997	513	A/T	513		1992-1994	172 clinical isolates from Japanese institutions	Japan	Sequencing	450-944	S	20-200ug/ml	Absolute concentration method	95/172	9/0				
SM	rrs	Dobner P MolCellProbes  1997	516	C/T	516		1996	Germans, Eastern European immigrants in Germany, Sierra Leone	Germany, Sierra Leone	Sequencing	530 loop, 912 region	S	N.S		1/50	1/0	none			
SM	rrs	Brzostek A IntJ TubLungDis 2004	627	G/C	627		2000	88 patients with positive cultures from Poland's 2000 national survey	Poland	Sequencing	530 loop, 912 region	S	N.S	Proportion method, BACTEC 460	1/88	1/0	none			
SM	rrs	Sreevatsan S AAC 1996	798	C/T	798		1995	139 strains of mtb from various geographical localities	USA	Sequencing	530 loop, 912 region	S	N.S	Proportion method, BACTEC 460	39814	1/0	"only NY isolate with both rrs and rpsL (AAG/AGG; K43-->R) mutations "			
SM	rrs	Cooksey RC, AAC 1996	865	C/G	865		1994	New Yorkers	USA	Sequencing	306 bp	RHS	10	Agar dilution method	45/367	1/0	none			
SM	rrs	Okamoto S MolMicro 2007 	887	G/A	887		Before 2000	132  Japanese TB patients (57 STR-res, 75 STR-suscept.)	Japan	Sequencing		R, H, S, E, K, PAS	20 ug/ml	Absolute concentration method	57/132	1/0 	A276C, T563G (gidB)			
SM	rrs	Honore N AAC 1994	904	C/A	904		1994	mtb strains from various sources	N.S.	PCR-SSCP	530 loop, 912 region	SH	>1280	Agar dilution method	39974	1/0	none			
SM	rrs	Honore N AAC 1994	904	C/G	904					PCR-SSCP	530 loop, 912 region	SHR	160	Agar dilution method	39974	1/0	none			
SM	rrs	Dobner P MolCellProbes  1997	905	A/G	905		1996	Germans, Eastern European immigrants in Germany, Sierra Leone	Germany, Sierra Leone	Sequencing	530 loop, 912 region	S	N.S		1/50	1/0	AAG/CAG, 88 Lys/Thr (rpsL)			
SM	rrs	Dobner P MolCellProbes  1997	906	A/T	906		1996	Germans, Eastern European immigrants in Germany, Sierra Leone	Germany, Sierra Leone	Sequencing	530 loop, 912 region	S	N.S		1/50	1/0	none			
SM	rrs	Katsukawa C J Appl Micro 1997	906	A/C	906		1992-1994	172 clinical isolates from Japanese institutions	Japan	Sequencing	450-944	S	20-200ug/ml	Absolute concentration method	95/172	1/0				
SM	rrs	Katsukawa C J Appl Micro 1997	907	A/G	907		1992-1994	172 clinical isolates from Japanese institutions	Japan	Sequencing	450-944	S	20-200ug/ml	Absolute concentration method	95/172	1/0				
SM	rrs	Katsukawa C J Appl Micro 1997	907-908	ins T	907		1992-1994	172 clinical isolates from Japanese institutions	Japan	Sequencing	450-944	S	20-200ug/ml	Absolute concentration method	95/172	1/0				
SM	rrs	Sekigushi J JCM 2007	1061	ins C	1061		2006	TB patients in Japan and Poland	Japan	Multiplex PCR	530 loop, 912 region	N.S	N.S	Proportion method, Rapid broth method	55/138	1/0	Lys121Lys (rpsL), silent mutation, not assoc w/ STR-res.			
SM	rrs	Ramaswamy SV J Med Micro 2004	1238	T/C	1238		1996-1998	patients from Jose E. Gonzalez Univ. Hosp	Mexico	Sequencing	Whole rrs	RHSE	N.S	Proportion method	39897	3/0	"315, AGC/ACC, Ser/Thr (katG); 435, GAC/GTC, Asp/Val (rpoB); 43, AAG/AGG, Lys/Arg (rpsL); 306, ATG/CTG, Met/Leu (embB)"			
SM	rrs	Sekigushi J JCM 2007	1400	A/G	1400		2006	TB patients in Japan and Poland	Japan	Multiplex PCR	428-1737	N.S	N.S	Proportion method, Rapid broth method	55/138	1/0	Lys121Lys (rpsL), silent mutation, not assoc w/ STR-res.			
SM	rrs	Sekigushi J JCM 2007	1539	A/G	1539		2006	TB patients in Japan and Poland	Japan	Multiplex PCR	428-1737	N.S	N.S	Proportion method, Rapid broth method	55/138	1/0	"A1400G (rrs); Lys121Lys (rpsL), silent mutation, not assoc w/ STR-res."